Dossier na temat Anthony Fauciego/COVID-19 – dr David Martin

Dossier na temat Anthony Fauciego/COVID-19

Ta praca została częściowo wsparta przez zbiórkę pieniędzy, w której około 330 osób przekazało fundusze na wsparcie zespołu technologicznego New Earth i Urban Global Health Alliance. Jest ona udostępniona na licencji Creative Commons CC- BY-NC-SA. Wszelkie pochodne wykorzystanie tego dossier musi być upublicznione dla dobra innych. Wszystkie dokumenty, referencje i informacje zawarte w niniejszym dokumencie, mają charakter taki jaki mają w chwili ich opublikowania. Autor nie ponosi odpowiedzialności za błędy w zapisie publicznym lub w odniesieniach do niego. W całym dokumencie, użycie terminów powszechnie przyjętych w literaturze medycznej i naukowej, nie oznacza akceptacji lub odrzucenia dogmatu, który reprezentują.

[Dossier – zbiór dokumentów dotyczących jakiejś sprawy]

SARS-CoV-2 w kontekście patentów sprzed 20 lat – dr David Martin

Wersja po angielsku – The Fauci COVID-19 Dossier

 

Dossier na temat Anthony Fauciego/COVID-19

 

Tło:

Przez ostatnie dwie dekady, moja firma – M-CAM – monitorowała możliwe naruszenia Protokołu o zakazie używania gazów duszących, trujących lub innych w czasie wojny; bakteriologicznych metod prowadzenia wojny (Protokół Genewski z 1925 roku) oraz Konwencji o zakazie prowadzenia badań, produkcji i gromadzenia zapasów broni bakteriologicznej i toksycznej oraz ich zniszczeniu (BTWC z 1972 roku). W naszej Globalnej Ocenie Technologii na lata 2003-2004: Zbrojenia Wektorowe [Global Technology Assessment: VectorWeaponization]. W M-CAM zwróciliśmy uwagę na rosnące zaangażowanie Chin, w technologię łańcuchowej reakcji polimerazy (PCR), w odniesieniu do dołączenia do światowej sceny w konstrukcji chimerycznych wektorów wirusowych. Od tego czasu, co tydzień, monitorujemy rozwój badań i wysiłki komercyjne w tej dziedzinie, włączając w to, ale nie ograniczając się, do synergii badawczej tworzącej się pomiędzy amerykańskim Centrum Kontroli i Prewencji Chorób (CDC), Narodowym Instytutem Alergii i Chorób Zakaźnych (NIAID), Uniwersytetem Północnej Karoliny w Chapel Hill (UNC), Uniwersytetem Harvarda, Uniwersytetem Emory, Uniwersytetem Vanderbilta, Uniwersytetem Tsinghua, Uniwersytetem Pensylwanii oraz wieloma innymi instytucjami badawczymi i ich komercyjnymi powiązaniami.

Grant AI23946-08 przyznany przez Narodowy Instytut Zdrowia dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z Narodowym Instytutem Alergii i Chorób Zakaźnych [NIAID] dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenów, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych, skierowanych na te same czynniki. Już 21 maja 2000 roku dr Ralph Baric i Uniwersytet Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów, dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000]. W jednej z kilku prac, powstałych w wyniku prac sponsorowanych przez ten grant, dr R. Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV był oparty na złożonym segmencie DNA.

“Używając panelu przylegających cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy molekularnie sklonowane wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.”- PNAS October 28, 2003 100 (22) 12995-13000; Reversegenetics with a full-lengthinfectiouscDNA of severeacute respiratory syndromecoronavirus https://www.pnas.org/content/100/22/12995

Wiosną, 19 kwietnia 2002 roku, przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent U.S. 7279372 na metodę wytwarzania rekombinowanego koronawirusa. W pierwszym publicznym zapisie stwierdzeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusów w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe wysiłki CDC w zakresie podejmowanych starań uzyskania patentów, gdy 25 kwietnia 2003 r. starało się ono o opatentowanie koronawirusa SARS wyizolowanego od ludzi, który podobno przeniósł się na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] dotyczący wynalazków podlegających opatentowaniu zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent USA 7220852 i ograniczał każdego, kto nie był licencjonowany [upoważniony] przez ich patent, do manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały: znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakteryzację wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica [USA 6593111] (roszczenia 1 i 5) oraz patentowi CDC o numerze 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez zezwolenia lub naruszenia tychże patentów.

Zauważyliśmy, że specjalista w dziedzinie badań nad uzyskiwaniem funkcji [gain-of-function], dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich w postaci dotacji na badania od kilku agencji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów [International Committee on Taxonomy of Viruses (ICTV)] Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG).

W tym charakterze, dr Ralph Baric był odpowiedzialny za określanie “nowości” wśród kladów różnych gatunków wirusów, ale także bezpośrednio korzystał z deklarowanych nowości – w formie nowych wniosków na finansowanie badań i związanej z nimi współpracy patentowej i handlowej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi, posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i inne), potężna grupa interesów tworzyła coś, odnośnie czego sugerowalibyśmy, że jest “wzajemnym powiązaniem/zazębianiem się dyrekcji”, zgodnie z amerykańskimi prawami antymonopolowymi.

Podmioty te były również powiązane z Globalną Radą Monitorowania Gotowości [Global Preparedness Monitoring Board [GPMB)] pod WHO, której członkowie odegrali zasadniczą rolę w finansowanym przez Open Philanthropy globalnym ćwiczeniu „przy stole” odnośnie pandemii koronawirusów o nazwie “Wydarzenie 201” w październiku 2019 roku.

To wydarzenie [Event 201], sfinansowane przez głównego inwestora w Sherlock Biosciences oraz Fundację Billa i Melindy Gatesów w mandat Globalnej Rady Monitorowania Gotowości [GPMB] na globalne ćwiczenie w sprawie gotowości na choroby układu oddechowego, które ma być zakończone do września 2020 roku, zaalarmowało nas to, bo pojawiła się wskazówka dotycząca scenariusza przyszłej “epidemii”. Spodziewaliśmy się, że taki scenariusz pojawi się w Wuhan lub Guangdong w Chinach, w północnych Włoszech, w Seattle, w Nowym Jorku lub w kombinacji tych miejsc, ponieważ prace dr Zhengli Shi i dr Barica nad odzwierzęcym przenoszeniem się koronawirusa, zidentyfikowały nakładające się mutacje koronawirusa w populacjach nietoperzy znajdujących się w tych obszarach.

Dossier ten nie jest bynajmniej wyczerpujący. Wskazuje on jednak na liczne naruszenia prawa karnego, które mogą być związane z terroryzmem COVID-19. Wszystkie materiały źródłowe są w nim cytowane. Dodatkowe szczegółowe zestawienie wszystkich osób, instytucji badawczych, fundacji, źródeł finansowania i przedsiębiorstw komercyjnych jest dostępne na życzenie.

 

Spis treści:

35 U.S.C. § 101 – Wynalazki Podlegające Opatentowaniu
18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia
18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich
18 U.S.C. § 1001 – Okłamywanie Kongresu
15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej
15 U.S.C. §8 – Manipulacja i Alokacja Rynku
15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami
35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego
21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne
Podmioty komercyjne

 

 

 

Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101]

 

Z opinii sędziego Clarence’a Thomasa dla większości

Paragraf 101 ustawy o patentach stanowi: „Ktokolwiek wymyśli lub odkryje nowy i użyteczny proces, maszynę, produkcję lub skład materii, lub jakiekolwiek nowe i użyteczne ich ulepszenie, może uzyskać na nie patent, z zastrzeżeniem warunków i wymagań niniejszego rozdziału.” –35 U.S.C. § 101.

Od dawna “uważamy, że przepis ten zawiera ważny domyślny wyjątek: prawa natury, zjawiska naturalne i abstrakcyjne idee nie podlegają opatentowaniu”. Mayo, 566 U.S., at , 132 S.Ct., at 1293 (wewnętrzne cytaty i nawiasy pominięte). Są one raczej “podstawowymi narzędziami pracy naukowej i technologicznej”, które leżą poza domeną ochrony patentowej. Tamże 132 S.C., 1293. Jak wyjaśnił Sąd, bez tego wyjątku, istniałoby znaczne niebezpieczeństwo, że przyznanie patentów “uwięziłoby” wykorzystanie takich narzędzi i w ten sposób “zahamowałoby przyszłe innowacje oparte na nich”. Tamże, w 132 S.Ct., na 1301. Byłoby to sprzeczne z samym sensem istnienia patentów, które istnieją po to, by promować twórczość. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.C. 2204, 65 L.Ed.2d 144 (1980) (Produkty natury nie są wytwarzane, a “‘manifestacje… natury [są] wolne dla wszystkich ludzi i nie są zastrzeżone na wyłączność dla kogokolwiek'”). – Association for MolecularPathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

W swojej większościowej opinii z 2013 roku Sąd Najwyższy USA wyraźnie zaznaczył, że Sąd “od dawna utrzymywał”, że natura nie podlega patentowaniu. Samo wyizolowanie DNA nie stanowi przedmiotu patentu. W swoim patencie CDC przedstawiło fałszywe i wprowadzające w błąd twierdzenia w Biurze Patentów i Znaków Towarowych Stanów Zjednoczonych, stwierdzając, że “nowo wyizolowany ludzki koronawirus został zidentyfikowany jako czynnik wywołujący SARS i nazwany SARS-CoV ” [U.S. Patent 7220852] . Na poparcie tego stwierdzenia nie przedstawiono żadnych danych “przyczynowych”.

Kiedy 25 kwietnia 2003 r. złożyli wniosek patentowy, ich pierwszym roszczeniem (i jedynym, które przetrwało do ostatecznego wydania, mimo sprzeciwu eksperta patentowego w 2006 i 2007 r.) był genom wirusa SARS CoV.

Chociaż patent ten jest wyraźnie nielegalny zgodnie z 35 U.S.C. §101, CDC nie tylko nalegało na jego przyznanie pomimo nieostatecznych i ostatecznych odrzuceń, ale także nadal płaciło opłaty za utrzymanie patentu po tym, jak decyzja Sądu Najwyższego z 2013 r. potwierdziła, że był on sprzeczny z prawem.

Ponadto CDC opatentowało wykrywanie wirusa SARS CoV przy użyciu wielu metod, w tym reakcji łańcuchowej polimerazy z odwrotną transkrypcją (RT-PCR). Dzięki temu patentowi wykluczyli oni kogokolwiek spoza ich licencjonowanych lub spiskujących interesów z legalnego angażowania się w niezależną weryfikację ich twierdzeń, że wyizolowali wirusa, że jest on czynnikiem powodującym SARS, lub że jakakolwiek terapia może być skuteczna przeciwko zgłoszonemu patogenowi.

Należy zauważyć, że wnioski patentowe CDC zostały również odrzucone w odmowach nieostatecznych i ostatecznych z powodu niekwalifikowalności na podstawie 35 U.S.C. § 102, ponieważ zostały publicznie ujawnione przed ich złożeniem. W pierwszym nieostatecznym odrzuceniu USPTO stwierdził, że genom CDC został opublikowany w czterech wpisach akcesyjnych Genbank 14, 18 i 21 kwietnia 2003 r. z identycznością od 96,8% do 99,9% identycznych sekwencji. [Źródło: USPTO Non-FinalRejection File #10822904, September 7, 2006, page 4.]

Dr Fauci wiedział i nie ujawnił dowodów na to, że patent CDC był sprzeczny z prawem, w oparciu o prace, które finansował w latach poprzedzających wybuch SARS.

Po uzyskaniu nielegalnego patentu, złożeniu petycji o unieważnienie decyzji eksperta o jego odrzuceniu, a następnie ostatecznym przyznaniu patentu, CDC okłamało opinię publiczną, twierdząc, że kontroluje patent, aby był on “publicznie dostępny”.

Rzecznik CDC Llelwyn Grant powiedział, że: „Całym celem tego patentu jest uniemożliwienie ludziom kontrolowania technologii. Robi się to po to, aby zapewnić przemysłowi i innym badaczom rozsądny dostęp do próbek.” – Źródło: 6 maj 2003, Race to Patent SARS VirusRenewsDebate]

Tragikomicznym jest fakt, że to publiczne oświadczenie obala prosty fakt, że ich własna publikacja w Genbanku w rzeczywistości uczyniła go domeną publiczną, a tym samym nie nadawała się do opatentowania. Fakt ten, potwierdzony przez inspektorów patentowych, został unieważniony przez CDC w ramach płatnej akwizycji mającej na celu obejście prawa.

Chociaż nie jest to objęte 35 U.S.C. §101, nadużycie prawa patentowego przez dr Anthony Fauciego jest szczegółowo opisany poniżej. Na uwagę zasługuje jednak jego rozmyślne i zwodnicze użycie terminu “szczepionka” w patentach i publicznych wypowiedziach, w celu wypaczenia znaczenia tego terminu dla manipulacji opinią publiczną.

W sprawie Jacobson v. Mass z 1905 roku sąd jasno stwierdził, że aby szczepionka była obowiązkowa, wymagana jest KORZYŚĆ PUBLICZNA. Ani Pfizer, ani Moderna nie udowodniły zakłócenia w transmisji [zaraźliwości] wirusa. W sprawie Jacobson v. Massachusetts, 197 U.S. 11 (1905), sąd stwierdził, że kontekst ich opinii opiera się na następującej zasadzie:

“Ten sąd więcej niż raz uznał to za fundamentalną zasadę, że ‘osoby i własność podlegają wszelkiego rodzaju ograniczeniom i obciążeniom w celu zabezpieczenia ogólnego komfortu, zdrowia i dobrobytu państwa…”.

W testach “rzekomej szczepionki” Moderna i Pfizer wyraźnie przyznali, że ich technologia terapii genowej nie ma żadnego wpływu na infekcję wirusową lub przenoszenie wirusa, a jedynie przekazuje biorcy zdolność do endogennej produkcji białka kolcowego S1 poprzez wprowadzenie syntetycznej sekwencji mRNA. Dlatego podstawa statutu Massachusetts i ustalenia Sądu Najwyższego jest w tym przypadku nieistotna.

Co więcej, Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych [USPTO], podczas procesu REJESTRACJI szczepionki przeciwko HIV, który to wniosek Anthony Fauci złożył, otrzymał następującą odpowiedź na poparcie odrzucenia jego fałszywego “wynalazku”:

Wniosek/numer kontrolny: 09/869,003 Strona 5

Te argumenty są przekonujące w zakresie, w jakim antygenowy peptyd stymuluje odpowiedź immunologiczną, która może wytworzyć przeciwciała wiążące się z określonym peptydem lub białkiem, ale nie są przekonujące w odniesieniu do szczepionki. Odpowiedź immunologiczna wywołana przez szczepionkę musi być czymś więcej niż tylko pewną reakcją immunologiczną, ale musi mieć charakter ochronny. Jak zauważono w poprzedniej skardze do Urzędu, w sztuce [medycznej] termin “szczepionka” oznacza środek, który zapobiega infekcji. Wnioskodawca nie wykazał, że zgłoszona szczepionka spełnia nawet niższy standard określony w specyfikacji, a tym bardziej standardową definicję sztuki, aby być skuteczną w tym zakresie.

Dlatego roszczenia 5, 7 i 9 nie są skuteczne jako szczepionka przeciw HIV-1, a zatem nie mają patentowej użyteczności.

 

18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia

 

Pośrednio, bezprawnie i umyślnie dostarcza lub gromadzi fundusze z zamiarem ich wykorzystania lub ze świadomością, że fundusze te mają zostać wykorzystane, w całości lub w części, w celu przeprowadzenia:

(A) czynu, który stanowi przestępstwo w ramach traktatu określonego w podsekcji (e)(7), wdrożonego przez Stany Zjednoczone, lub

(B) jakiegokolwiek innego czynu mającego spowodować śmierć lub poważne uszkodzenie ciała osoby cywilnej lub każdej innej osoby nie biorącej czynnego udziału w działaniach wojennych w sytuacji konfliktu zbrojnego, jeżeli celem takiego czynu, ze względu na jego charakter lub kontekst, jest zastraszenie ludności lub zmuszenie rządu lub organizacji międzynarodowej do podjęcia lub zaniechania działania….

Nie później niż 11 kwietnia 2005 r. dr Anthony Fauci publicznie uznał związek SARS z potencjałem bioterrorystycznym. Wykorzystując strach przed bioterroryzmem wywołanym przez wąglik w 2001 roku, publicznie świętował gospodarcze dobrodziejstwo, jakie ludzie od zajmowania się terroryzmem krajowym skierowali na jego budżet. W szczególności stwierdził, że NIAID aktywnie finansuje badania nad mikromacierzą DNA “SARS Chip” do szybkiego wykrywania SARS (coś, co nie zostało udostępnione podczas obecnej “pandemii”) i dwoma kandydatami na szczepionki skoncentrowane na białku kolcowych SARS-CoV.

Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/

Pod kierownictwem trzech zatrudnionych przez siebie chińskich badaczy – Zhi-yong Yanga, Wing-pui Konga i YueHuanga – Fauci miał do 2004 roku co najmniej jedną szczepionkę DNA w trakcie badań na zwierzętach.

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/

Zespół ten, wchodzący w skład Centrum Badań nad Szczepionkami przy NIAID, koncentrował się przede wszystkim na opracowywaniu szczepionek przeciwko HIV, ale jego zadaniem było również zidentyfikowanie kandydatów na szczepionkę przeciwko SARS. We współpracy z Sanofi, ScrippsInstitute, Harvardem, MIT i NIH, decyzja dr Fauci o jednostronnym promowaniu szczepionek jako podstawowej interwencji w przypadku kilku wyznaczonych “chorób zakaźnych” uniemożliwiła zastosowanie sprawdzonych terapii u chorych i umierających.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/

Dr Peter McCullough o blokowaniu metod leczenia Covid-19
Leczenie chorób wirusowych: czy prawdę ukrywano przez dziesięciolecia? – dr Lee D. Merritt

CDC i NIAID pod kierownictwem Anthony’ego Fauci weszły w wymianę handlową między państwami (w tym, ale nie tylko, współpraca z EcoHealth Alliance Inc.) i z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk) poprzez grant z 2014 roku, o oznaczeniu R01AI110964 Narodowego Instytutu Zdrowia [NIH], w celu wykorzystania swoich praw patentowych. Wiadomo było, że badania te dotyczyły białek powierzchniowych koronawirusów, które miały zdolność do bezpośredniego zakażania ludzkich układów oddechowych. Mimo rażącego naruszenia moratorium NIH na badania typu uzyskiwania funkcji [gain of function], NIAID i dr Ralph Baric kontynuowali prace nad chimerycznymi składnikami koronawirusów, specjalnie w celu wzmocnienia patogenności materiału biologicznego.

Do października 2013 roku, w ramach prac finansowanych przez NIAID w Chinach, Instytut Wirusologii w Wuhan opisał białko kolcowe S1 1 koronawirusa. W prace te zaangażowane były NIAID, USAID oraz Peter Daszak, szef EcoHealth Alliance. Praca ta, finansowana w ramach grantu R01AI079231, była kluczowa w izolowaniu i manipulowaniu fragmentami wirusów wybranych z różnych miejsc w całych Chinach, które zawierały wysokie ryzyko poważnej reakcji u ludzi.

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
https://pubmed.ncbi.nlm.nih.gov/24172901/

Do marca 2015 r. wiadomo było, że zarówno wirulencja białka kolcowe S1, jak i receptor ACE2 stanowią znaczne zagrożenie dla zdrowia ludzkiego. NIAID, EcoHealth Alliance i liczni badacze ubolewali nad faktem, że opinia publiczna nie była wystarczająco zaniepokojona koronawirusem, aby odpowiednio finansować ich pożądane badania.

National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses https://www.ncbi.nlm.nih.gov/books/NBK349040/

Dr Peter Daszak z EcoHealth Alliance zaproponował następującą ocenę sytuacji:

“Daszak powtórzył, że dopóki kryzys związany z chorobami zakaźnymi nie stanie się bardzo realny i nie przekroczy progu sytuacji kryzysowej, jest często w dużym stopniu ignorowany. Aby utrzymać bazę finansową po zakończeniu kryzysu, musimy zwiększyć świadomość opinii publicznej odnośnie konieczności opracowania medycznych środków zapobiegawczych, takich jak powszechny program uniwersalnych szczepień przeciwko koronawirusom. Kluczowym elementem napędzającym ten proces są media, a gospodarka szybko podchwyci ten trend. Musimy wykorzystać ten szum medialny i zaadresować prawdziwe problemy. Inwestorzy się pojawią, gdy tylko wyczują potencjalne zyski z finalizacji tego procesu, stwierdził Daszak.” – Źródło: Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.

Ekonomia będzie podążać za trendem/szumem.

CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie ograniczając się do pracy z Uniwersytetem Północnej Karoliny w Chapel Hill [UNC]) i z zagranicą (w szczególności, Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowanych przez Shi Zheng-Li) poprzez U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), i dofinansowanie z Narodowej Fundacji Nauk Przyrodniczych w Chinach 81290341 (Zheng-Li Shi) i wsp. 2015-2016. Projekty te miały miejsce w czasie, gdy wykonywane prace były zakazane przez amerykańskie Narodowy Instytut Zdrowia [NIH].

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

Opinia publiczna została wyraźnie poinformowana o niebezpieczeństwach, jakie niosą ze sobą badania finansowane przez NIAID w 2015 i 2016 roku, kiedy materiał z Instytutu Wirusologii w Wuhan był obrabiany w placówce Uniwersytetu Północnej Karoliny [UNC], czyli laboratorium dr Ralpha Barica.

“Jedynym skutkiem tej pracy, jest stworzenie w laboratorium nowego, nienaturalnego zagrożenia” – zgadza się Richard Ebright, biolog molekularny i ekspert ds. obrony biologicznej na Rutgers University w Piscataway, w stanie New Jersey. Zarówno Ebright jak i Wain-Hobson są długoletnimi krytykami badań typu gain-of-function [uzyskiwania funkcji].

W swoim artykule autorzy badania przyznają również, że fundatorzy mogą/powinni się dobrze zastanowić o dopuszczeniu takich eksperymentów w przyszłości. “Panele naukowe mogą uznać, że podobne badania, nad budową wirusów chimerycznych, opartych na krążących szczepach, są zbyt ryzykowne, aby je prowadzić” – piszą, dodając, że potrzebna jest dyskusja na temat tego, “czy tego typu badania nad wirusami chimerycznymi uzasadniają dalsze badania w porównaniu z nieodłącznym ryzykiem”.

Ale dr Baric i inni twierdzą, że badania przyniosły korzyści. Wyniki badań “przesuwają tego wirusa z kandydata na nowo pojawiający się patogen do wyraźnego i obecnego zagrożenia”, mówi dr Peter Daszak, który był współautorem pracy z 2013 roku. Peter Daszak jest prezesem EcoHealth Alliance, międzynarodowej sieci naukowców z siedzibą w Nowym Jorku, która pobiera próbki wirusów od zwierząt i ludzi w miejscach występowania nowych chorób na całym świecie.

Dr Peter Daszak zgadza się, że badania testujące hybrydowe wirusy w ludzkich hodowlach komórkowych i modelach zwierzęcych mają ograniczony zakres, jeśli chodzi o to, co mogą powiedzieć o zagrożeniu stwarzanym przez dzikiego wirusa. Twierdzi on jednak, że mogą one pomóc wskazać, które patogeny powinny być traktowane priorytetowo w dalszych badaniach.” – Nature, 12 listopad 2015, Engineered bat virus stirs debate over risky research https://www.nature.com/articles/nature.2015.18787

Anthony Fauci: „Korzyści ze zgromadzonych danych przeważają nad ryzykiem związanym z pandemią” – dr Chris Martenson
EcoHealth Alliance dr Petera Daszaka ukryło prawie 40 milionów dolarów z Pentagonu i zmilitaryzowało naukę o pandemii – Sam Husseini

Wiedząc, że amerykański Departament Zdrowia i Usług Społecznych [HHS] (poprzez CDC, NIH, NIAID oraz finansowane przez nich laboratoria i partnerów komercyjnych) miał patenty na każdy proponowany element medycznych środków zaradczych i ich finansowanie, dr Fauci, dr Gao (Chińskie CDC) i dr Elias (Fundacja Billa i Melindy Gates) spiskowali, aby popełnić akty terroru na globalnej populacji – w tym obywatelach Stanów Zjednoczonych – kiedy we wrześniu 2019 r. opublikowali następujące informacje w corocznym raporcie na temat globalnej gotowości na sytuacje kryzysowe związane ze zdrowiem:

“Kraje, darczyńcy i instytucje wielostronne muszą być przygotowane na najgorsze.

Szybko rozprzestrzeniająca się pandemia spowodowana śmiertelnym patogenem oddechowym (czy to naturalnie pojawiającym się, czy też przypadkowo lub celowo uwolnionym), stawia dodatkowe wymagania dotyczące gotowości. Darczyńcy i instytucje wielostronne muszą zapewnić odpowiednie inwestycje w rozwój innowacyjnych szczepionek i terapii, zdolności produkcyjnych, leków antywirusowych o szerokim spektrum działania oraz odpowiednich interwencji niefarmakologicznych. Wszystkie kraje muszą opracować system natychmiastowego udostępniania sekwencji genomu każdego nowego czynnika chorobotwórczego do celów zdrowia publicznego, a także środki umożliwiające wymianę ograniczonych medycznych środków zaradczych między krajami.

Wskaźnik(i) postępu do września 2020 roku:

– Darczyńcy i kraje zobowiązują się i określają harmonogramy: finansowania i opracowania uniwersalnej szczepionki przeciwko grypie, leków antywirusowych o szerokim spektrum działania i terapii celowanych. WHO i jej państwa członkowskie opracowują opcje standardowych procedur i harmonogramów udostępniania danych dotyczących sekwencji, próbek i medycznych środków zaradczych dla patogenów innych niż grypa.

– Darczyńcy, kraje i instytucje wielostronne opracowują wieloletni plan i podejście do wzmocnienia zdolności badawczych w zakresie badań i rozwoju, przed i w trakcie epidemii.

– WHO, Fundusz Narodów Zjednoczonych na rzecz Dzieci, Międzynarodowa Federacja Stowarzyszeń Czerwonego Krzyża i Czerwonego Półksiężyca, partnerzy akademiccy i inni partnerzy określają strategie zwiększania możliwości i integracji podejść i badaczy z dziedziny nauk społecznych w całym kontinuum gotowości i reagowania ” – str. 8, Annual report on global preparedness for health emergencies

Jakby na potwierdzenie użyteczności żądania z września 2019 r. o “finansowanie i rozwój” szczepionki oraz fortunnego rzekomego wybuchu SARS CoV-2 w grudniu 2019 r., dr Fauci zaczął napawać się, że jego losy w zakresie dodatkowego finansowania prawdopodobnie zmieniają się na lepsze. W wywiadzie w STAT z 10 lutego 2020 roku, został on zacytowany w następujący sposób:

“”Pojawienie się nowego wirusa zmieni tę liczbę, prawdopodobnie znacznie”, powiedział Fauci. “Nie wiem, jak dużo to będzie. Ale myślę, że to będzie generować bardziej trwałe zainteresowanie koronawirusami, ponieważ jest bardzo jasne, że koronawirusy mogą dokonywać naprawdę interesujących rzeczy.”” – Fluctuating funding and flagging interest hurt coronavirus research, leaving crucial knowledge gaps

 

18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich

 

Sekcja 802 amerykańskiej ustawy PATRIOT Act (Pub. L. No. 107-52) rozszerzyła definicję terroryzmu, aby objąć “krajowy,” w przeciwieństwie do międzynarodowego, terroryzm. Osoba angażuje się w terroryzm krajowy, jeśli dokonuje czynu “niebezpiecznego dla życia ludzkiego”, który jest pogwałceniem praw karnych stanu lub Stanów Zjednoczonych, jeśli czyn ten wydaje się być zamierzony, aby: (i) zastraszyć lub wymusić [coś] na ludności cywilnej; (ii) wywrzeć wpływ na politykę rządu poprzez zastraszenie lub wymuszenie;

Dr Anthony Fauci zastraszał i zmuszał ludność cywilną oraz próbował wpłynąć na politykę rządu poprzez zastraszenie i przymus.

Bez żadnego potwierdzenia, dr Anthony Fauci promował symulację komputerową profesora Neila Fergusona, wywodząc z niej twierdzenia, że:

“Świat stoi w obliczu najpoważniejszego kryzysu zdrowia publicznego od pokoleń. Tutaj przedstawiamy konkretne szacunki skali zagrożenia, przed jakim stoją obecnie kraje.”

“Używamy najnowszych szacunków dotkliwości, aby pokazać, że strategie polityczne, których celem jest złagodzenie epidemii, mogą zmniejszyć liczbę zgonów o połowę i ograniczyć szczyt zapotrzebowania na opiekę zdrowotną o dwie trzecie, ale to nie wystarczy, aby zapobiec przeciążeniu systemów opieki zdrowotnej. Aby ograniczyć przenoszenie choroby do niskiego poziomu, konieczne będą zatem bardziej intensywne i społecznie destrukcyjne interwencje. Jest prawdopodobnym, że takie środki – przede wszystkim dystans społeczny na dużą skalę – będą musiały być stosowane przez wiele miesięcy, być może aż do momentu, gdy dostępna będzie szczepionka.” – Imperial College London, 17 marca 2020, COVID-19: Imperial researchers model likely impact of public healthmeasures

Przegląd kodu źródłowego z modelu Fergusona
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Plusy i minusy środków zaradczych przeciw pandemii grypy – dr Thomas Inglesby, prof. Jennifer Nuzzo, prof. Tara O’Toole i prof. Donald Henderson [listopad 2006]
Lockdown jest ponad 10 razy bardziej śmiertelny niż sama pandemia

Informując prezydenta, że aż 2,2 miliona zgonów może być skutkiem patogenu, który nie został jeszcze wyizolowany i którego nie można było zmierzyć z żadną dokładnością, dr Fauci zastraszył i zmusił ludność oraz rząd do lekkomyślnych, niesprawdzonych i szkodliwych działań, powodujących nieodwracalne szkody dla życia i środków do życia.

Ani Imperial College, ani “niezależny” Institute for HealthMetrics and Evaluation [Instytut Mierzenia i Oceny Zdrowia] (finansowany głównie przez Fundację Billa i Melindy Gatesów)nie miały żadnych dowodów na sukces w szacowaniu wcześniejszych obciążeń spowodowanych koronawirusem, ale bez konsultacji czy wzajemnej weryfikacji dr Fauci przyjął ich przerażające szacunki za podstawę interwencji, które są wyraźnie sprzeczne z zaleceniami medycznymi.

– Nałożenie dystansu społecznego było oparte na symulacji komputerowej i modelach środowiskowych, które nie zawierały żadnych dowodów na przenoszenie chorób.

– Narzucenie noszenia masek na twarz było bezpośrednio sprzeczne z dowodami z kontrolowanych badań klinicznych i z pisemną polityką w czasopiśmie Amerykańskiego Stowarzyszenia Medycznego [AMA].

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.” – JAMA. 2020;323(15):1517-1518; Medical Masks

– Zarówno w symulacjach Imperial College, jak i IHME, kwarantanny były modelowane dla osób chorych, a nie zdrowych.

Geneza idei zamykania kraju [Lockdown] sięga 2006 roku – Jeffrey A. Tucker [American Institute for Economic Research]
Maseczki nie działają: Przegląd literatury naukowej w kontekście zasadności polityki społecznej wobec COVID-19 – dr Denis Rancourt

Naleganie na szczepionki, przy jednoczesnym blokowaniu awaryjnego stosowania sprawdzonych interwencji farmaceutycznych, mogło przyczynić się do śmierci wielu pacjentów i zdrowych osób.

Wykorzystując władzę NIAID podczas domniemanej pandemii, dr Anthony Fauci aktywnie tłumił sprawdzone medyczne środki zaradcze, stosowane i potwierdzone w postępowaniach naukowych, które oferowały alternatywę dla produktów finansowanych przez jego spiskujące podmioty, którym zapewnił bezpośrednie finansowanie i dla których miał otrzymywać korzyści materialne i niematerialne.

Alan Jones: Biurokraci zaprzeczają, że hydroksychlorochina zmniejsza śmiertelność
Koronawirus: Jak sobie z nim poradzić? – Prof. Didier Raoult [Chlorochina]
Hydroksychlorochina – czy działa na koronawirusa? – Dr Vladimir Zelenko
Wywiad z dr Stellą Immanuel o Hydroksychlorochinie [30 lipiec 2020]
COVID-19 – Dr Richard Bartlett: Strategia oparta na leku Budezonid

 

 

18 U.S.C. § 1001 – Okłamywanie Kongresu

 

(a)O ile niniejsza sekcja nie stanowi inaczej, każdy, kto w jakiejkolwiek sprawie podlegającej jurysdykcji władzy wykonawczej, ustawodawczej lub sądowniczej Rządu Stanów Zjednoczonych, świadomie i umyślnie-

(1) fałszuje, ukrywa lub tuszuje za pomocą jakiejkolwiek sztuczki, schematu lub urządzenia istotny fakt;

(2) składa jakiekolwiek materialnie fałszywe, fikcyjne lub oszukańcze oświadczenie lub reprezentację; lub

(3) sporządza lub wykorzystuje fałszywe pismo lub dokument, wiedząc, że zawiera on fałszywe, fikcyjne lub oszukańcze oświadczenie lub wpis; podlega grzywnie na mocy niniejszego paragrafu, karze pozbawienia wolności na okres nie dłuższy niż 5 lat lub, jeśli przestępstwo wiąże się z międzynarodowym lub krajowym terroryzmem (zgodnie z definicją w sekcji 2331), karze pozbawienia wolności na okres nie dłuższy niż 8 lat, lub obu tym karom. Jeżeli sprawa dotyczy przestępstwa z rozdziału 109A, 109B, 110 lub 117, lub sekcji 1591, wówczas kara pozbawienia wolności nałożona na mocy niniejszej sekcji nie przekracza 8 lat.

 

W dniu 22 października 2020 r. Biuro Odpowiedzialności Rządu Stanów Zjednoczonych (GAO) opublikowało raport zatytułowany:

BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.

W dokumencie tym autorzy poinformowali, że Narodowy Instytut Zdrowia (NIH) otrzymał “do 2 miliardów dolarów w tantiemach z tytułu wkładu w 34 leki sprzedane w latach 1991-2019”.

Pobieżny przegląd raportu NIH Office of Technology Transfer dotyczącego aktywnych licencji wydaje się sprzeczny z raportem GAO w odniesieniu do kilku istotnych faktów. W raporcie GAO wyraźnie brakuje ponad 30 patentów związanych z aktywnymi związkami generującymi miliardy dolarów przychodu. Dlaczego GAO i NIH nie mogły dojść do porozumienia w sprawie czegoś tak prostego, jak leki generujące dochód dla NIH?

Od czasu uchwalenia ustawy Bayh Dole Act (Pub. L. 96-517, 12 grudnia 1980 r.), badania finansowane z funduszy federalnych były ekonomiczną bonanzą dla amerykańskich uniwersytetów, agencji federalnych i ich wybranych patronów. W pierwszej dekadzie po wprowadzeniu ustawy Bayh-Dole, fundusze NIH podwoiły się z 3,4 miliarda dolarów do 7,1 miliarda dolarów. Dekadę później- podwoiły się ponownie- osiągając 15,6 miliarda dolarów. W następstwie września 2001 roku, Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID) odnotował bezpośredni wzrost swojego budżetu o ponad 300%, bez uwzględnienia funduszy DARPA, które od 2005 roku wynosiły aż 1,7 miliarda dolarów rocznie. W 2020 roku budżet NIH wynosił ponad 41 miliardów dolarów.

Co się stało z 763 miliardami dolarów z funduszy podatników przeznaczonych na uczynienie Ameryki zdrowszą, odkąd wynalazcy są zachęcani do komercyjnego działania? Kto się wzbogacił?

Odpowiedź, niestety, jest taka, że skrupulatne rozliczenia nie są prowadzone, aby móc odpowiedzieć na te pytania.

Narodowy Instytut Zdrowia [NIH] jest wymienionym z nazwy właścicielem co najmniej 138 patentów od 1980 roku.

Amerykański Departament Zdrowia i Opieki Społecznej [HHS] jest wymienionym z nazwy właścicielem co najmniej 2600 patentów.

Dotacje lub współpraca z NIAID zaowocowały 2655 patentami i wnioskami patentowymi, z których tylko 95 zawiera przypisanie do Departamentu Zdrowia i Usług Społecznych jako właściciela. Większość z tych patentów jest przypisana do uniwersytetów, co sprawia, że ostateczni beneficjenci komercyjni są całkowicie nieprzejrzyści. Jednym z największych posiadaczy jest SIGA Technologies (NASDAQ: SIGA), która, choć publicznie informuje o bliskich związkach z NIAID, nie jest wymieniona w raporcie NIH GAO. Dyrektor generalny SIGA, dr Phillip L. Gomez spędził 9 lat w NIAID, rozwijając program szczepionek przeciwko HIV, SARS, Ebola, Wirusa Zachodniego Nilu i grypy, zanim przeszedł do przedsięwzięć komercyjnych. Chociaż ich technologia wyraźnie wywodzi się z osiągnieć naukowych do których przyczynił się NIAID, firma zgłasza przychody z NIAID, ale nie ma żadnych opłat licencyjnych ani płatności komercyjnych na rzecz NIH lub któregokolwiek z jego programów.

Dyrektor NIAID, dr Anthony Fauci, jest wymieniony jako wynalazca w 8 przyznanych patentach amerykańskich. Żaden z nich nie został zgłoszony w raportach NIAID, NIH lub GAO dotyczących aktywnego licencjonowania, pomimo faktu, że dr Fauci został podobno zmuszony do otrzymania zapłaty za swój “wynalazek” w postaci Interleukiny-2 – płatności, które podobno przekazał nienazwanej organizacji charytatywnej.

Z 21 patentów wymienionych w pomarańczowej księdze amerykańskiej Agencji ds. Żywności i Leków (FDA), wymienionych w raporcie GAO, żaden z patentów dr Anthony’ego Fauci nie jest wymieniony. Co więcej, żaden z patentów NIAID nie jest wymieniony pomimo wyraźnych dowodów na to, że Gilead Sciences i Janssen Pharmaceuticals (oddział Johnson & Johnson) wygenerowały ponad 2 miliardy dolarów rocznie ze sprzedaży, która była bezpośrednim rezultatem osiągnięć naukowych finansowanych przez NIAID. W raporcie GAO brakuje 2 patentów na Velclade, który od kilku lat generuje sprzedaż przekraczającą 2,18 miliarda dolarów rocznie. Żaden z patentów dla Yescarta nie jest wymieniony w raporcie GAO. Żaden z patentów na Lumoxiti nie jest wymieniony w raporcie GAO. Żaden z patentów na lek Kepivance nie został wymieniony w raporcie GAO. Z naruszeniem 37 USC §410.10 i 35 USC §202(a), ponad 13 z 21 patentów w raporcie GAO nie ujawnia interesów rządu, mimo że są one bezpośrednim wynikiem finansowania przez NIH.

Odporność i bezkarność: korupcja w relacjach Państwo-Farmacja – dr PaddyRawlinson
Prawda o firmach farmaceutycznych. Jak nas oszukują i co z tym robić – dr MarciaAngell

Własny dorobek patentowy dr Anthony’ego Fauci:

Patent US 6190656 i 6548055 Wzmocnienie immunologiczne z przerywaną terapią interleukiną-2

Metoda aktywacji układu odpornościowego ssaków obejmuje serię podań IL-2, co odbywa się z przerwami przez dłuższy okres czasu. Każde podanie IL-2 jest wystarczające, aby umożliwić wzrost i szczyt spontanicznej syntezy DNA w komórkach krwi obwodowej lub węzłów chłonnych pacjenta, a każde następne podanie następuje po poprzednim podaniu w serii przez okres czasu, który jest wystarczający, aby umożliwić ekspresję receptora IL-2 w krwi obwodowej lub węzłach chłonnych pacjenta, aby wzrosnąć, osiągnąć szczyt, a następnie zmniejszyć się do 50% wartości szczytowej. Ta przerywana terapia IL-2 może być łączona z inną terapią, która jest ukierunkowana na określony stan chorobowy, taką jak terapia antyretrowirusowa- obejmująca, na przykład, podawanie AZT, ddI lub interferonu alfa. Ponadto, podawanie IL-2 może być stosowane w celu ułatwienia transdukcji in situ limfocytów T w kontekście terapii genowej. W tym podejściu komórki są najpierw aktywowane in vivo przez wspomnianą terapię IL-2, a następnie transdukcja jest dokonywana przez dostarczenie genetycznie zmodyfikowanego wektora retrowirusowego bezpośrednio do pacjenta.

Niniejsze zgłoszenie jest kontynuacją amerykańskiego zgłoszenia patentowego nr ser. 08/487075, złożonego 7 czerwca 1995 r., obecnie zaniechanego, które jest kontynuacją w części amerykańskiego zgłoszenia patentowego nr ser. 08/063315, złożonego 19 maja 1993 r., obecnie wydanego jako patent US 5419900, oraz zgłoszenie patentowe USNr ser. 08/452440, złożone 26 maja 1995 r., obecnie wydane jako patent nr U.S. 5696079, który jest Krajowym Etapem zgłoszonego na podstawie 35 USC 371 zgłoszenia PCT/US94/05397, złożonego 19 maja 1994 r., którego treść jest włączona do niniejszego dokumentu przez przypis.

Zgłoszono 19 maja 1993 r.

Wydano Ostateczne Odrzucenie 20 stycznia 1998 r. odrzucony po odstąpieniu 14 sierpnia 1998 r. i 12 kwietnia 1999 r. ograniczone i zmodyfikowane roszczenia przyznane 8 maja 2000 r.

Ta rodzina patentów była podstawą kłamstwa Fauci’ego dla czasopisma British Medical Journal, w którym fałszywie stwierdził:

“Dr Anthony Fauci powiedział BMJ, że jako pracownik rządowy, był zobowiązany przez prawo do umieszczenia swojego nazwiska na patencie dotyczącym rozwoju interleukiny 2 [IL-2] i był również zobowiązany przez prawo do otrzymania części zapłaty, którą rząd otrzymał za wykorzystanie patentu. Powiedział, że uważa otrzymanie zapłaty za niestosowne (sic) i przekazał całą kwotę na cele charytatywne.” – BMJ. 2005 Jan 22; 330(7484): 162.

Nie był “zobowiązany przez prawo” do popełnienia oszustwa wobec urzędu patentowego, a następnie otrzymania za to zapłaty!

 

Patent US 6911527 Peptydy związane z HIV

Wynalazek ten polega na odkryciu nowych specyficznych epitopów i przeciwciał związanych z długotrwałym przeżyciem infekcji HIV-1. Te epitopy i przeciwciała mają zastosowanie w przygotowywaniu szczepionek do zapobiegania infekcji HIV-1 lub do kontrolowania progresji do AIDS.

Zgłoszony 6 maja 1999 r.

Odrzucony jako niepatentowalny 22 stycznia 2003 roku. Wydane z ostatecznym odrzuceniem 15 lipca 2004 r. po złożeniu wniosków o ponowne rozpatrzenie. Zmodyfikowane i ograniczone roszczenia dopuszczone 29 września 2004 roku.

 

Patent US 7368114 Białko fuzyjne, w tym CD4

Odkryto tu nowe rekombinowane polipeptydy, które zawierają polipeptyd CD4 podwiązany na jego końcu C z częścią immunoglobuliny zawierającą region zawiasowy i stałą domenę łańcucha ciężkiego immunoglobuliny ssaków.

Część lub IgG jest połączona na swoim końcu C z polipeptydem zawierającym końcówkę z końcem C łańcucha ciężkiego przeciwciała IgA lub końcówkę z końca C łańcucha ciężkiego przeciwciała IgM. Ujawnione są tu również metody stosowania tych białek fuzyjnych CD4.

Zgłoszono 24 października 2002 r.

Odrzucony jako niepatentowalny 18 sierpnia 2006 roku. Opłacone odwołanie w celu uchylenia ustaleń eksperta 15 lutego 2007 roku. Ponownie odrzucony 11 maja 2007 roku. W dniu 10 października 2007 r. wnioskodawcy jeszcze bardziej zawęzili konstrukcję tego, co wyraźnie nie było patentem, a USPTO przyznało mniej niż połowę roszczeń, o które ubiegano się w pierwotnym zgłoszeniu.

 

Patent US 9896509, 9193790 i 9441041 Zastosowanie antagonistów interakcji pomiędzy HIV GP120 i integryną alfa 4 beta 7

Podano metody leczenia zakażenia HIV. Metody mogą obejmować podawanie podmiotowi z zakażeniem HIV terapeutycznie skutecznej ilości środka, który zakłóca interakcję gp120 i alfa 4 integryny, takiego jak antagonista alfa 4 beta 1 lub integryny alfa 4 beta 7, lecząc w ten sposób zakażenie HIV. W kilku przykładach, antagonistą integryny alfa 4 jest przeciwciało monoklonalne, które wiąże się swoiście z podjednostką integryny alfa 4, beta 1 lub beta7 lub cyklicznym heksapeptydem o sekwencji aminokwasowej CWLDVC. Przedstawiono również metody zmniejszania replikacji lub infekcji HIV. Metody obejmują kontakt komórki ze skuteczną ilością środka, który zakłóca interakcję gp120 i integryny alfa 4, takiego jak antagonista integryny alfa 4 beta 1 lub alfa 4 beta 7. Ponadto, dostarczane są metody określania, czy środek jest użyteczny w leczeniu HIV.

Odrzucony 22 maja 2017 roku jako podwójnie opatentowany. W swojej odpowiedzi wnioskodawcy przyznają się do bezprawnego działania i dążą do uzyskania tylko tych elementów swojego zgłoszenia, które wykraczają poza okres obowiązywania wydanych patentów. W dniu 11 października 2017 r. wydano ograniczone roszczenia.

 

Próbka zagmatwanego przepływu funduszy, który wymyka się publicznemu ujawnieniu.

 

US Patent 8999351 został wydany Tekmira Pharmaceuticals Corporation w Burnaby, Kolumbia Brytyjska, w Kanadzie. W swoim patencie ujawniają oni, że ich badania były wspierane przez grant z Narodowego Instytutu Alergii i Chorób Zakaźnych (Grant HHSN266200600012C). Jak na ironię, ten grant o wartości 23 milionów dolarów został przyznany w 2006 roku firmie Alnylam Pharmaceuticals, Inc, a nie firmie Tekmira.

W 2012 roku firma Alnylam zgodziła się zapłacić firmie Tekmira 65 milionów dolarów w celu rozstrzygnięcia sporów prawnych, w tym roszczenia o odszkodowanie w wysokości 1 miliarda dolarów za “bezlitosne i okrutne” przywłaszczenie tajemnic handlowych firmy Tekmira. Od najwcześniejszego pierwszeństwa zgłoszenia patentowego z 10 listopada 2008 r., nie ma żadnego publicznego zapisu wskazującego na firmę Tekmira jako beneficjenta tego grantu NIAID. Niezależnie od tego, technologia nanocząstek lipidowych opracowana w ramach tego grantu jest technologią wykorzystywaną obecnie w interwencji [szprycy] firmy Moderna na COVID-19. W swoim zgłoszeniu 10-Q firma Alnylam informuje, że posiada licencję na technologię od firmy Arbutus – dawniej Tekmira – która oskarżyła firmę Acuitas o przywłaszczenie tajemnic handlowych i przekazanie licencji na nie firmie Moderna oraz koncernowi Pfizer współpracującego z firmą BioNTech.

Dodatkowe przypisy:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej

 

Każda umowa, kombinacja w formie powiernictwa lub w inny sposób, lub zmowa, w celu ograniczenia handlu pomiędzy kilkoma Stanami lub z obcymi narodami, jest uznana za nielegalną. Każda osoba, która zawrze jakąkolwiek umowę lub zaangażuje się w jakąkolwiek kombinację lub zmowę uznaną niniejszym za nielegalną, zostanie uznana za winną przestępstwa, a po skazaniu będzie podlegać karze grzywny nieprzekraczającej 100.000.000 dolarów, jeśli jest korporacją, lub, 1.000.000 dolarów jeśli jest inną osobą, lub karze pozbawienia wolności nieprzekraczającej 10 lat, lub obu tym karom, według uznania sądu.

Grant AI23946-08 z Narodowego Instytutu Zdrowia przyznany dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z NIAID dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenności, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych skierowanych na te same czynniki/patogeny. Już 21 maja 2000 roku dr R. Baric z Uniwersytetem Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000].

W jednej z kilku prac powstałych w wyniku prac sponsorowanych przez ten grant, dr Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV opierał się na kompozycji segmentów DNA.

“Używając panelu sąsiadujących cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy sklonowane molekularnie wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.” – PNAS October 28, 2003 100 (22) 12995-13000; Reverse genetics with a full-length infectiousc DNA of severe acute respiratory syndrome coronavirus

Dnia 19 kwietnia 2002 roku – wiosną przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent nr US 7279372 na metodę produkcji rekombinowanego koronawirusa. W pierwszym publicznym zapisie roszczeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusa w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe starania amerykańskiego Centrum Kontroli i Prewencji Chorób [CDC] na opatentowanie koronawirusa SARS wyizolowanego z ludzi, który według doniesień został przeniesiony na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent US 7220852 i ograniczał każdego, kto nie był licencjonowany przez ich patent, od manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakterystykę wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica US 6593111 (roszczenia 1 i 5) oraz patentowi CDC US 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez ich zezwolenia lub naruszenia tego patentu.

Zauważyliśmy, że specjalista w dziedzinie badań typu gain-of-function, dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich dotacji na badania od kilku instytucji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów (ICTV) Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG). W ramach tej funkcji był zarówno odpowiedzialny za określanie “nowości” kladów gatunków wirusów, jak i bezpośrednio korzystał z deklaracji o nowościach w postaci nowych zezwoleń na finansowanie badań oraz związanej z nimi współpracy patentowej i komercyjnej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i, inne), potężna grupa interesów tworzyła to, co sugerowalibyśmy jako “wzajemnympowiązaniem dyrekcji” zgodnie z amerykańskimi prawem antymonopolowym.

1986-1990 NIAID Grant AI 23946 prowadzący do uzyskania patentu US 7279327 “Methods for Producing Recombinant Coronavirus”. Zgłoszony w 2002 r. i wydany w 2007 roku

Praca opublikowana po raz pierwszy na podstawie grantu NIAID to:

An Experimental Model for Dilated Cardiomyopathy after Rabbit Coronavirus Infection

https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

1990 Pfizer zgłasza patent US 6372224 na szczepionkę przeciwko koronawirusowi opartą o białko S 14 listopada 2000 r. który został porzucony w kwietniu 2010 r., co czyni go domeną publiczną.

Lata 90. Prace koncentrowały się na związku koronawirusów z kardiomiopatią (patrz wyżej)

Wczesne odniesienie do “pojawienia się” koronawirusa jako patogenu układu oddechowego:

High Recombination And Mutation Rates In Mouse Hepatitis Virus Suggest That Coronaviruses May Be Potentiall Y Important Emerging Viruses

https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

2000Dr Ralph Baric w ramach grantów AI23946 i GM63228 z Narodowego Instytutu Zdrowia [NIH] aktywnie pracuje nad rekombinowanym koronawirusem

2001 Narodowy Instytut Zdrowia, Alergie i Choroby Zakaźne. “Reverse Genetics with a Coronavirus Infectious cDNA Construct”. 4/1/2001-3/31/005 całkowity roczny koszty to 1 milion dolarów. RS Baric, PI

2002 Wybuch epidemii koronawirusa SARS w Azji

2003 25 kwietnia 2003 CDC złożyło patent, który ostatecznie uzyskała, jego numer to US 7220852 (patent na sekwencję RNA) oraz US 7776521 (patent na metodologię badań). Patenty te dają amerykańskiemu Departamentowi Zdrowia i Usług Społecznych [HHS] możliwość kontrolowania komercyjnego wykorzystania koronawirusa SARS.

Dr Anthony Fauci zostaje mianowany członkiem Naukowej Rady Doradczej Global Grand Challenges Fundacji Billa i Melindy Gatesów (pełnił tę funkcję do 2010 roku).

28 kwietnia 2003 r. Sequoia Pharmaceuticals składa wniosek o patent US 7151163(Środki przeciwwirusowe do leczenia, kontroli i zapobiegania zakażeniom koronawirusami). Otrzymało w tym samym roku dwa granty w wysokości 953 tysięcy dolarów od HHS.

21 lipca 2003 r. zespół Ralpha Barica (wykorzystujący granty AI23946 i GM63228) zgłasza patent US 7618802 (Kompozycje koronawirusów z genomem odpornym na rekombinację), który został wydany 17 listopada 2009 roku.

Instytut Onkologii Dana-Farber w listopadzie 2003 zgłasza patent US 7750123 na przeciwciało monoklonalne neutralizujące wirusa SARS CoV. Badania te są wspierane przez kilka grantów NIH, w tym przez granty z Narodowego Instytutu Zdrowia o oznaczeniach A128785, A148436 i A1053822.

2004 6 stycznia 2004 – SARS i bioterroryzm na konferencji Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators.

Na tej konferencji termin “Nowa Normalność” został wprowadzony przez firmę Merck.

Dr FAUCI I dr BARIC zaczynają zarabiać pieniądze!!! Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID). SARS Reverse Genetics. AI059136-01. Koszty całkowite 1,7 miliona dolarów, RS Baric, PI. 10% wysiłku. 4/1/04- 3/31/09. Projekt ma na celu opracowanie pełnej długości zakaźnego cDNA wirusa SARS-CoV, opracowanie cząstek replikonowych SARS-CoV wyrażających heterologiczne geny oraz adaptację SARS-CoV na myszy, co pozwoli na stworzenie mysiego modelu patogennej infekcji SARS-CoV.

Narodowy Instytut Alergii i Chorób Zakaźnych. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% nakładu pracy. 7/1/04-6/30/09. 2,1 miliona dolarów.

22 listopada 2004 Uniwersytet w Hong Kongu patentuje białko kolcowe związane z SARS i ubiega się o patent US 7491489 (Syntetyczny peptyd celujący w krytyczne miejsca na białku kolca koronawirusa związanym z SARS odpowiedzialnym za infekcję wirusową i sposób jego zastosowania).

2005 Agencja ds. Zaawansowanych Projektów Badawczych w Obszarze Obronności (DARPA).Biohacking: Biological Warfare Enabling Technologies, czerwiec 2005. Waszyngton, Dystrykt Kolumbia. Wydarzenie sponsorowane przez DARPA/MITRE.

Przegląd osi czasu z https://www.youtube.com/watch?v=rO EeYBQiQU i https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

2008 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 rozpoczyna się od 10.189.682 milionów dolarów dla UNC w Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

2009 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano kolejne 5.448.656 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2010 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 8.747.142 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

Liczba wydanych patentów na koronawirus SARS osiągnęła szczyt od czasu wybuchu epidemii w Azji (391 patentów).

6 sierpnia 2010 r., Moderna (przed jej założeniem) składa wniosek o patent US 9447164, który przyciągnął inwestorów (i “wynalazców”) z Flagship Ventures. Patent ten wyrósł z pracy dr Jasona P. Schruma z Harvard Medical School, wspieranego przez National Science Foundation Grant#0434507. Podczas gdy wniosek rości sobie prawo do pierwszeństwa z sierpnia 2010 roku, wniosek nie został sfinalizowany aż do października 2015 roku. W dniu 4 listopada 2015 roku USPTO wydał nieostateczne odrzucenie tego oryginalnego patentu, odrzucając wszystkie roszczenia.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 z odniesieniem do finansowania w

https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

2011 Crucell dołączył do Janssen Pharmaceutical Companies będącego częścią Johnson & Johnson w lutym, zabierając ze sobą całą swoją technologię dotyczącą SARS.

Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano 7.344.820 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2012 MERS wyizolowany w Egipcie

Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.627.657 USD dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2013 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.226.237 milionów dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2014 23 kwietnia 2014, Moderna zgłasza patent na szczepionkę na bazie kwasu nukleinowego, patenty US9872900 i US10022435

2015 Moderna podpisuje umowę o rozwoju szczepionki z NIAID i realizuje ją z wiodącym na rynku twórcą i wynalazcą mRNA-1273 Guiseppe Ciaramella.

https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

2016 Narodowy Instytut Zdrowia [NIH] poprzez Scripps Institute i Dartmouth College składają wniosek patentowy WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use [Białka kolcowe koronawirusa sprzed fuzji i ich zastosowanie]” ujawniający technologię mRNA, która pokrywa się (i jest używana w tandemie z) technologią Moderny.

Główny wynalazca Barney Scott Graham był dobrze znany firmie Moderna, jako że jest on osobą w Narodowym Instytucie Zdrowia [NIH], do której Moderna “wysłała e-maila” w celu uzyskania sekwencji dla SARS CoV-2, zgodnie z raportem Moderny tutaj (“W styczniu 2020 roku, gdy odkryto, że infekcja w Wuhan była spowodowana nowym koronawirusem, Bancel szybko wysłał e-maila do dr Barneya Grahama, zastępcy dyrektora Centrum Badań nad Szczepionkami w Narodowym Instytucie Zdrowia, prosząc go o przesłanie sekwencji genetycznej wirusa.” – Źródło: Executives of vaccine developer Moderna cash in, cutcorners, 26 maj 2020)

Ponadto, współwynalazca Jason McLellan pracował z dr Barney’em Grahamem nad patentem na szczepionkę będącą wspólną własnością rządu chińskiego złożonym w Australii w 2013 roku. AU 2014231357A1 – Epitope of RSV fusion protein and antibody identifying same

2017 sierpień – Sanofi kupuje firmę Protein Science Corp posiadającą znaczne zasoby patentów na SARS

2018 czerwiec – firma Sanofi kupuje firmę Ablynx posiadającą znaczne zasoby patentów na SARS

2019 marzec, Sherlock Biosciences licencjonuje technologię Wyss, aby tworzyć przystępną cenowo diagnostykę molekularną – finansowane przez Open Philanthropy – tę samą organizację, która będzie sponsorem finansowym ćwiczeń “przy stole” o nazwie Wydarzeni 201, które ułożyło plan “pandemii” w październiku 2019 roku.

 

15 U.S.C. §8 – Manipulacja i Alokacja Rynku

 

Za sprzeczne z porządkiem publicznym, nielegalne i nieważne uznaje się wszelkie kombinacje, zmowy, powiernictwa, porozumienia lub umowy zawierane przez lub pomiędzy dwiema lub więcej osobami lub korporacjami, z których każda, jako agent lub zleceniodawca, zajmuje się importem jakiegokolwiek artykułu z jakiegokolwiek obcego kraju do Stanów Zjednoczonych, oraz gdy takie kombinacje, zmowy, powiernictwa, porozumienia lub umowy mają na celu ograniczenie legalnego handlu lub wolnej konkurencji w legalnym handlu, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych jakiegokolwiek artykułu lub artykułów importowanych lub przeznaczonych do importu. Porozumienie lub umowa mają na celu ograniczenie handlu zgodnego z prawem lub wolnej konkurencji w handlu zgodnym z prawem, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych artykułu lub artykułów importowanych lub przeznaczonych do importu do Stanów Zjednoczonych, lub jakiejkolwiek produkcji, do której taki importowany artykuł wchodzi lub ma wejść. Każda osoba, która zajmuje się importem jakichkolwiek towarów z jakiegokolwiek obcego kraju, z naruszeniem przepisów niniejszej sekcji, lub która łączy się lub spiskuje z innymi w celu naruszenia tych przepisów, jest winna wykroczenia i po skazaniu jej w jakimkolwiek sądzie Stanów Zjednoczonych taka osoba zostanie ukarana grzywną w wysokości nie mniejszej niż 100 dolarów i nie przekraczającej 5000 dolarów, a ponadto zostanie ukarana więzieniem, według uznania sądu, na okres nie krótszy niż trzy miesiące i nie przekraczający dwunastu miesięcy.

Poprzez niekonkurencyjne przyznawanie grantów dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny [UNC]w Chapel Hill, wybór lokalizacji laboratoriów bezpieczeństwa biologicznego poziomu 4 (BSL-4), ustalanie cen Remdesiviru i terapii mRNA firm Moderna i Pfizer, NIAID, CDC i Departament Zdrowia i Opieki Społecznej [HHS] były zaangażowane w przydzielanie funduszy federalnych spiskującym stronom bez niezależnej kontroli.

Od około 12 marca 2020 roku, w celu wzbogacenia własnych interesów ekonomicznych poprzez zapewnienie dodatkowych funduszy zarówno od podmiotów federalnych, jak i fundacji, CDC i dr Fauci z NIAID postanowili zawiesić badania i sklasyfikować COVID-19 wyłącznie na podstawie kapryśnej prezentacji objawów. Zmuszając opinię publiczną do polegania na The COVID Tracking Project – finansowanym przez Fundację Bloomberga, Zuckerberga i Gatesa i prezentowanym przez media (The Atlantic) – a nie agencję zdrowia publicznego – dr Fauci użył oszukańczej technologii testowania (RT-PCR), aby mylić “przypadki COVID” z pozytywnymi testami PCR u żywych, jednocześnie nalegając, aby zgony z powodu COVID były liczone wyłącznie na podstawie objawów. To utrwaliło popyt rynkowy na jego pożądany program szczepień, który był powtarzany przez niego i spiskujące z nim strony na całym świecie aż do chwili obecnej. Nic dziwnego, że było to konieczne z powodu widocznego spadku liczby przypadków, które stanowiły kryteria dr Fauci’ego i innych do pozbawiania obywateli ich praw wynikających z 1. Poprawki Konstytucji.

Myślenie pojęciowe, a myślenie stereotypowe – Andrzej Wronka, Kazimierz Ajdukiewicz
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Jak dokładne są testy na COVID? – dr Sebastian Rushworth
Testy PCR: Po 35 cyklach odcięcia nie wyhodujesz wirusa – dr Anthony Fauci
Nawet połowa testów na koronowirusa może być fałszywie pozytywna [Chiny]
Nieoczekiwane wykrycie przeciwciał na SARS-CoV-2 w okresie przed pandemicznym we Włoszech. [wrzesień 2019]

15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami

 

(1) Żadna osoba nie może w tym samym czasie pełnić funkcji dyrektora lub urzędnika w dwóch korporacjach (innych niż banki, stowarzyszenia bankowe i spółki powiernicze), które są-

(A) zaangażowane w całości lub częściowo w handel; oraz

(B) ze względu na swoją działalność i miejsce prowadzenia działalności są konkurentami, tak że wyeliminowanie konkurencji w drodze porozumienia między nimi stanowiłoby naruszenie jakichkolwiek przepisów antymonopolowych; jeżeli każda z tych korporacji posiada kapitał, nadwyżkę i niepodzielne zyski o łącznej wartości przekraczającej 10.000.000 dolarów, skorygowane zgodnie z ustępem (5) niniejszej podsekcji.

Dr Anthony Fauci jest członkiem Rady Przywódczej [Leadership Council] Globalnego Planu Działań na rzecz Szczepionek [Gates Global Vaccine Action Plan] Billa i Malindy Gates.

Dr Fauci, kontrolując wydawanie federalnych funduszy na badania, był i nadal jest członkiem Rady Monitorowania Globalnej Gotowości [Global Preparedness Monitoring Board] Światowej Organizacji Zdrowia. Dołączył do niego w tej radzie skonfliktowany darczyńca z Fundacji Billa i Melindy Gates, dr Chris Elias, oraz dr George F. Gao z Chińskiej Rady Państwowej ichniego Centrum Kontroli i Prewencji Chorób. Ta Rada Monitorowania Globalnej Gotowości [GPMB] przewidywała, że wszystkie państwa członkowskie muszą wziąć udział w globalnej symulacji uwolnienia patogenu układu oddechowego.

Dr Ralph Baric jest jednym z głównych beneficjentów funduszy federalnych USA, prowadzi ośrodek BSL-4 i zasiada w grupie roboczej International Committee on Taxonomy of Virus Corona viridae, której zadaniem jest potwierdzenie obecności lub jego braku patogenu, za co otrzymuje bezpośrednie wynagrodzenie.

Jak wspomniano w części dotyczącej naruszeń 18 U.S.C. § 1001 powyżej, istnieją liczne nieujawnione relacje handlowe pomiędzy naukowcami otrzymującymi finansowanie, ich instytucjami finansującymi oraz interesami handlowymi, w których występują ujawnione i nieujawnione warunki handlowe. Pełna lista wszystkich potencjalnie zaangażowanych stron jest wymieniona w poniższej części zatytułowanej “Podmioty komercyjne”.

Wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny są sprzeczne z prawem, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych kierowany przez Anthony’ego Fauci (dalej odpowiednio “NIAID” i “dr Fauci”) weszły w wymianę handlową między państwami (w tym m.in. współpracując z Ecohealth Alliance Inc. ) oraz z zagranicą (w szczególności z Instytutem Wirusologii w Wuhan oraz Chińską Akademią Nauk) za pośrednictwem grantu R01AI110964 z programu grantów Narodowego Instytutu Zdrowiaz 2014 r. i następnych, w celu wykorzystania swoich praw patentowych.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych (dalej “NIAID”) weszły w wymianę handlową między stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) oraz z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowaną przez dr Shi Zheng-Li) poprzez U19AI109761 (dr Ralph S. Baric), U19AI107810 (Ralph S. Baric) oraz grant Narodowej Fundacji Nauk Przyrodniczych w Chinach o oznaczeniu 81290341 (ShiZheng-Li) i wsp. 2015-2016.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) i z obcymi narodami w celu prowadzenia chimerycznej konstrukcji nowatorskiego materiału koronawirusowego o specyficznych właściwościach wirulencji przed, w trakcie i po określeniu przez Narodowy Instytut Zdrowia [NIH] w październiku 17, 2014, że praca ta nie była wystarczająco zrozumiała w odniesieniu dostandardów bezpieczeństwa biologicznego tej instytucji.

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

W tym dochodzeniu zakłada się, że CDC i jej współpracownicy byli:
a) w pełni świadomi prac wykonywanych przy użyciu ich opatentowanej technologii;
b) zawarli wyraźne lub dorozumiane umowy obejmujące licencjonowanie, lub inne wynagrodzenie; i, c) świadomie zaangażowali jeden lub więcej zagranicznych interesów, aby kontynuować eksploatację ich zastrzeżonej technologii, gdy Sąd Najwyższy Stanów Zjednoczonych potwierdził, że takie patenty były nielegalne i gdy Narodowy Instytut Zdrowia [NIH] wydał moratorium na takie badania.

Podobno w styczniu 2018 r. ambasada USA w Chinach wysłała śledczych do Instytutu Wirusologii w Wuhan i stwierdziła, że

“Podczas interakcji z naukowcami w laboratorium Instytucie w Wuhan zauważyli oni, że nowe laboratorium ma poważny niedobór odpowiednio wyszkolonych techników i badaczy potrzebnych do bezpiecznego prowadzenia tegolaboratorium wysokiego poziomu bezpieczeństwa [szczelności biologicznej].” Gazeta Washington Post podała, że informacje te zostały zawarte w depeszy z 19 stycznia 2018 roku. Ponad rok później, w czerwcu 2019 r., CDC przeprowadziło inspekcję w Instytucie Badań Medycznych Chorób Zakaźnych Armii Stanów Zjednoczonych w Fort Detrick (zwanym dalej “USAMRIID”) i nakazało jego zamknięcie po stwierdzeniu, że ich inspekcja znalazła zagrożenia dla bezpieczeństwa biologicznego. Publikacja w czasopiśmie Nature z 2003 r. (423(6936): 103) donosi o współpracy między CDC a USAMRIID w zakresie badań nad koronawirusami, po której nastąpiła późniejsza znacząca współpraca.

„Naukowcy z NIH i armii amerykańskiej połączyli siły w systematycznym programie badań przesiewowych, aby znaleźć kandydatów na leki do zwalczania ciężkiego ostrego zespołu oddechowego (SARS). Współpraca, która już trwa, została ogłoszona na zeszłotygodniowej Międzynarodowej Konferencji na temat Badań Antywirusowych w Savannah w stanie Georgia.” – Nature, 8 maj 2003, US Army join shunt for SARS drug

CDC, ze względu na to, co wydaje się być tym samym rodzajem obaw zidentyfikowanych w Wuhan, zdecydowało się kontynuować współpracę z rządem chińskim, zamykając jednocześnie placówkę armii amerykańskiej.

CDC zgłosiło pierwszy przypadek choroby podobnej do SARS-CoV w Stanach Zjednoczonych w styczniu 2020 r., przy czym Służba Wywiadu Epidemiologicznego CDC zgłosiła 650 przypadków klinicznych i 210 testów. Biorąc pod uwagę, że podejrzany patogen po raz pierwszy pojawił się w oficjalnych raportach 31 grudnia 2019 r., można jedynie stwierdzić, że CDC:
a) posiadało mechanizm i środki do przeprowadzenia testów potwierdzających istnienie “nowego koronawirusa”; lub
b) nie posiadało takiego mechanizmu i fałszywie ogłosiło taki komunikat w styczniu.
Naiwnością jest sugerować, że WHO lub CDC mogły wyprodukować i rozprowadzić testy na “nowy” patogen, kiedy ich własne późniejsze osiągnięcia w zakresie rozwoju i wdrażania testów okazały się niewiarygodne…

Zagrożenie pandemią i wycieki z laboratoriów: Samospełniające się przepowiednie – dr Martin Furmanski
Długa historia przypadkowych ucieczek laboratoryjnych potencjalnie pandemicznych patogenów jest ignorowana w reportażach na temat COVID-19 – Sam Husseini

 

35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego

 

35 U.S.C. §202 (c)(6)

Zobowiązanie wykonawcy, w przypadku złożenia wniosku patentowego w Stanach Zjednoczonych przez wykonawcę lub w jego imieniu, lub przez jakiegokolwiek cesjonariusza wykonawcy, do umieszczenia w specyfikacji takiego wniosku i każdego patentu wydanego na jego podstawie, oświadczenia określającego, że wynalazek został dokonany przy wsparciu rządu i że rząd posiada pewne prawa do wynalazku.

Ponad 5000 patentów i wniosków patentowych zawierało odniesienie do koronawirusa SARS sięgające dat pierwszeństwa z 1998 roku. Są one streszczone poniżej.

23 lipca 2020 roku Komisja Patentowa i Odwoławcza Biura Patentów i Znaków Towarowych Stanów Zjednoczonych odrzuciła starania firmy Moderna o unieważnienie patentu US 8058069. Patent ten, będący własnością Arbutus Biopharma Corp (należącej głównie do Roivant Science Ltd), obejmuje nanocząstki lipidowe (LNP) wymagane jako medium do dostarczenia mRNA w szczepionce. Niektóre z podstawowych technologii zostały oparte na pracach wykonanych pierwotnie na Uniwersytecie Kolumbii Brytyjskiej i zostały po raz pierwszy licencjonowane w 1998 roku.

Szczepionki mRNA na COVID-19 – dr James Odell

mRNA-1273 – eksperymentalna szczepionka opracowana przez Modernę na COVID-19 – wykorzystuje technologię nanocząstek lipidowych [LNP], na którą firma Moderna uważała że ma licencje od Acuitas Therapeutics Inc, firmy utworzonej przez byłego dyrektora wcześniejszej firmy Tekmira, należącej do Arbutusa. Ta licencja nie upoważniała firmy Moderna do wykorzystania tej technologii w szczepionce COVID-19.

Firmy M-CAM i Knowledge Ecology International niezależnie potwierdziły, że Moderna naruszyła prawo amerykańskie, nie ujawniając udziału rządu USA w finansowaniu swoich patentów i wniosków patentowych. Chociaż zaniedbanie to ma wpływ na wszystkie z ponad 130 przyznanych amerykańskich patentów firmy Moderna, jest ono szczególnie problematyczne w przypadku amerykańskiego patentu US 10702600 (Beta coronavirus mRNA vaccine), który jest patentem odnoszącym się do, “informacyjnego/matrycowego kwasu rybonukleinowego (mRNA) zawierającego otwartą ramkę odczytu kodującą białko kolca [S] lub podjednostkę białka S betakoronawirusa (BetaCoV), sformułowanego w nanocząstce lipidowej”.

Konkretne roszczenia odnoszące się do kluczowego elementu koronawirusa SARS zostały opatentowane 28 marca 2019 roku – 9 miesięcy przed wybuchem epidemii SARS CoV-2! Zarówno patent, jak i finansowanie DARPA dla tej technologii zostały ujawnione w publikacji naukowej (New England Journal of Medicine), ale fundusze rządowe nie zostały wspomniane w patencie.

W 2013 r. w ramach programu Autonomiczna Diagnostyka Umożliwiająca Profilaktykę i Terapię [Autonomous Diagnostics to Enable Prevention and Therapeutics – ADEPT] przyznano grant firmie Moderna Therapeutics na opracowanie nowego typu szczepionki opartej na informacyjnym RNA [mRNA]. Pierwotny grant DARPA nosił numer W911NF-13-1-0417. Firma wykorzystała tę technologię do opracowania swojej szczepionki na COVID-19, która w momencie opublikowania tego dossier przechodziła I fazę badań klinicznych we współpracy z NIH.29

Zgodnie z przepisami Federal Acquisition Regulation (FAR), kontrahenci rządu federalnego muszą w ramach kontraktu przedstawić informacje dotyczące kwestii naruszenia własności intelektualnej. Zgodnie z FAR §27.201-1(c) i (d) rząd wymaga zarówno zawiadomienia o naruszeniu lub potencjalnym naruszeniu, jak i zachowania odpowiedzialności ekonomicznej za naruszenie patentu. Konkretnie, w FAR §52.227.3 (a),

“Wykonawca zabezpieczy rząd i jego urzędników, agentów i pracowników przed odpowiedzialnością, w tym kosztami, za naruszenie jakiegokolwiek patentu Stanów Zjednoczonych…”. Oprócz patentów cytowanych przez USPTO podczas badań, które doprowadziły do patentu US 10702600, M-CAM zidentyfikowało czternaście innych wydanych patentów poprzedzających patent US 10702600, które zostały wykorzystane przez egzaminatorów patentowych do ograniczenia patentów wynikających z tych samych finansowanych badań, w tym patentów poszukiwanych przez CureVac.

Krótko mówiąc, podczas gdy Moderna cieszy się setkami milionów dolarów finansowania i wsparcia ze strony Anthony’ego Fauci i jego NIAID, od początku swego istnienia była zaangażowana w nielegalną działalność patentową i okazywała pogardę dla amerykańskiego prawa patentowego. Co gorsza, rząd Stanów Zjednoczonych udzielił firmie Moderna wsparcia finansowego w obliczu nieujawnionego ryzyka naruszenia prawa, potencjalnie przyczyniając się do tego samego naruszenia, za które otrzymali odszkodowanie.

 

21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne

 

Prowadzenie badań medycznych (nawet w nagłych przypadkach) jest niezgodne z prawem bez podjęcia szeregu kroków w celu:

1. Zorganizowania badań przez uprawnioną i instytucjonalną komisją rewizyjną;
2. Zapewnienia świadomej zgody wszystkim uczestnikom, w tym oświadczenia o ryzyku i korzyściach; oraz,
3. Zaangażowania się w konsultacje ze społecznością, w której badanie ma być przeprowadzone.

 

Dr Anthony Fauci wymusił na zdrowej populacji Stanów Zjednoczonych bezprawne badanie kliniczne, w którym amerykański Departament Zdrowia i Usług Społecznych [HHS] ekstrapoluje dane epidemiologiczne. Nie uzyskano ani nie zabezpieczono świadomej zgody na żaden z “medycznych środków zaradczych” narzuconych populacji i nie powołano żadnej niezależnej komisji rewizyjnej – zgodnie z definicją zawartą w ustawie.

Do kwietnia 2020 roku, oficjalne zalecenie Journal of the American Medical Association było jednoznaczne.

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.” – JAMA. 2020;323(15):1517-1518; MedicalMasks

Część tego braku dowodów w rzeczywistości wykazała, że płócienne maski na twarz w rzeczywistości zwiększyły liczbę zachorowań związanych z grypą.

Maski z tkanin: niebezpieczne dla twojego zdrowia? – prof. Raina MacIntyre [2015]

Wbrew ustaleniom naukowym, stany, hrabstwa i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas sytuacji zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że maski na twarz ograniczają rozprzestrzenianie się wirusa SARS CoV-2. Jak dotąd, żadne z badań nie potwierdziło, że maska zapobiega przenoszeniu lub zakażeniu się SARS CoV-2.

Wydychany aerozol i maski na twarz

Wszystkie strony nakazujące stosowanie masek na twarz nie tylko świadomie ignorują ugruntowaną wiedzę z badań empirycznych, ale angażują się w coś, co jest równoznaczne z badaniem klinicznym całej populacji. Do takiego wniosku prowadzi fakt, że stosowanie masek na twarz i zapadalność na COVID-19 są omawiane w artykułach medycznych [naukowych] promowanych przez Amerykańskie Centrum Kontroli i Prewencji Chorób i inne instytucje.

2 metry czy 20 metrów, dystans nie ma większego znaczenia dla Covid-19 – prof. Martin Bazant i prof. John Bush z MIT

Dystans społeczny do 2 metrów był promowany jako środek zapobiegający przenoszeniu się wirusów grypy z osoby na osobę. Chociaż w jednym z badań wysunięto hipotezę, że do zakażenia może dojść w odległości do około 2 metrów, w badaniu tym wyraźnie stwierdzono, że nie testowano przenoszenia się wirusa między osobami, a żywotność wirusa w odległości 2 metrów nie była nawet przedmiotem badania. Nie powstrzymało to jednak przeinaczenia wyników badania, które wykorzystano jako podstawę dla niezweryfikowanego medycznego środka zaradczego, jakim jest dystans społeczny. Do tej pory żadne badanie nie wykazało skuteczności dystansu społecznego w modyfikowaniu przenoszenia wirusa SARS CoV-2. Urzędnicy zdrowia publicznego powołują się na publikację J InfectDis. 2013 Apr;207(7):1037-46:

„Wyniki: Piętnaście badań, w tym 12 modelujących i trzy epidemiologiczne, spełniło kryteria kwalifikacji. Badania epidemiologiczne wykazały, że dystans społeczny był związany z redukcją zachorowań na choroby grypopodobne i serokonwersji na grypę A (H1N1) z 2009 roku. Jednak ogólne ryzyko błędu systematycznego w badaniach epidemiologicznych było poważne. W badaniach modelujących oszacowano, że same środki dystansu społecznego w miejscu pracy spowodowały medianę obniżenia o 23% skumulowanego wskaźnika zachorowań na grypę w populacji ogólnej. Opóźniły one również i zmniejszyły szczytową częstotliwość ataków grypy. Redukcja skumulowanego wskaźnika ataków była bardziej wyraźna, gdy dystans społeczny w miejscu pracy był połączony z innymi interwencjami niefarmakologicznymi lub farmaceutycznymi. Oceniono jednak, że skuteczność zmniejszała się wraz z wyższymi wartościami podstawowej liczby reprodukcyjnej, opóźnieniem uruchomienia dystansu społecznego w miejscu pracy lub mniejszą zgodnością.

Wnioski: Badania modelowe przemawiają za stosowaniem dystansu społecznego w miejscach pracy niezwiązanych z opieką zdrowotną, ale brakuje dobrze zaprojektowanych badań epidemiologicznych.” – BMC Public Health. 2018; 18: 518; Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review

Wbrew ustaleniom naukowym, państwa, powiaty i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że dystans społeczny zdrowej populacji ogranicza rozprzestrzenianie się SARS CoV-2. Jak dotąd, ani jedno badanie nie potwierdziło, że dystansowanie społeczne jakiejkolwiek populacji zapobiegło rozprzestrzenianiu się lub zakażeniu SARS CoV-2.

Zgodnie z ustawą o Federalnej Komisji Handlu [FTC Act], Rozdział 15, paragraf 41 Kodeksu Stanów Zjednoczonych [15 U.S.C. § 41] i następne, niezgodne z prawem jest reklamowanie, że produkt lub usługa może zapobiegać, leczyć lub uzdrawiać choroby ludzkie, chyba że posiada się kompetentne i wiarygodne dowody naukowe, w tym, w stosownych przypadkach, rzetelne kontrolowane badania kliniczne z udziałem ludzi, potwierdzające, że twierdzenia te są prawdziwe w chwili ich wygłaszania. W związku z tym, każda strona promująca stosowanie maseczek na twarz, narusza Ustawę o Federalnej Komisji Handlu.

Wszystkie te przepisy zostały złamane. Wszystkie właściwe władze w Stanach Zjednoczonych muszą zaprzestać stosowania masek na twarz do czasu skorygowania powyższych spraw.

 

Podmioty komercyjne

 

Dla wielu osób koronawirus SARS jest nowym tematem. Od 1999 roku możliwość manipulacji i wykorzystania koronawirusów do różnych celów przyciągnęło uwagę wielu osób, instytucji i organizacji komercyjnych, zarówno w sektorze publicznym, prywatnym jak i non-profit. Poniżej znajduje się lista ponad 5100 patentów i wniosków patentowych, zgłoszonych w wyraźnym celu kontrolowania jakiegoś aspektu koronawirusa SARS.

 

 

 

 

 

PATENT

Tytuł

Właściciel

Priorytet

Data złożenia

Data otrzymania

US9995706	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9995705	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9994558	Multicyclic compounds and methods of using same	Karyopharm Therapeutics Inc.	20- Sep- 13	19- Sep -14	12- Jun- 18
US9994550	Heterocyclic modulators of lipid synthesis for use against cancer and viral infections	3-V Biosciences, Inc.	7- Jan- 14	7- Jan -15	12- Jun- 18
US9993543	Immunogenic compositions comprising silicified virus and methods of use	Portland State University	31- Jan- 13	31- Jan -14	12- Jun- 18
US9982257	Chiral control	WAVE LIFE SCIENCES LTD.	13- Jul-12	12- Jul- 13	29- May -18
US9982241	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14- May- 10	1- Oct -15	29- May -18
US9982025	Monomeric griffithsin tandemers	The United States of America, as represented by the Secretary, Department of Health and Human Services	5- Jun- 13	5- Jun -14	29- May -18
US9981036	Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12- Dec- 11	26- Feb -16	29- May -18
US9975885	Broad-spectrum non-covalent coronavirus protease inhibitors	PURDUE RESEARCH FOUNDATION	28- Apr- 16	28- Apr -17	22- May -18
US9974850	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	25- Mar- 15	25- Mar -16	22- May -18
US9974848	Tetanus toxoid and CCL3 improve DC vaccines	Duke University	14- Nov- 13	14- Nov -14	22- May -18
US9974845	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22- Feb- 13	21- Feb -14	22- May -18
US9970061	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27- Dec- 11	27- Dec -12	15- May -18
US9969793	Compositions and methods for the treatment of immunodeficiency	ADMA Biologics, Inc.	28- Oct- 14	13- Nov -17	15- May -18
US9963718	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8- Oct- 08	7- Apr -17	8- May -18
US9963611	Composition for use in decreasing the transmission of human pathogens	Innonix Technologies, Incorporated	29- May- 09	21- May -10	8- May -18
US9963427	Dithiol mucolytic agents	PARION SCIENCES, INC.	23- Aug- 13	11- Mar -16	8- May -18
US9962439	Injectable vaccine composition	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	8- May -18
US9957302	Treating cancer with viral nucleic acid	Mayo Foundation for Medical Education and Research	20- Feb- 07	6- Jul- 15	1- May -18
US9957300	Virus-like particles, methods of preparation, and immunogenic compositions	Emory University	17- May- 02	4- May -15	1- May -18
US9957238	Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	1- Mar -17	1- May -18
US9951317	Highly efficient influenza matrix (M1) proteins	NOVAVAX, INC.	11- Jul-03	6- Oct -16	24- Apr- 18

 

US9951124	Antibody producing non-human mammals	MERUS N.V.	27- Jun- 08	25- Jan -13	24- Apr- 18
US9951122	Antibodies against influenza virus and methods of use thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6- Dec- 07	12- Aug -13	24- Apr- 18
US9950062	Compounds and compositions as TLR activity modulators	GLAXOSMITHKLINE BIOLOGICALS SA	2- Sep- 09	1- Sep -10	24- Apr- 18
US9945856	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.	18- Aug- 03	13- Aug -14	17- Apr- 18
US9945780	Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer	GEN-PROBE INCORPORATED	14- Jun- 12	7- Jun -13	17- Apr- 18
US9944928	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions	York Yuan Yuan Zhu	23- Jul-07	2- Jul- 15	17- Apr- 18
US9944695	Antibody producing non-human mammals	Menus N.V.	27- Jun- 08	30- Apr -14	17- Apr- 18
US9944686	Treatment of tumors with recombinant interferon alpha	SUPERLAB FAR EAST LIMITED	28- Feb- 01	5- Sep -13	17- Apr- 18
US9944649	Compounds and compositions as toll-like receptor 7 agonists	Novartis Ag	1- May- 14	29- Apr -15	17- Apr- 18
US9943614	Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods	BRIGHAM YOUNG UNIVERSITY	17- Jun- 08	16- Jun -09	17- Apr- 18
US9938300	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	10- Apr- 18
US9938275	Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	23- Jan -17	10- Apr- 18
US9938258	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof	Karyopharm Therapeutics Inc.	29- Nov- 12	27- Nov -13	10- Apr- 18
US9932351	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	3- Apr- 18
US9932323	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11- Sep- 12	13- Jan -17	3- Apr- 18
US9931316	Antiviral activity from medicinal mushrooms and their active constituents	Not Available	31- Mar- 15	14- Sep -15	3- Apr- 18
US9926340	NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants	Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH	8- Apr- 15	1- Apr -16	27- Mar -18
US9925215	Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative	UNIWERSYTET JAGIELLONSKI	29- Jul-14	25- Oct -17	27- Mar -18
US9920314	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21- Feb- 06	6- May -15	20- Mar -18
US9920128	Synthetic antiserum for rapid-turnaround therapies	The Johns Hopkins University	28- Jan- 15	20- Jan -16	20- Mar -18
US9919034	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V	TAMIR BIOTECHNOLOGY, INC.	28- Mar- 14	10- Jun -15	20- Mar -18
US9915613	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	GEN-PROBE INCORPORATED	24- Feb- 11	21- Mar -14	13- Mar -18
US9914976	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA	25- Mar- 11	27- May -16	13- Mar -18
US9913801	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione	YOUR ENERGY SYSTEMS, LLC	15- Feb- 13	15- Mar -13	13- Mar -18
US9909176	Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)	The Johns Hopkins University	8- Sep- 14	1- Sep -15	6- Mar -18
US9908946	Generation of binding molecules	Merus N.V.	26- Sep- 11	16- Sep -15	6- Mar -18
US9908675	Powdered pouch and method of making same	MONOSOL, LLC	16- Apr- 12	19- Jul- 16	6- Mar -18

 

US9907796	Methods of treating tumoral diseases, or bacterial or viral infections	INHIBIKASE THERAPEUTICS, INC.	4- Oct- 12	15- Sep -16	6- Mar -18
US9895692	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29- Jan- 10	5- Aug -15	20- Feb -18
US9895411	Analogs of C5a and methods of using same	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	29- Jun- 10	29- Jun -11	20- Feb -18
US9895341	Inflammation and immunity treatments	Ocean Spray Cranberries, Inc.	1- Apr- 11	30- Mar -12	20- Feb -18
US9894888	Transgenic immunodeficient mouse expressing human SIRP-alpha	INSTITUT PASTEUR	26- Mar- 12	26- Mar -13	20- Feb -18
US9890419	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23- Dec- 05	20- May -16	13- Feb -18
US9890408	Multiple displacement amplification	IBIS BIOSCIENCES, INC.	15- Oct- 09	15- Oct -10	13- Feb -18
US9890362	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5- Dec- 08	19- Sep -14	13- Feb -18

US9890361 Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids LIFE TECHNOLOGIES CORPORATION

26-Jan-12
25-Jan-13
13-Feb-18

US9890206 H1N1 flu virus neutralizing antibodies Medigen Biotechnology Corporation
20-Aug-15
20-Aug-15
13-Feb-18

US9890169 Triazolinone compounds as HNE inhibitors CHIESI FARMACEUTICI S.P.A.
14-Dec-15
12-Dec-16
13-Feb-18
US9890124 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc.
15-Dec-15
14-Jun-17
13-Feb-18
US9889194 Immunogenic composition for MERS coronavirus infection New York Blood Center, Inc.
1-Mar-13
28-Feb-14
13-Feb-18
US9885092 Materials and methods for detection of HPV nucleic acids QIAGEN GAITHERSBURG INC.
24-Feb-11
23-Feb-12

6-Feb-18
US9885082 Embodiments of a probe and method for targeting nucleic acids University of Idaho
19-Jul-11
19-Jul-12
6-Feb-18
US9885037 Chiral control WAVE LIFE SCIENCES LTD.
13-Jul-12
12-Jul-13
6-Feb-18
US9884895 Methods and compositions for chimeric coronavirus spike proteins The University of North Carolina at Chapel Hill
20-Mar-14
20-Mar-15
6-Feb-18
US9884876 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Kineta, Inc.
9-May-14
8-May-15
6-Feb-18
US9884129 Release of agents from cells The Brigham and Women’s Hospital, Inc.
15-Oct-09
5-Jan-15
6-Feb-18
US9884032 Esters of short chains fatty acids for use in the treatment of immunogenic disorders PROPONENT BIOTECH GMBH
3-Oct-12
3-Mar-16
6-Feb-18

US9884026 Modular particles for immunotherapy YALE UNIVERSITY

1-Nov-13
31-Oct-14
6-Feb-18
US9880151 Method of determining, identifying or isolating cell-penetrating peptides Phylogica Limited
23-May-11
23-May-12
30-Jan-18

US9879026 Substituted spirocycles Boehringer Ingelheim International GmbH
12-Sep-14
29-Nov-16
30-Jan-18
US9879003 Host targeted inhibitors of dengue virus and other viruses Dana-Farber Cancer Institute, Inc.
11-Apr-12
15-Mar-13
30-Jan-18
US9878988 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC.
29-May-12
5-Jan-16
30-Jan-18
US9873678 Chemical compounds AstraZeneca AB
18-Mar-14
17-Mar-15
23-Jan-18
US9873674 C-Rel inhibitors and uses thereof CORNELL UNIVERSITY

21-Sep-12
19-Sep-13
23-Jan-18
US9872900 Nucleic acid vaccines ModernaTX, Inc.
23-Apr-14
5-Apr-16
23-Jan-18
US9872898 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome Ohio State Innovation Founation
24-Apr-12
3-Oct-16
23-Jan-18
US9872895 TLR5 ligands, therapeutic methods, and compositions related thereto Emory University
24-Sep-10
20-Sep-11
23-Jan-18

 

US9868952	Compositions and methods for âCœresistance-proofâC SiRNA therapeutics for influenza	Sirnaomics, Inc.	8-Jul- 12	7- Jul- 13	16- Jan- 18
US9868740	Pyrimidinone compounds which are HNE inhibitors	CHIESI FARMACEUTICI S.p.A.	12- Jun- 14	12- Jun -14	16- Jan- 18
US9868736	Deubiquitinase inhibitors and methods for use of the same	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	10- Oct- 13	10- Oct -14	16- Jan- 18
US9867882	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	25- Aug -15	16- Jan- 18
US9867877	Methods for preparing squalene	NOVARTIS AG	12- May- 10	22- Nov -16	16- Jan- 18
US9862706	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	9- Jan- 18
US9861614	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	23- Jun -15	9- Jan- 18
US9856254	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	13- Jun -16	2- Jan- 18
US9856241	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul- 13	3- Jul- 14	2- Jan- 18
US9856228	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	PROZYMEX A/S	9- Sep- 13	8- Sep -14	2- Jan- 18
US9856224	Stable sodium channel blockers	PARION SCIENCES, INC.	30- Jun- 14	30- Jan -17	2- Jan- 18
US9855287	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28- Jul-10	20- Aug -15	2- Jan- 18
US9855284	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3- Aug- 15	6- Dec -16	2- Jan- 18
US9849143	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17- Apr- 06	16- Feb -17	26- Dec -17
US9845342	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria	Spogen Biotech Inc.	17- Sep- 14	17- Sep -15	19- Dec -17
US9840731	Preservation of biological materials in non-aqueous fluid media	Gentegra, LLC	14- Mar- 13	14- Mar -14	12- Dec -17
US9840719	Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues	The Children’s Hospital of Philadelphia	22- Jul-13	22- Jul- 14	12- Dec -17
US9840491	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5- Feb- 15	4- Feb -16	12- Dec -17
US9839687	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	15- Jul- 15	12- Dec -17
US9834812	Probe kit for detecting a single strand target nucleotide sequence	Fondazione Istituto Italiano Di Tecnologia	27- Dec- 12	27- Dec -13	5- Dec -17
US9834791	CRISPR-related methods and compositions with governing gRNAS	Editas Medicine, Inc.	7- Nov- 13	7- Nov -14	5- Dec -17
US9834757	Hand, foot, and mouth vaccines and methods of manufacture and use thereof	Takeda Vaccines, Inc.	7- Nov- 14	6- Nov -15	5- Dec -17
US9834595	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5- Jun- 08	29- Oct -15	5- Dec -17
US9833504	Virus-like particles and process for preparing same	Folia Biotech Inc.	13- May- 11	1- May -12	5- Dec -17
US9833492	Combinations of a caspase inhibitor and an antiviral agent	Centre National de la Recherche Scientifique	2- Nov- 07	15- May -15	5- Dec -17
US9832998	Antiviral compositions	Long Island University	30- May- 07	19- Mar -15	5- Dec -17
US9828382	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18- Dec- 12	10- May -16	28- Nov -17
US9828379	Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof	ABIDE THERAPEUTICS, INC.	3-Jul- 13	1- Jul- 14	28- Nov -17
US9828370	Compositions and methods for inhibiting kinases	INHIBIKASE THERAPEUTICS, INC.	23- Apr- 15	22- Apr -16	28- Nov -17
US9828346	N-myristoyl transferase inhibitors	University of Dundee	2- Sep- 08	31- Aug -15	28- Nov -17

 

US9828342	Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof	CITY OF HOPE	24- Feb- 12	25- Feb -13	28- Nov -17
US9827190	Intradermal delivery of immunological compositions comprising toll­like receptor 7 agonists	GLAXOSMITHKLINE BIOLOGICALS SA	1- Feb- 13	30- Jan -14	28- Nov -17
US9822339	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9- Dec- 05	26- Aug -15	21- Nov -17
US9822173	Heterodimeric immunoglobulins	AMGEN INC.	21- Nov- 12	21- Nov -13	21- Nov -17
US9822165	Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region	DANA-FARBER CANCER INSTITUTE, INC.	18- Jun- 09	18- Jun -10	21- Nov -17
US9822155	Method of preventively treating a subject at the risk of developing infections of a respiratory virus	Xiangxue Group (Hong Kong) Company Limited	9- May- 13	23- Aug -16	21- Nov -17
US9822127	GAK modulators as antivirals	The Board of Trustees of the Leland Stanford Junior University	23- Jul-14	23- Jul- 15	21- Nov -17
US9822065	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	14- Feb -17	21- Nov -17
US9821052	Reverse genetics systems	Seqirus UK Limited	31- Jul-09	30- Jul- 10	21- Nov -17
US9821051	Reducing hospitalization in elderly influenza vaccine recipients	Seqirus UK Limited	28- Oct- 10	21- Oct -11	21- Nov -17
US9816078	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OAre	19- Nov- 09	11- Mar -16	14- Nov -17
US9815886	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	8- Jan -15	14- Nov -17
US9815805	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24- Jan- 14	8- Nov -16	14- Nov -17
US9814777	Targeting lipids	Arbutus Biopharma Corporation	4- Dec- 07	22- Oct -13	14- Nov -17
US9810683	Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells	The Regents of the University of California	6- May- 09	25- Nov -13	7- Nov -17
US9809845	Methods and reagents for amplifying nucleic acids	The United States of America, as represented by the Secretary, Department of Health and Human Services	6- Aug- 12	6- Aug -12	7- Nov -17
US9809796	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	18- May -17	7- Nov -17
US9809632	Universal protein tag for double stranded nucleic acid delivery	University of Washington Through its Center for Commercialization	23- Oct- 13	22- Oct -14	7- Nov -17
US9809591	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	5- Oct -15	7- Nov -17
US9808490	Induced hepatocytes and uses thereof	ACCELERATED BIOSCIENCES CORP.	26- Nov- 14	25- Nov -15	7- Nov -17
US9803236	Microarray-based assay integrated with particles for analyzing molecular interactions	CapitalBio Corporation	6- Aug- 10	6- Aug -10	31- Oct- 17
US9803197	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25- Jun- 12	27- Feb -13	31- Oct- 17
US9802937	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors	ORIGENIS GMBH	21- Apr- 11	23- Apr -12	31- Oct- 17
US9802919	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	31- Oct- 17
US9801948	Antimicrobial compositions and methods of use thereof	Yale University	21- Sep- 11	21- Sep -12	31- Oct- 17
US9801947	Methods and compositions for enhancing immune response	3M INNOVATIVE PROPERTIES COMPANY	10- Apr- 03	6- Oct -14	31- Oct- 17
US9801935	Soluble needle arrays for delivery of influenza vaccines	SEQIRUS UK LIMITED	20- Aug- 10	11- Oct -16	31- Oct- 17
US9801897	Delivery of RNA to trigger multiple immune pathways	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	6- Jul- 11	31- Oct- 17
US9797000	Non-target amplification method for detection of RNA splice-forms in a sample	QIAGEN GAITHERSBURG INC.	1- May- 09	30- Apr -10	24- Oct- 17
US9796979	Oligonucleotide modulators of the toll-like receptor pathway	Quark Pharmaceuticals Inc.	3- Mar- 11	28- Jul- 16	24- Oct- 17

 

US9796735	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20- Jun- 07	7- Nov -14	24- Oct- 17
US9795669	Lipidated immune response modifier compound compositions, formulations, and methods	3M INNOVATIVE PROPERTIES COMPANY	17- Aug- 10	15- Dec -15	24- Oct- 17
US9795668	Delivery of self-replicating RNA using biodegradable polymer particles	GlaxoSmithKline Biologicals S.A.	6-Jul- 10	23- Nov -15	24- Oct- 17
US9795666	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5- Sep- 06	11- Feb -15	24- Oct- 17
US9791437	Multianalyte assay	Nexus Dx, Inc.	30- Apr- 07	15- Jun -15	17- Oct- 17
US9789180	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30- Nov- 12	31- Mar -16	17- Oct- 17
US9786050	Stain-free histopathology by chemical imaging	The Board of Trustees of the University of Illinois	15- Mar- 13	14- Mar -14	10- Oct- 17
US9783595	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7- Nov- 11	2- Aug -16	10- Oct- 17
US9782470	Method of obtaining thermostable dried vaccine formulations	Merck Sharp & Dohme Corp.	16- Oct- 13	13- Oct -14	10- Oct- 17
US9782434	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Sonoma Pharmaceuticals, Inc.	20- Jan- 06	7- Jul- 15	10- Oct- 17
US9770504	Generating peptoid vaccines	The Board of Regents of the University of Texas System	3- May- 13	2- May -14	26- Sep -17
US9770463	Delivery of RNA to different cell types	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	7- Jun -11	26- Sep -17
US9765395	System and method for DNA sequencing and blood chemistry analysis	Nanomedical Diagnostics, Inc.	28- Apr- 14	10- Apr -15	19- Sep -17
US9765133	Antibody producing non-human mammals	Merus N.V.	27- Jun- 08	29- Apr -14	19- Sep -17
US9765071	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25- Nov- 03	14- Mar -16	19- Sep -17
US9764027	Outer membrane vesicles	GLAXOSMITHKLINE BIOLOGICALS SA	18- Sep- 12	18- Sep -13	19- Sep -17
US9759723	B-cell antigen presenting cell assay	University of Pittsburgha€”Of the Commonwealth System of Higher Education	8- Apr- 10	21- Mar -16	12- Sep -17
US9758840	Parasite detection via endosymbiont detection	IBIS BIOSCIENCES, INC.	14- Mar- 10	11- Mar -11	12- Sep -17
US9758820	Organism identification panel	BioFire Diagnostics, LLC	2- Apr- 07	1- Apr -08	12- Sep -17
US9758775	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	14- Apr -14	12- Sep -17
US9758568	Oligopeptide-free cell culture media	Baxalta GmbH	4- Jan- 06	16- Nov -15	12- Sep -17
US9758553	Yeast strain for the production of proteins with terminal alpha-1,3- linked galactose	MERCK SHARP & DOHME CORP.	30- May- 08	2- Jul- 14	12- Sep -17
US9757478	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11- May- 10	7- Jan -16	12- Sep -17
US9757470	Peptides for assisting delivery across the blood brain barrier	Children’s Medical Center Corporation	22- May- 06	30- Apr -14	12- Sep -17
US9757446	Influenza virus vectors and uses therefor	FLUGEN, INC.	17- Mar- 14	13- Mar -15	12- Sep -17
US9757407	T reatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1- Jun- 07	21- Dec -15	12- Sep -17
US9751945	Sortase-modified VHH domains and uses thereof	Whitehead Institute for Biomedical Research	13- Apr- 12	15- Apr -13	5- Sep -17
US9750798	Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses	STICHTING WAGENINGEN RESEARCH	21- May- 13	21- May -14	5- Sep -17
US9750797	Sustained release vaccine composition	VIRBAC CORPORATION	16- Jun- 04	16- Jun -05	5- Sep -17
US9750690	Circulation of components during microfluidization and/or homogenization of emulsions	NOVARTIS AG	3- Dec- 09	5- Sep -14	5- Sep -17

 

US9746985	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25- Feb- 08	20- Apr -11	29- Aug -17
US9746459	Antigen presenting cell assay	University of Pittsburgha€”Of the Commonwealth System of Higher Education	8- Apr- 10	11- Oct -13	29- Aug -17
US9745306	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors	Respivert Li mited	15- Mar- 13	14- Mar -14	29- Aug -17
US9744231	Quality control methods for oil-in-water emulsions containing squalene	NOVARTIS AG	8- Nov- 06	27- Aug -13	29- Aug -17
US9744229	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4- Apr- 08	28- Apr -14	29- Aug -17
US9744183	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD.	6-Jul- 09	6- Jul- 10	29- Aug -17
US9738894	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21- Mar- 03	28- Mar -16	22- Aug -17
US9738624	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	21- Jun- 13	20- Jun -14	22- Aug -17
US9737618	Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30- Sep- 03	20- Jul- 15	22- Aug -17
US9737593	Carbon nanotube compositions and methods of use thereof	Yale University	19- Mar- 08	15- Mar -13	22- Aug -17
US9730997	Alphavirus vectors for respiratory pathogen vaccines	Novartis Vaccines and Diagnostics, Inc.	21- May- 04	20- Aug -14	15- Aug -17
US9730912	Pharmaceutical compounds	ASTEX THERAPEUTICS LIMITED	12- Oct- 06	12- Oct -07	15- Aug -17
US9727810	Spatially addressable molecular barcoding	Cellular Research, Inc.	27- Feb- 15	26- Feb -16	8- Aug -17
US9726607	Systems and methods for detecting multiple optical signals	GEN-PROBE INCORPORATED	10- Mar- 05	3- Mar -14	8- Aug -17
US9725770	Methods and compositions for identification of source of microbial contamination in a sample	The Regents of the University of California	6- Mar- 12	6- Mar -13	8- Aug -17
US9725487	Compositions and methods for measles virus inhibition	Autoimmune Technologies, LLC	4- Nov- 03	13- May -15	8- Aug -17
US9719106	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof	The Trustees of the University of Pennsylvania	29- Apr- 13	29- Apr -14	1- Aug -17
US9719083	Bioagent detection methods	IBIS BIOSCIENCES, INC.	8- Mar- 09	8- Mar -10	1- Aug -17
US9718774	Indole carboxamide derivatives as P2X7 receptor antagonist	IDORSIA PHARMACEUTICALS LTD	12- Dec- 12	11- Dec -13	1- Aug -17
US9717755	Method of treating inflammation	Cytosorbents Corporation	1- Apr- 10	1- Apr -11	1- Aug -17
US9717749	Production of stable non-polyadenylated RNAs	Massachusetts Institute of Technology	16- Oct- 12	16- Oct -13	1- Aug -17
US9717732	Drug combination	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	1- Aug -17
US9714411	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	30- Nov -15	25- Jul- 17
US9714283	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	2- Jul- 15	25- Jul- 17
US9714226	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	13- Nov -15	25- Jul- 17
US9713641	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	13- Feb- 17	13- Feb -17	25- Jul- 17
US9713606	Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	1- Dec -15	25- Jul- 17
US9708375	Inhibitory polypeptides specific to WNT inhibitors	Amgen Inc.	15- Mar- 13	14- Mar -14	18- Jul- 17
US9707278	Methods of modulating immune responses by modifying Akt3 bioactivity	Augusta University Research Institute, Inc.	17- Apr- 14	17- Apr -15	18- Jul- 17

 

US9701736	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20- Oct- 10	9- Oct -14	11- Jul- 17
US9701638	Therapeutic hydroxyquinolones	Rutgers, The State University of New Jersey	9- Nov- 12	8- Nov -13	11- Jul- 17
US9700616	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3- Dec- 09	22- Mar -16	11- Jul- 17
US9700614	Intranasal vaccination dosage regimen	Eurocine Vaccines AB	17- Dec- 12	17- Dec -13	11- Jul- 17
US9700558	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	11- Jul- 17
US9696247	Sample fixation and stabilization	RNASSIST LTD.	1- Mar- 13	28- Feb -14	4- Jul- 17
US9695445	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	ID Pharma Co., Ltd.	16- Jul-08	29- Jul- 15	4- Jul- 17
US9695135	Therapeutic catechols	Rutgers, The State University of New Jersey	12- May- 14	11- May -15	4- Jul- 17
US9695134	3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compounds	Parion Sciences, Inc.	17- Dec- 12	8- Jan -15	4- Jul- 17
US9689018	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	24- Apr- 98	4- Aug -14	27- Jun- 17
US9688982	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	11- Oct -13	27- Jun- 17
US9687536	Methods and compositions for intranasal delivery	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	15- Apr- 10	15- Apr -11	27- Jun- 17
US9683256	Biological specimen collection and transport system	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	15- Dec -15	20- Jun- 17
US9683017	Inhibitory peptides of viral infection	UNIVERSITY TENNESSEE RESEARCH FOUNDATION	17- Jul-14	16- Jul- 15	20- Jun- 17
US9682133	Disrupted adenovirus-based vaccine against drugs of abuse	CORNELL UNIVERSITY	17- Mar- 10	17- Mar -11	20- Jun- 17
US9677089	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	30- Mar -16	13- Jun- 17
US9676867	Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody	Dana-Farber Cancer Institute Inc.	2- Dec- 05	8- May -13	13- Jun- 17
US9676857	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human Services	16- Mar- 12	14- Mar -13	13- Jun- 17
US9676727	Myxovirus therapeutics, compounds, and uses related thereto	Children’s Healthcare of Atlanta, Inc.	24- Oct- 11	7- Jul- 16	13- Jun- 17
US9675550	Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26- Jul-10	25- Jan -13	13- Jun- 17
US9670507	Directed evolution and in vivo panning of virus vectors	The University of North Carolina at Chapel Hill	CO 1 1	28- Jun -16	6- Jun- 17
US9670166	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6- Feb- 13	5- Aug -16	6- Jun- 17
US9669092	Antagonism of the VIP signaling pathway	Emory University	2- Feb- 11	31- Jan -12	6- Jun- 17
US9669089	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	CureVac AG	15- Feb- 12	15- Feb -13	6- Jun- 17
US9669088	Vaccination with multiple clades of H5 influenza A virus	Seqirus UK Limited	26- Nov- 07	25- Nov -08	6- Jun- 17
US9661856	Synergy of plant antimicrobials with silver	The Arizona Board of Regents on Behalf of The University of Arizona	24- Aug- 12	26- Aug -13	30- May -17
US9657278	Methods to produce bunyavirus replicon particles	Stichting Dienst Landbouwkundig Onderzoek	20- Sep- 10	10- Jul- 15	23- May -17
US9657076	GM-CSF and IL-4 conjugates, compositions, and methods related thereto	Children’s Healthcare of Atlanta, Inc.	23- Oct- 12	23- Oct -13	23- May -17
US9657048	Enantiomers of the 1a€2,6a€2-isomer of neplanocin A	Auburn University	4- Aug- 14	4- Aug -15	23- May -17

 

US9657015	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	23- May -17
US9655896	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27- Jun- 11	12- Jan -15	23- May -17
US9655845	Oil-in-water emulsions that contain nucleic acids	GlaxoSmithKline Biologicals, S.A.	6-Jul- 11	6- Jul- 12	23- May -17
US9655367	Disinfecting composition and wipes with reduced contact time	LONZA, INC.	6- Nov- 13	4- Nov -14	23- May -17
US9651543	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31- Aug- 05	19- Apr -13	16- May -17
US9650685	Selective detection of human rhinovirus	The United States of America, as represented by the Secretary, Department of Health and Human Services	5- Dec- 08	15- Dec -14	16- May -17
US9650649	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8- Oct- 08	8- Oct -09	16- May -17
US9649324	Use of tylvalosin as antiviral agent	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES	13- Jul-06	8- Jun -15	16- May -17
US9649309	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	16- May -17
US9644180	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18- Nov- 13	12- Jun -15	9- May -17
US9642876	Method of preventing or treating sinusitis with oxidative reductive potential water solution	SONOMA PHARMACEUTICALS, INC.	30- Dec- 03	27- Oct -15	9- May -17
US9642873	Combinations of TGFÎ2 and COX-2 inhibitors and methods for their therapeutic application	Sirnaomics, Inc.	4- May- 10	4- May -11	9- May -17
US9637524	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27- Feb- 09	5- Nov -14	2- May -17
US9637491	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors	ORIGENIS GMBH	19- Oct- 12	18- Oct -13	2- May -17
US9636410	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 11	6- Jul- 12	2- May -17
US9636397	Adjuvant compositions and related methods	Vaxliant, LLC	24- Mar- 15	24- Mar -16	2- May -17
US9636370	AAV vectors targeted to oligodendrocytes	The University of North Carolina at Chapel Hill	28- Sep- 12	27- Sep -13	2- May -17
US9629907	Compositions for and methods of inducing mucosal immune responses	The Trustees of the University of Pennsylvania	19- Nov- 04	28- Oct -11	25- Apr- 17
US9624173	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	19- Mar -15	18- Apr- 17
US9623040	Immunomodulation by controlling expression levels of microRNAs in dendritic cells	The Board of Trustees of the Leland Stanford Junior University	14- Jul-14	10- Jul- 15	18- Apr- 17
US9618508	Flow cytometry analysis of materials adsorbed to metal salts	GlaxoSmithKline Biologicals SA	14- Dec- 10	14- Dec -11	11- Apr- 17
US9618476	System and method for electronic biological sample analysis	NANOMEDICAL DIAGNOSTICS, INC.	28- Apr- 14	28- Apr -14	11- Apr- 17
US9618429	Polymer stabilization of chromogen solutions	Ventana Medical Systems, Inc.	23- Jan- 12	18- Jan -13	11- Apr- 17
US9611481	Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof	UNIVERSITE DE MONTPELLIER	24- Sep- 09	23- Sep -10	4- Apr- 17
US9611474	Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof	QUARK PHARMACEUTICALS, INC.	12- Sep- 12	12- Sep -13	4- Apr- 17
US9605276	Replication defective adenovirus vector in vaccination	Etubics Corporation	24- Aug- 12	15- Mar -13	28- Mar -17
US9603864	Substituted nucleosides, nucleotides and analogs thereof	Alios BioPharma, Inc.	24- Jun- 14	22- Jun -15	28- Mar -17
US9603850	MerTK-specific pyrazolopyrimidine compounds	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	28- Mar -17
US9599606	ADP-ribose detection reagents	The Board of Regents of the University of Texas System	10- Jun- 14	9- Jun -15	21- Mar -17
US9598459	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3- Aug- 15	28- Jul- 16	21- Mar -17

 

US9597333	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	28- Sep -16	21- Mar -17
US9593334	Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagy	University of Pittsburgh—Of the Commonwealth System of Higher Education	7- Mar- 12	6- Mar -13	14- Mar -17
US9593331	Double-stranded nucleic acid molecule for gene expression control	Osaka City University	2- Nov- 11	1- Nov -12	14- Mar -17
US9593084	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity	Parion Sciences, Inc.	17- Dec- 12	13- Dec -13	14- Mar -17
US9592284	Immunization regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost	The Trustees of the University of Pennsylvania	28- Apr- 04	27- Apr -05	14- Mar -17
US9592277	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases	Avirid, Inc.	14- Apr- 04	14- Apr -05	14- Mar -17
US9588069	Methods for performing thermal melt analysis	GEN-PROBE INCORPORATED	31- Jul-12	31- Jul- 13	7- Mar -17
US9587250	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	Trustees of the University of Pennsylvania	17- Dec- 01	16- Jan -15	7- Mar -17
US9586998	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9- Nov- 09	4- Aug -15	7- Mar -17
US9586911	Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	19- Dec -14	7- Mar -17
US9586910	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide	Parion Sciences, Inc.	27- Jun- 11	18- Dec -13	7- Mar -17
US9585968	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	14- Aug -15	7- Mar -17
US9585953	Immunogenic compositions in particulate form and methods for producing the same	MUCOSIS B.V.	22- Mar- 11	22- Mar -12	7- Mar -17
US9585874	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	6- Jan -16	7- Mar -17
US9585849	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17- Apr- 06	17- Apr -07	7- Mar -17
US9580474	Polyionic papilloma virus-like particle (VLP) vaccines	THE JOHNS HOPKINS UNIVERSITY	8- Sep- 10	8- Sep -11	28- Feb -17
US9580468	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRE DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN)	13- Jan- 11	13- Jan -12	28- Feb -17
US9580429	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6- Dec- 04	15- Sep -14	28- Feb -17
US9574189	Enzymatic encoding methods for efficient synthesis of large libraries	Nuevolution A/S	1- Dec- 05	1- Dec -06	21- Feb -17
US9574181	Influenza virus reassortment method	Seqirus UK Limited	21- May- 10	24- Oct -14	21- Feb -17
US9573955	Compounds	Chiese Farmaceutici S.p.A.	16- Dec- 13	16- Dec -14	21- Feb -17
US9573938	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11- Sep- 12	11- Sep -13	21- Feb -17
US9572899	Compositions for enhancing transport of molecules into cells	AVI BIOPHARMA, INC.	29- Apr- 03	5- Nov -08	21- Feb -17
US9572864	Compositions and uses of lectins	Emory University	12- Feb- 10	11- Dec -15	21- Feb -17
US9572823	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	5- Apr -16	21- Feb -17
US9567336	Conjugated TLR7 and/or TLR8 and TLR2 agonists	INVIVOGEN	19- Nov- 12	15- Mar -13	14- Feb -17
US9566326	Adjuvanted influenza vaccines for pediatric use	Seqirus UK Limited	22- Feb- 08	21- Jun -13	14- Feb -17
US9566291	Nutritional composition comprising indigestible oligosaccharides	N.V. Nutricia	24- Aug- 04	24- Aug -05	14- Feb -17
US9566290	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	20- Apr -16	14- Feb -17

 

US9566289	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	17- Feb -16	14- Feb -17
US9565857	Antimicrobial solutions	Board of Regents, The University of Texas System	10- Sep- 10	9- Sep -11	14- Feb -17
US9562110	Bispecific antibody	Wuhan YZY Biopharma Co., Ltd.	21- Nov- 12	21- Nov -12	7- Feb -17
US9561263	Treatment of inflammatory illnesses with ACE2	Apeiron Biologics AG	18- Dec- 07	18- Dec -08	7- Feb -17
US9556237	Antiviral rift valley fever virus peptides and methods of use	The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases	6- Dec- 12	4- Jun -15	31- Jan- 17
US9556229	Modification of peptides using a bis(thioether)arylbridge approach	The Regents of the University of California	18- May- 12	17- May -13	31- Jan- 17
US9556184	Phosphoinositide 3-kinase inhibitors	Respivert, Ltd.	15- Mar- 13	4- Dec -15	31- Jan- 17
US9556117	Indole carboxamide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	18- Dec- 12	17- Dec -13	31- Jan- 17
US9555031	Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	31- Jan- 17
US9555030	Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	31- Jan- 17
US9550773	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	13- Apr -15	24- Jan- 17
US9550757	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	5- Mar- 10	28- Jun -13	24- Jan- 17
US9549949	Antiviral agent	NBC MESHTEC, INC.	3- Sep- 08	31- Aug -09	24- Jan- 17
US9549938	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	11- Mar -16	24- Jan- 17
US9546371	Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	18- Mar- 08	18- Mar -09	17- Jan- 17
US9546184	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	13- Aug- 08	8- Jun -15	17- Jan- 17
US9546150	Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7	HYBRIGENICS SA	2- Sep- 11	29- Aug -12	17- Jan- 17
US9545440	Methods for preparing squalene	NOVARTIS AG	12- May- 10	23- Oct -15	17- Jan- 17
US9540373	Substituted spirocycles	Boehringer Ingelheim International GmbH	12- Sep- 14	10- Sep -15	10- Jan- 17
US9539321	HMGBl-derived peptides enhance immune response to antigens	The Regents of the University of California	27- Jul-10	9- Mar -15	10- Jan- 17
US9539217	Nanoparticle compositions	Allertein Therapeutics, LLC	3- Apr- 13	3- Apr -14	10- Jan- 17
US9533978	Pyrimidine derivatives and their use in the treatment of cancer and further diseases	Sumitomo Dainippon Pharma Co., Ltd	21- May- 09	26- Aug -14	3- Jan- 17
US9533037	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes	Declion Holdings LLC	16- Oct- 07	16- Oct -08	3- Jan- 17
US9529974	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25- Feb- 08	27- Jul- 11	27- Dec -16
US9527903	Engineered antibody constant domain molecules	The United States of America, as represent by the Secretary, Department of Health and Human Services	31- Jan- 08	1- Oct -13	27- Dec -16
US9526803	Diagnostic chewing gum for pathogens	Julius-Maximilians-Universitaet Wuerzburg	8- Mar- 12	8- Mar -13	27- Dec -16
US9526700	Composition for inactivating an enveloped virus	VIROBLOCK SA	19- May- 06	17- Nov -14	27- Dec -16
US9522962	Peptides, conjugates and method for increasing immunogenicity of a vaccine	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	15- Mar- 10	15- Mar -11	20- Dec -16
US9522894	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors	AstraZeneca AB	24- Jan- 14	21- Jan -15	20- Dec -16

 

US9522171	EV576 for use in the treatment of viral infections of the respiratory tra ct	Volution Immuno Pharmaceuticals SA	8- Jan- 10	2- Jan -15	20- Dec -16
US9518093	Topical formulation of arginine-rich cyclic antimicrobial peptides	NOVABIOTICS LIMITED	24- Feb- 06	9- Nov -15	13- Dec -16
US9518083	Gadd45beta targeting agents	Imperial Innovations Limited	22- Oct- 09	10- Feb -15	13- Dec -16
US9517263	Benzonaphthyridine-containing vaccines	GlaxoSmithKline Biologicals SA	10- Jun- 09	10- Jun -10	13- Dec -16
US9517205	Soluble needle arrays for delivery of influenza vaccines	Seqirus UK Limited	20- Aug- 10	19- Aug -11	13- Dec -16
US9512471	Methods and kits for detecting human papillomavirus	DIACARTA Inc	30- Jun- 10	30- Jun -10	6- Dec -16
US9512443	Recombinant expression of multiprotein complexes using polygenes	ETH ZURICH	8- Nov- 05	6- Nov -06	6- Dec -16
US9512181	Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor	Tetragenetics, Inc.	27- May- 11	29- May -12	6- Dec -16
US9511070	Heterocyclyl carboxamides for treating viral diseases	NovaDrug, LLC	31- Aug- 12	30- Aug -13	6- Dec -16
US9506063	SiRNA compositions and methods for treatment of HPV and other infections	Sirnaomics, Inc.	29- Jul-10	29- Jan -13	29- Nov -16
US9504747	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8- Mar- 13	7- Mar -14	29- Nov -16
US9504673	Agent for the prophylaxis and treatment of highly pathogenic infectious diseases	LTD “Valenta-Intellektâ€	21- May- 09	10- May -10	29- Nov -16
US9504255	Physical antimicrobial method	NMS TECHNOLOGIES CO., LTD.	1- Aug- 12	16- Jul- 13	29- Nov -16
US9499799	Cells and methodology to generate non-segmented negative-strand RNA viruses	Centre National De La Recherche Scientifique	22- Dec- 06	15- Oct -13	22- Nov -16
US9499535	Kinase inhibitors	ORIGENIS GMBH	21- Apr- 11	23- Apr -12	22- Nov -16
US9499489	Myxovirus therapeutics, compounds, and uses related thereto	Children’s Healthcare of Atlanta, Inc.	24- Oct- 11	24- Oct -12	22- Nov -16
US9498548	Method of using oxidative reductive potential water solution in dental applications	Oculus Innovative Sciences, Inc.	2- May- 05	2- May -06	22- Nov -16
US9498544	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21- Apr- 08	13- Mar -15	22- Nov -16
US9498527	Vaccine composition	NITTO DENKO CORPORATION	4- Apr- 12	3- Apr -13	22- Nov -16
US9494571	Methods of testing for intracellular pathogens	Novartis AG	8- Mar- 10	7- Mar -11	15- Nov -16
US9493788	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	16- Jan -15	15- Nov -16
US9493572	GITR antibodies and methods of inducing or enhancing an immune response	GITR, Inc.	25- Mar- 05	23- Mar -15	15- Nov -16
US9493518	Compositions and methods for treating clostridium difficile- associated diseases	National Health Research Institutes	14- Mar- 13	13- Mar -14	15- Nov -16
US9492528	Influenza virus-like particles (VLPS) comprising hemagglutinin	MEDICAGO INC.	13- Jul-07	2- Jul- 09	15- Nov -16
US9492413	Use of salt of an acetylsalicylic acid for the treatment of viral infections	Ventaleon GMBH	14- Jan- 08	14- Jan -09	15- Nov -16
US9489495	System and method for detecting, collecting, analyzing, and communicating event-related information	GEORGETOWN UNIVERSITY	25- Feb- 08	28- Aug -08	8- Nov -16
US9487838	Oligonucleotide probe for the detection of adenovirus	QIAGEN HAMBURG GMBH	28- Dec- 10	28- Dec -10	8- Nov -16
US9487837	Exosome-mediated diagnosis of hepatitis virus infections and diseases	MOREHOUSE SCHOOL OF MEDICINE	6- Oct- 08	21- Jan -14	8- Nov -16
US9487778	Oligonucleotide modulators of the toll-like receptor pathway	QUARK PHARMACEUTICALS, INC.	3- Mar- 11	1- Mar -12	8- Nov -16
US9487749	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30- Oct- 09	12- Aug -14	8- Nov -16

 

US9487528	Compounds	Chiesi Farmaceutici S.p.A.	9- Jun- 14	5- Jun -15	8- Nov -16
US9486479	Antimicrobial solutions containing dichloride monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13- Mar- 07	21- Jul- 14	8- Nov -16
US9481912	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples	Longhorn Vaccines and Diagnostics, LLC	12- Sep- 06	8- Oct -13	1- Nov -16
US9481724	hDC-sign binding peptides	Sloan-Kettering Institute for Cancer Research	19- Dec- 11	10- Dec -12	1- Nov -16
US9481630	Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	19- Oct- 11	28- Sep -12	1- Nov -16
US9476090	Signal propagation biomolecules, devices and methods	STC.UNM	21- May- 13	21- May -14	25- Oct- 16
US9476032	Attenuated viruses useful for vaccines	The Research Foundation for The State University of New York	30- Mar- 07	31- Mar -08	25- Oct- 16
US9475872	Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F	ImmunoQure AG	28- Dec- 11	2- Jan -13	25- Oct- 16
US9475862	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7- Nov- 11	7- Nov -12	25- Oct- 16
US9475832	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14- Apr- 10	29- Sep -14	25- Oct- 16
US9475804	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	1- Jun -12	25- Oct- 16
US9475779	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	25- Oct- 16
US9475775	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	4- Mar -16	25- Oct- 16
US9474844	Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux LLC	22- Oct- 14	29- Dec -15	25- Oct- 16
US9474759	Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses	Kansas State University Research Foundation	27- Sep- 11	27- Sep -12	25- Oct- 16
US9469876	Circulating biomarkers for metastatic prostate cancer	Caris Life Sciences Switzerland Holdings GmbH	6- Apr- 10	6- Apr -11	18- Oct- 16
US9464276	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11- Jul-03	23- Feb -15	11- Oct- 16
US9464123	Peptides having activity of inhibiting infections of respiratory viruses and use of the same	XIANGXUE GROUP (HONG KONG) COMPANY LIMITED	9- May- 13	21- Feb -14	11- Oct- 16
US9463240	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3- Dec- 09	11- Jul- 14	11- Oct- 16
US9459247	Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry	Academia Sinica	29- Mar- 10	29- Mar -11	4- Oct- 16
US9459233	Amperometric gas sensor	Steris Corporation	25- Jun- 12	26- Feb -13	4- Oct- 16
US9458492	Methods and cells for identifying RIG-I pathway regulators	Kineta, Inc.	25- Feb- 11	23- Feb -12	4- Oct- 16
US9458470	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin	MEDICAGO INC.	21- Jan- 08	23- Jan -13	4- Oct- 16
US9458184	Compositions of TLR7 and/or TLR8 agonists conjugated to lipids	INVIVOGEN	15- Jun- 12	15- Mar -13	4- Oct- 16
US9458113	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	4- Oct- 16
US9457074	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24- Apr- 12	23- Feb -15	4- Oct- 16
US9453043	Nucleic acid chemical modifications	ALNYLAM PHARMACEUTICALS, INC.	2- Mar- 09	22- Jan -15	27- Sep -16
US9452973	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES	4- May- 12	15- Mar -13	27- Sep -16
US9452210	Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant	MEDICAGO INC.	13- Jul-07	4- Jan -13	27- Sep -16

 

US9447462	Methods for concurrent identification and quantification of an unknown bioagent	IBIS BIOSCIENCES, INC.	18- Feb- 04	27- Jan -14	20- Sep -16
US9447132	Highly active nucleoside derivative for the treatment of HCV	Achillion Pharmaceuticals, Inc.	12- Apr- 13	14- Apr -14	20- Sep -16
US9447097	4-amino-imidazoquinoline compounds	Hoffmann-La Roche Inc.	22- Apr- 14	7- Apr -16	20- Sep -16
US9446062	Methods of treating ischemia-reperfusion injury with siRNAs	Quark Pharmaceuticals, Inc.	25- Oct- 06	8- Jan -15	20- Sep -16
US9442107	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27- Apr- 10	21- Apr -15	13- Sep -16
US9441247	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18- May- 04	6- Jul- 15	13- Sep -16
US9440960	Substituted oxetanes and their use as inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	1- Aug- 14	31- Jul- 15	13- Sep -16
US9440930	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	13- Sep -16
US9435795	Enhanced deposition of chromogens utilizing pyrimidine analogs	Ventana Medical Systems, Inc.	30- Dec- 10	6- Oct -14	6- Sep -16
US9435000	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	20- Sep -13	6- Sep -16
US9434997	Methods, compounds and systems for detecting a microorganism in a sample	Lawrence Livermore National Security, LLC	24- Aug- 07	21- Aug -08	6- Sep -16
US9434769	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30- Oct- 09	9- Jul- 14	6- Sep -16
US9433672	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	26- Apr- 12	28- Apr -14	6- Sep -16
US9430610	Re-sequencing pathogen microarray	The United States of America, as represented by the Secretary of the Navy	2-Jul- 04	10- Apr -08	30- Aug -16
US9428739	Norovirus and Sapovirus antigens	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	24- Mar- 01	27- Nov -12	30- Aug -16
US9428574	Polypeptides and uses thereof for treatment of autoimmune disorders and infection	COMPUGEN LTD.	30- Jun- 11	1- Jul- 12	30- Aug -16
US9428571	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16- May- 08	18- Mar -15	30- Aug -16
US9428490	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	26- Jul- 12	30- Aug -16
US9428439	Hydrobenzamide derivatives as inhibitors of Hsp90	ASTEX THERAPEUTICS LTD.	12- Oct- 06	7- Jan -14	30- Aug -16
US9426989	Organic peroxide compounds for microorganism inactivation	NOVARTIS AG	6- May- 10	6- May -11	30- Aug -16
US9422367	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	7- Feb- 06	26- Nov -13	23- Aug -16
US9421254	Immunostimulatory combinations of TLR ligands and methods of use	The United States of America, as represented by the Secretary, Department of Health and Human Services	24- Sep- 07	24- Sep -08	23- Aug -16
US9416416	Biological specimen collection/transport compositions and methods	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	16- Dec -11	16- Aug -16
US9416409	Capture primers and capture sequence linked solid supports for molecular diagnostic tests	IBIS BIOSCIENCES, INC.	31- Jul-09	30- Jul- 10	16- Aug -16
US9416396	Covalently linked thermostable kinase for decontamination process validation	The Secretary of State for Health	20- Feb- 08	18- Feb -09	16- Aug -16
US9415392	Slip chip device and methods	The University of Chicago	24- Mar- 09	23- Mar -10	16- Aug -16
US9415087	Compositions and methods for treating coronavirus infection	Ludwig-Maximilians-Universitaet Muenchen	11- Mar- 14	8- May -15	16- Aug -16
US9415033	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3- Oct- 12	3- Oct -13	16- Aug -16
US9409987	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer	COMPUGEN LTD	15- Apr- 11	16- Apr -12	9- Aug -16
US9409917	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	20- Jan- 12	18- Jan -13	9- Aug -16

 

US9409870	Compounds	CHIESI FARMACEUTICI S.p.A.	15- Dec- 14	27- Nov -15	9- Aug -16
US9408908	Combination adjuvant formulation	Not Available	16- Oct- 08	15- Feb -13	9- Aug -16
US9408907	Homogenous suspension of immunopotentiating compounds and uses thereof	GlaxoSmithKline Biologicals SA	15- Dec- 09	15- Dec -10	9- Aug -16
US9404160	Methods for the detection of microorganisms	Becton, Dickinson and Company	22- Dec- 09	21- Dec -10	2- Aug -16
US9403868	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	5- Mar -15	2- Aug -16
US9402921	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30- Apr- 08	22- Oct -14	2- Aug -16
US9402878	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3- Dec- 12	1- Jul- 15	2- Aug -16
US9402812	Methods for the preparation of liposomes	Indu Javeri	23- Sep- 09	23- Sep -10	2- Aug -16
US9394092	Powdered pouch and method of making same	MONOSOL, LLC	16- Apr- 12	14- Mar -13	19- Jul- 16
US9393564	Bioagent detection systems, devices, and methods	IBIS BIOSCIENCES, INC.	30- Mar- 09	30- Mar -10	19- Jul- 16
US9393295	Nanoparticles for use in pharmaceutical compositions	Novartis AG	28- Apr- 08	28- Apr -09	19- Jul- 16
US9393215	Nanoparticles for use in immunogenic compositions	Novartis AG	2- Dec- 05	1- Dec -06	19- Jul- 16
US9388429	Method for propagating adenoviral vectors encoding inhibitory gene products	GenVec, Inc.	10- Nov- 05	28- May -14	12- Jul- 16
US9388234	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds	Not Available	6- Jun- 03	19- Jun -13	12- Jul- 16
US9388198	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	21- Jan- 14	21- Jan -14	12- Jul- 16
US9388197	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22- Jan- 13	21- Jan -14	12- Jul- 16
US9387242	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount Sinai	2- Dec- 05	1- Dec -06	12- Jul- 16
US9382590	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25- Mar- 11	20- May -15	5- Jul- 16
US9382545	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	COLEY PHARMACEUTICAL GMBH	27- Sep- 06	4- Oct -13	5- Jul- 16
US9382288	Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action	Justus-Liebig-Universitat Giessen	6- Oct- 10	6- Oct -11	5- Jul- 16
US9381244	VISTA modulators for diagnosis and treatment of cancer	KING’S COLLEGE LONDON	7- Sep- 12	9- Sep -13	5- Jul- 16
US9381239	VLPS derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25- May- 07	14- Apr -14	5- Jul- 16
US9381226	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8- Feb- 07	8- Feb -08	5- Jul- 16
US9381220	Sceletium extract and uses thereof	H. L. Hall & Sons Limited	20- Mar- 09	15- Jul- 14	5- Jul- 16
US9380785	Antiviral resin member	NBC MESHTEC, INC.	6-Jul- 11	6- Jul- 12	5- Jul- 16
US9376486	Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof	DSO National Laboratories	14- Dec- 10	14- Dec -11	28- Jun- 16
US9376398	Carboxylic acid compounds	Astrazeneca Aktiebolag	18- May- 12	17- May -13	28- Jun- 16
US9375465	Conjugates of GM-CSF and IL-7, compositions and methods related thereto	Children’s Healthcare of Atlanta, Inc.	14- Nov- 11	13- Nov -12	28- Jun- 16
US9372156	System for processing contents of a receptacle to detect an optical signal emitted by the contents	GEN-PROBE INCORPORATED	10- Mar- 05	22- Feb -11	21- Jun- 16
US9371563	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23- Dec- 05	11- Mar -13	21- Jun- 16

 

US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	11- Jul- 14	21- Jun- 16
US9370581	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	11- Jul- 14	21- Jun- 16
US9370570	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28- Dec- 07	10- Dec -13	21- Jun- 16
US9370531	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders	New York University	31- Aug- 07	1- Sep -08	21- Jun- 16
US9365577	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18- Dec- 12	17- Dec -13	14- Jun- 16
US9365567	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	30- Sep -14	14- Jun- 16
US9365523	Imidazolyl amide compounds and uses related thereto	Children’s Healthcare of Atlanta, Inc.	31- Mar- 11	28- Mar -12	14- Jun- 16
US9365506	Compounds and compositions as TLR2 agonists	NOVARTIS AG	23- Mar- 10	9- Jul- 14	14- Jun- 16
US9364511	Antiviral preparations obtained from a natural cinnamon extract	RAMOT AT TEL-AVIV UNIVERSITY LTD.	24- Dec- 03	22- Jun -06	14- Jun- 16
US9359360	TLR agonists	The Regents of The University of California	22- Aug- 05	20- Nov -12	7- Jun- 16
US9358280	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9- Sep- 04	11- Jan -13	7- Jun- 16
US9353133	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	7- Mar -14	31- May -16
US9352048	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	22- Jul- 14	31- May -16
US9347055	Method and kit for preparation of sample for use in nucleic acid amplification	EIKEN KAGAKU KABUSHIKI KAISHA	5- Nov- 07	5- Nov -08	24- May -16
US9346866	Inhibition of tace activity with cyclic peptides	The Regents of the University of California	2- Jun- 11	19- Sep -14	24- May -16
US9346794	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	29- Dec -15	24- May -16
US9346769	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	23- Aug -13	24- May -16
US9346753	Dithiol mucolytic agents	PARION SCIENCES, INC.	23- Aug- 13	13- Aug -14	24- May -16
US9345760	IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same	Advanced Bionutrition Corporation	9- Sep- 11	7- Sep -12	24- May -16
US9340507	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	2- Sep -15	17- May -16
US9339561	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	5- May -14	17- May -16
US9339525	Inhibition of biofilm organisms	Novabiotics Limited	31- Mar- 09	31- Mar -10	17- May -16
US9334268	4-amino-imidazoquinoline compounds	HOFFMAN-LA ROCHE INC.	22- Apr- 14	22- Apr -15	10- May -16
US9328110	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25- Nov- 03	11- Mar -14	3- May -16
US9328093	Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications	HYBRIGENICS SA	15- Jan- 10	17- Sep -14	3- May -16
US9326972	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression	Ohio University	16- Mar- 04	9- Feb -12	3- May -16
US9322827	B-cell antigen presenting cell assay	University of Pittsburgh – Of the Commonwealth System of Higher Education	8- Apr- 10	8- Apr -11	26- Apr- 16
US9321999	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OAre	19- Nov- 09	19- Nov -10	26- Apr- 16
US9321847	Activatable toxin complexes comprising a cleavable inhibitory peptide	RAMOT at Tel Aviv University Ltd.	20- Sep- 10	22- Aug -11	26- Apr- 16

 

US9321831	RSV-specific binding molecules and means for producing them	MedImmune Limited	1- Jun- 07	13- Sep -13	26- Apr- 16
US9320784	Peptides shared among lethal cancers and therapeutic compositions comprising said peptides	Not Available	7- Aug- 09	19- Jul- 12	26- Apr- 16
US9320748	Immunologically useful arginine salts	Novartis AG	7- Mar- 12	7- Mar -13	26- Apr- 16
US9315530	Adsorption of immunopotentiators to insoluble metal salts	Novartis AG	1- Sep- 10	1- Sep -11	19- Apr- 16
US9310375	Luminophore-labeled molecules coupled with particles for microarray-based assays	CapitalBio Corporation	27- Oct- 10	27- Oct -10	12- Apr- 16
US9310088	Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter	Technical University of Denmark	17- Jul-09	14- Jul- 10	12- Apr- 16
US9309325	Antibodies and methods of use thereof	The Regents of the University of California	7- May- 09	4- May -10	12- Apr- 16
US9303068	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30- Nov- 12	27- Nov -13	5- Apr- 16
US9303000	Olefin containing nuclear transport modulators and uses thereof	KARYOPHARM THERAPEUTICS INC.	17- Jan- 11	16- Jan -12	5- Apr- 16
US9297010	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21- Mar- 03	11- Feb -14	29- Mar -16
US9295732	Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists	INVIVOGEN	22- Feb- 13	22- Feb -13	29- Mar -16
US9295708	Modified release formulations for oprozomib	Onyx Therapeutics, Inc.	24- Oct- 12	24- Oct -13	29- Mar -16
US9295646	Cationic oil-in-water emulsions	Novartis AG	6-Jul- 10	18- Sep -11	29- Mar -16
US9291628	Direct clone analysis and selection technology	Dublin City University	13- Jul-10	13- Jul- 11	22- Mar -16
US9291597	Detecting targets using mass tags and mass spectrometry	VENTANA MEDICAL SYSTEMS, INC.	2-Jul- 10	1- Jul- 11	22- Mar -16
US9290794	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	12- Nov -12	22- Mar -16
US9290786	Monoclonal antibody production by EBV transformation of B cells	Institute for Research in Biomedicine	26- Feb- 03	25- Apr -13	22- Mar -16
US9290760	Modified iRNA agents	ALNYLAM PHARMACEUTICALS, INC.	15- Sep- 10	14- Sep -11	22- Mar -16
US9290745	Luciferase biosensor	PROMEGA CORPORATION	10- Oct- 03	14- Feb -14	22- Mar -16
US9290545	Compositions and methods for the treatment of viral infections	Dana-Farber Cancer Institute, Inc.	23- Jan- 08	23- Jul- 10	22- Mar -16
US9290459	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6- Feb- 13	9- Nov -15	22- Mar -16
US9290457	Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	22- Mar -16
US9289487	II-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	14- Sep- 99	11- Jan -05	22- Mar -16
US9284560	Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs	Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.	19- Sep- 11	19- Sep -11	15- Mar -16
US9278128	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14- Sep- 09	6- Jan -14	8- Mar -16
US9278126	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10- Feb- 09	10- Feb -10	8- Mar -16
US9272024	Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	The Trustees of the University of Pennsylvania	12- Dec- 11	11- Dec -12	1- Mar -16
US9271494	Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions	Ecolab USA, Inc.	30- Aug- 07	30- Aug -07	1- Mar -16
US9266844	Suppression of SARS replication by SARS helicase inhibitors	The Curators of the University of Missouri	15- Jun- 12	17- Jun -13	23- Feb -16

 

US9266843	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	9- May -13	23- Feb -16
US9265876	Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux Technologies LLC	22- Oct- 14	22- Oct -14	23- Feb -16
US9260398	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29- May- 12	9- Dec -14	16- Feb -16
US9255144	Anti-IL-18 antibodies and their uses	MedImmune Limited	20- Dec- 10	20- Dec -11	9- Feb -16
US9255140	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	NEW YORK BLOOD CENTER, INC.	15- Jun- 04	23- Mar -09	9- Feb -16
US9254315	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	Not Available	28- Apr- 04	3- Feb -10	9- Feb -16
US9254265	Small liposomes for delivery of immunogen encoding RNA	NOVARTIS AG	31- Aug- 10	31- Aug -11	9- Feb -16
US9249427	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14- May- 10	14- Nov -12	2- Feb -16
US9249195	Reovirus vaccines and methods of use therefor	Vanderbilt University	7- Apr- 10	4- Apr -11	2- Feb -16
US9248201	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	5- May -14	2- Feb -16
US9248178	Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens	Not Available	8- Jun- 09	8- Jun -10	2- Feb -16
US9242980	Lipidated immune response modifier compound compositions, formulations, and methods	3M Innovative Properties Company	17- Aug- 10	16- Aug -11	26- Jan- 16
US9238809	Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material	QIAGEN GAITHERSBURG, INC.	24- Sep- 09	5- Aug -10	19- Jan- 16
US9234175	Creating bioengineered lymph nodes	H. Lee Moffitt Cancer Center and Research Institute, Inc.	17- Nov- 09	16- Nov -10	12- Jan- 16
US9233148	Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza	Not Available	9- Jan- 09	16- Oct -09	12- Jan- 16
US9227977	Phosphoinositide 3-kinase inhibitors	Respivert Ltd.	15- Mar- 13	14- Mar -14	5- Jan- 16
US9222075	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	2- May -14	29- Dec -15
US9221832	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22- Jul-11	20- Jul- 12	29- Dec -15
US9221807	Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	21- Feb- 14	12- Feb -15	29- Dec -15
US9220768	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9- Sep- 04	14- Oct -11	29- Dec -15
US9217745	Arrayed detector system for measurement of influenza immune response	University of Rochester	2- May- 08	11- Jul- 13	22- Dec -15
US9217157	Recombinant influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	27- Jul-09	27- Jul- 10	22- Dec -15
US9216192	Toll-like receptor agonist formulations and their use	VentiRx Pharmaceuticals, Inc.	1- Aug- 08	16- Jul- 12	22- Dec -15
US9213027	Lipoparticles comprising proteins, methods of making, and using the same	Integral Molecular, Inc.	30- Jul-03	1- Nov -13	15- Dec -15
US9212399	Biological specimen collection and transport system and method of use	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	7- Jan -14	15- Dec -15
US9212205	Nucleic acid binding compounds and methods of use	University of Rochester	26- Jul-07	28- Jul- 08	15- Dec -15
US9206396	Methods and devices for quantitative viral assays	Wisconsin Alumni Research Foundation	16- Nov- 05	16- Nov -06	8- Dec -15
US9206158	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	10- Jun -15	8- Dec -15
US9200329	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19- May- 08	18- May -09	1- Dec -15

 

US9200287	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity	AdiuTide Pharmaceuticals GmbH	18- May- 07	15- May -08	1- Dec -15
US9200280	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	9- Jun -14	1- Dec -15
US9200279	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	14- Jan -14	1- Dec -15
US9200074	Antibodies to IL-1 R1 and methods of making them	MEDIMMUNE LIMITED	7- Nov- 08	16- Apr -14	1- Dec -15
US9199981	Compounds and compositions as C-kit kinase inhibitors	NOVARTIS AG	1- Sep- 11	27- Aug -12	1- Dec -15
US9199897	Methods for preparing squalene	NOVARTIS AG	12- May- 10	12- May -11	1- Dec -15
US9198927	Targeting opposite strand replication intermediates of single­stranded viruses by RNAI	ALNYLAM PHARMACEUTICALS, INC.	24- Sep- 04	1- Mar -10	1- Dec -15
US9193780	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5- Jun- 08	5- Jun -09	24- Nov -15
US9192661	Delivery of self-replicating RNA using biodegradable polymer particles	Novartis AG	6-Jul- 10	7- Jun -11	24- Nov -15
US9187748	Compositions and methods for silencing ebola virus gene expression	Not Available	20- Jul-09	28- Mar -14	17- Nov -15
US9187426	Organic compounds	Novartis AG	27- Jun- 08	25- Jun -09	17- Nov -15
US9186419	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30- Apr- 08	17- Jan -14	17- Nov -15
US9186399	Immune stimulatory oligonucleotide analogs containing modified sugar moieties	AdiutTide Pharmaceuticals GmbH	9- Oct- 07	29- Sep -08	17- Nov -15
US9181303	Treatment of bacterial infections with cyclic antimicrobial peptides	NovaBiotics Limited	22- Dec- 05	20- Jun -14	10- Nov -15
US9181290	Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose	CHANG GUNG UNIVERSITY	17- Jun- 11	19- Sep -11	10- Nov -15
US9175047	Peptidomimetic macrocycles	Aileron Therapeutics, Inc.	14- Jan- 09	14- Jan -10	3- Nov -15
US9174925	Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	26- Oct- 11	28- Sep -12	3- Nov -15
US9169318	Neutralizing molecules to viral antigens	Sea Lane Biotechnologies, Inc.	28- Mar- 08	18- Jul- 11	27- Oct- 15
US9168318	Oxidative reductive potential water solution and methods of using the same	Oculus Innovative Sciences, Inc.	30- Dec- 03	11- Aug -04	27- Oct- 15
US9168299	Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies	LIPUM AB	8- Apr- 09	30- Oct -13	27- Oct- 15
US9168269	Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals	THE TRUSTEES OF PRINCETON UNIVERSITY	18- Feb- 10	18- Feb -11	27- Oct- 15
US9163222	Mutations in OAS1 genes	Kineta Two, LLC	4- May- 05	14- Nov -12	20- Oct- 15
US9163065	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3- Dec- 12	3- Dec -13	20- Oct- 15
US9161976	Immunotherapy comprising TLR9 ligand and CD40 ligand	Trustees of Dartmouth College	30- Dec- 02	22- Oct -12	20- Oct- 15
US9156811	N-myristoyl transferase inhibitors	Univeristy of Dundee	2- Sep- 08	29- Aug -09	13- Oct- 15
US9155309	Virus inactivating sheet	NBC MESHTEC, INC.	2- Oct- 09	4- Oct -10	13- Oct- 15
US9149473	Targeted whole genome amplification method for identification of pathogens	IBIS BIOSCIENCES, INC.	14- Sep- 06	14- Sep -07	6- Oct- 15
US9149445	Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections	THE TRUSTEES OF PRINCETON UNIVERSITY	27- Jul-09	27- Jul- 10	6- Oct- 15
US9145588	Generation of binding molecules	MERUS BIOPHARMACEUTICALS B.V.	26- Sep- 11	26- Sep -12	29- Sep -15

 

US9145585	Method for using permuted nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	5- Aug -14	29- Sep -15
US9145410	Pyrazolopyridines and analogs thereof	3M Innovative Properties Company	3- Oct- 03	26- Jan -12	29- Sep -15
US9144575	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28- Jul-10	28- Jul- 11	29- Sep -15
US9139833	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	26- Jul-02	12- Mar -13	22- Sep -15
US9139647	Diagnosis and treatment of cancer using anti-TM4SF20 antibody	FORERUNNER PHARMA RESEARCH CO., LTD.	25- Dec- 08	25- Dec -09	22- Sep -15
US9139620	Feline morbillivirus and uses thereof	THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA	20- Jan- 12	22- Jan -13	22- Sep -15
US9138472	CD40L vaccines, compositions, and methods related thereto	EMORY UNIVERSITY	28- Sep- 10	28- Sep -11	22- Sep -15
US9134247	Method and apparatus for two-step surface-enhanced raman spectroscopy	REAL-TIME ANALYZERS, INC.	16- Dec- 11	16- Dec -11	15- Sep -15
US9133248	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9- Nov- 09	9- Nov -10	15- Sep -15
US9132423	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29- Jan- 10	28- Jan -11	15- Sep -15
US9132175	Bacillus based delivery system and methods of use	The Curators of the University of Missouri	18- Apr- 11	18- Apr -11	15- Sep -15
US9128101	Biomarkers for theranostics	Caris Life Sciences Switzerland Holdings GmbH	1- Mar- 10	1- Mar -11	8- Sep -15
US9127256	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	DNAVEC CORPORATION	16- Jul-08	16- Jul- 09	8- Sep -15
US9127251	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9- Dec- 05	8- Dec -06	8- Sep -15
US9127028	Substrates for chromogenic detection and methods of use in detection assays and kits	Ventana Medical Systems, Inc.	16- Aug- 10	12- Aug -11	8- Sep -15
US9125952	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17- Jul-09	13- Aug -14	8- Sep -15
US9115093	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	4- Mar- 13	20- Feb -14	25- Aug -15
US9115065	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses	Kineta, Inc.	6- Dec- 04	26- Feb -13	25- Aug -15
US9109199	Methods to produce bunyavirus replicon particles	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20- Sep- 10	20- Sep -11	18- Aug -15
US9107970	Method and a filter for capturing airborne agents	Not Available	15- Jul-08	13- Jul- 09	18- Aug -15
US9107958	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	1- Jun -12	18- Aug -15
US9107906	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	8- Jan -15	18- Aug -15
US9107904	Immunostimulatory compositions and methods of use thereof	Massachusetts Institute of Technology	5- Apr- 12	15- Mar -13	18- Aug -15
US9102938	2â€2 and 5â€2 modified monomers and oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	31- Mar- 11	31- Mar -11	11- Aug -15
US9102911	High density self-contained biological analysis	BioFire Diagnostics, LLC	15- May- 09	28- Jan -13	11- Aug -15
US9102741	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12- Sep- 07	13- Oct -14	11- Aug -15
US9102740	Cna-B domain antigens in vaccines against gram positive bacteria	NOVARTIS AG	12- Jan- 09	7- Jun -13	11- Aug -15
US9102633	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	13- Dec -13	11- Aug -15
US9102624	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	20- Aug -13	11- Aug -15

 

US9101597	Immunoprotective primary mesenchymal stem cells and methods	Autoimmune Technologies, LLC	14- Mar- 13	14- Mar -13	11- Aug -15
US9101582	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31- Jul-08	27- Mar -13	11- Aug -15
US9096585	Antiviral compounds and uses thereof	Icahn School of Medicine at Mount Sinai	28- May- 10	31- May -11	4- Aug -15
US9096543	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	9- May -13	4- Aug -15
US9090897	Production of IFN-lambda by conventional dendritic cells	Bavarian Nordic A/S	18- Dec- 09	17- Dec -10	28- Jul- 15
US9085641	Peptides regulating the surface expression of the T cell receptor	Max-Delbruck-Centrum Fur Molekulare Medizin	23- Jun- 06	23- Jun -07	21- Jul- 15
US9084808	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	1- Oct- 04	9- May -14	21- Jul- 15
US9084758	Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof	The Catholic University of Korea Industry-Academic Cooperation Foundation	24- Jul-12	25- Aug -14	21- Jul- 15
US9080209	Non-mass determined base compositions for nucleic acid detection	IBIS BIOSCIENCES, INC.	6- Aug- 09	6- Aug -10	14- Jul- 15
US9080204	Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009	Longhorn Vaccines and Diagnostics, LLC	12- Sep- 06	30- Dec -11	14- Jul- 15
US9079965	Bispecific antibody	Wuhan YZY Biopharma Co., LTD.	21- Nov- 12	13- Mar -14	14- Jul- 15
US9079943	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18- May- 04	28- Mar -14	14- Jul- 15
US9079865	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	29- Jul- 12	14- Jul- 15
US9078885	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7- Aug- 08	7- Apr -14	14- Jul- 15
US9078868	Therapeutic agent for accelerating recovery of animal under medical treatment	DAIICHI SANKYO COMPANY, LIMITED	15- Jan- 10	14- Jan -11	14- Jul- 15
US9073869	Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	11- Sep -14	7- Jul- 15
US9072738	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27- Jun- 11	27- Jun -12	7- Jul- 15
US9072726	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20- Jan- 06	21- Dec -09	7- Jul- 15
US9072702	Reverse genetics using non-endogenous pol I promoters	Novartis AG	21- May- 09	21- May -10	7- Jul- 15
US9067873	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Kineta Four, LLC	6- Dec- 04	19- Dec -13	30- Jun- 15
US9066964	Use of tylvalosin as antiviral agent	Cambridge University Technical Services	13- Jul-06	13- Jul- 07	30- Jun- 15
US9063150	Method for detection of antigen-specific antibodies in biological samples	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention	2- Sep- 08	25- Aug -09	23- Jun- 15
US9061001	Combination adjuvant formulation	Dalhousie University	16- Oct- 08	15- Oct -09	23- Jun- 15
US9056900	Compositions and methods for coronavirus inhibition	Autoimmune Technologies, LLC.	4- Nov- 03	8- Aug -13	16- Jun- 15
US9056898	Attenuated RNA virus and applications thereof	Washington University	20- Sep- 07	22- Sep -08	16- Jun- 15
US9056071	Compounds and methods for preventing or treating a viral infection	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)	2- Nov- 07	19- Jun -13	16- Jun- 15
US9051619	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25- Mar- 11	23- Mar -12	9- Jun- 15
US9051564	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21- Feb- 06	21- Feb -07	9- Jun- 15
US9051353	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	24- Sep -13	9- Jun- 15

 

US9050376	Conjugates of synthetic TLR agonists and uses therefor	The Regents of the University of California	7- Feb- 07	19- Jun -14	9- Jun- 15
US9046523	Rapid bioluminescence detection system	THE SECRETARY OF STATE FOR HEALTH	7- Jan- 09	2- Aug -13	2- Jun- 15
US9045855	Anti-viral member	NBC Meshtec, Inc.	26- Dec- 08	28- Dec -09	2- Jun- 15
US9045727	Virus-like particles, methods of preparation, and immunogenic compositions	EMORY UNIVERSITY	17- May- 02	4- Apr -06	2- Jun- 15
US9045472	Imidazoquinoline compounds	ASTRAZENECA AB	16- Dec- 10	16- Dec -11	2- Jun- 15
US9045470	Compounds and compositions as TLR activity modulators	IRM LLC	2- Sep- 09	1- Sep -10	2- Jun- 15
US9044420	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses	IMMUNE DESIGN CORP.	8- Apr- 11	6- Apr -12	2- Jun- 15
US9040310	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27- Apr- 10	27- Apr -11	26- May -15
US9034646	Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof	ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.	25- May- 10	26- Nov -12	19- May -15
US9034313	Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same	Inovio Pharmaceuticals, Inc.	8- Feb- 10	8- Feb -11	19- May -15
US9029413	T reatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1- Jun- 07	3- Apr -12	12- May -15
US9029382	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds	Parion Sciences, Inc.	17- Dec- 12	13- Dec -13	12- May -15
US9029315	Soluble PD-1 variants, fusion constructs, and uses thereof	The University of Hong Kong	11- Nov- 10	11- Nov -11	12- May -15
US9028841	Synergistic bacterial compositions and methods of production and use thereof	Seres Health, Inc.	23- Nov- 12	20- Mar -14	12- May -15
US9028837	Methods and compositions for poxvirus A35R protein	East Carolina University	7- Jun- 12	20- Dec -12	12- May -15
US9028823	Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies	GITR, Inc.	25- Mar- 05	1- Mar -13	12- May -15
US9024001	Alphavirus replicon packaging constructs	Novartis Vaccines and Diagnostics, Inc.	25- May- 04	20- May -05	5- May -15
US9023855	Compounds	Chiesi Farmaceutici S.p.A.	14- Sep- 11	11- Feb -14	5- May -15
US9023839	Compounds and compositions as c-kit kinase inhibitors	IRM LLC	1- Sep- 11	22- Apr -14	5- May -15
US9017699	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center, Inc.	15- Jun- 04	18- Feb -10	28- Apr- 15
US9017696	Adenovirus vectors	Isis Innovation Limited	10- Apr- 07	10- Apr -08	28- Apr- 15
US9012622	Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer	Not Available	31- Dec- 08	31- Dec -09	21- Apr- 15
US9011767	Transportable vacuum assisted decontamination unit and decontamination process	STERIS Inc.	1- Apr- 13	31- Mar -14	21- Apr- 15
US9006264	Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	9- Sep -13	14- Apr- 15
US9006194	Compositions and methods for diminishing viral infection and inflammation associated with viral infection	Drexel University	19- Dec- 08	17- Dec -09	14- Apr- 15
US9005974	Means and methods for influencing the stability of cells	Academish Medisch Centrum Bij de Universiteit van Amsterdam	9- Dec- 05	9- Dec -05	14- Apr- 15
US9005665	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24- Apr- 12	24- Apr -13	14- Apr- 15
US9005599	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21- Apr- 08	20- Apr -09	14- Apr- 15
US8999996	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	19- Mar -14	7- Apr- 15

 

US8999975	Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	19- Sep- 11	14- Sep -12	7- Apr- 15
US8999678	Method of increasing the function of an AAV vector	The Trustees of the University of Pennsylvania	7- Apr- 05	7- Apr -06	7- Apr- 15
US8999349	HMGBl-derived peptides enhance immune response to antigens	The Regents of the University of California	27- Jul-10	27- Jul- 11	7- Apr- 15
US8999316	Antiviral compounds	Long Island University	30- May- 07	30- May -08	7- Apr- 15
US8993717	Gadd45beta targeting agents	Imperial Innovations Limited	22- Oct- 09	22- Oct -10	31- Mar -15
US8993581	Methods for treating viral disorders	Trustees of Boston University	24- Sep- 09	11- Jun -13	31- Mar -15
US8993295	Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting	The General Hospital Corporation	20- Jul-06	20- Jul- 07	31- Mar -15
US8992939	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11- Jul-03	24- Oct -11	31- Mar -15
US8987249	Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of Cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	24- Mar -15
US8987191	Bioactive peptides and methods of using same	Compugen Ltd.	12- Jul-07	21- Jun -13	24- Mar -15
US8986933	Selective detection of human rhinovirus	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control	5- Dec- 08	5- Dec -08	24- Mar -15
US8986926	Compositions comprising oriented, immobilized macromolecules and methods for their preparation	NanoString Technologies, Inc.	23- Dec- 05	22- Dec -06	24- Mar -15
US8986702	Antibodies and processes for preparing the same	Taiga Biotechnologies, Inc.	16- May- 08	18- May -09	24- Mar -15
US8980898	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	Parion Sciences, Inc.	29- May- 12	29- May -13	17- Mar -15
US8980338	Sceletium extract and uses thereof	H.L. Hall & Sons Limited	20- Mar- 09	16- Mar -10	17- Mar -15
US8980281	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5- Sep- 06	12- Feb -10	17- Mar -15
US8975389	Nucleic acid chemical modifications	Alnylam Pharmaceuticals, Inc.	2- Mar- 09	2- Mar -10	10- Mar -15
US8969362	9-substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26- Mar- 04	21- Oct -13	3- Mar -15
US8969350	Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient	Astrazeneca AB	18- Dec- 08	17- Dec -09	3- Mar -15
US8962580	Chemical modifications of monomers and oligonucleotides with cycloaddition	Alnylam Pharmaceuticals, Inc.	23- Sep- 08	23- Sep -09	24- Feb -15
US8962332	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	13- Sep -13	24- Feb -15
US8962330	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	31- Oct -07	24- Feb -15
US8961983	Mucosal vaccine using cationic nanogel	National University Corporation Tokyo Medical and Dental University	31- Oct- 08	5- Sep -14	24- Feb -15
US8961477	Delivery of immune response modifier compounds	3M Innovative Properties Company	25- Aug- 03	25- Aug -04	24- Feb -15
US8956863	Agents from cells	The Brigham and Women’s Hospital, Inc.	15- Oct- 09	15- Oct -10	17- Feb -15
US8956616	Constructs binding to phosphatidylserine and their use in disease treatment	Board of Regents, The University of Texas System	24- Jan- 05	24- Jan -06	17- Feb -15
US8951768	Mutations in OAS1 genes	Kineta Two, LLC	4- May- 05	11- Jul- 11	10- Feb -15
US8951528	Immune response modifier conjugates	3M Innovative Properties Company	22- Feb- 06	21- Feb -07	10- Feb -15
US8945943	Personal glucose meters for detection and quantification of a broad range of analytes	The Board of Trustees of the University of Illinois	26- May- 10	26- May -11	3- Feb -15
US8945904	Influenza virus reassortment	Novartis AG	21- May- 10	20- May -11	3- Feb -15

 

US8945610	Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics	BASF SE	14- Nov- 07	11- Nov -08	3- Feb -15
US8940864	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5- Oct- 06	2- Oct -07	27- Jan- 15
US8940501	Methods for ligation and uses thereof	Whitehead Institute for Biomedical Research	30- Jan- 09	1- Feb -10	27- Jan- 15
US8937154	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5- Oct- 06	2- Feb -12	20- Jan- 15
US8933210	Label-free functional nucleic acid sensors for detecting target agents	The Board of Trustees of the University of Illinois	6- Oct- 10	6- Oct -11	13- Jan- 15
US8933019	Antiviral cell-penetrating peptides	New York Blood Center, Inc.	6- May- 08	31- Oct -12	13- Jan- 15
US8916552	Pharmaceutical combinations	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	23- Dec -14
US8916340	Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay	The John Hopkins University	6- Jan- 06	8- Jan -07	23- Dec -14
US8906872	Antisense antiviral compound and method for treating ssRNA viral infection	Sarepta Therapeutics, Inc.	16- Sep- 04	22- Dec -11	9- Dec -14
US8906863	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27- Feb- 09	1- Sep -11	9- Dec -14
US8906862	Multiple antigen delivery system using hepatitis E virus-like particle	National Institute of Infectious Disease	27- Feb- 09	29- Aug -11	9- Dec -14
US8901071	Compounds and their use	Novabiotics Limited	31- Mar- 10	30- Mar -11	2- Dec -14
US8900585	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20- Oct- 10	20- Oct -11	2- Dec -14
US8895629	Circulation of components during homogenization of emulsions	Novartis AG	3- Dec- 09	3- Dec -10	25- Nov -14
US8895577	Compounds and compositions as TLR activity modulators	Not Available	3- Mar- 08	22- Apr -13	25- Nov -14
US8895570	Purine derivatives	AstraZeneca AB	17- Dec- 10	14- Dec -11	25- Nov -14
US8895534	Boron containing small molecules	Anacor Pharmaceuticals, Inc.	20- Jun- 07	30- Jul- 10	25- Nov -14
US8895295	High density self-contained biological analysis	Biofire Diagnostics, LLC	15- Nov- 06	14- Nov -07	25- Nov -14
US8889708	Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	18- Nov -14
US8889692	Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses	AstraZeneca AB	27- Jun- 07	14- Sep -12	18- Nov -14
US8889656	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	30- Apr -13	18- Nov -14
US8889398	Composition for inactivating an enveloped virus	Viroblock SA	19- May- 06	18- May -07	18- Nov -14
US8889181	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17- Jul-09	16- Jun -10	18- Nov -14
US8889118	Anticancer agent containing dendritic cell having RNA virus transferred thereinto	DNA VEC Research Inc.	24- Jun- 04	28- Apr -05	18- Nov -14
US8889117	Modular nanoparticles for adaptable vaccines	Yale University	15- Feb- 07	15- Feb -08	18- Nov -14
US8884020	Indole compounds	Ironwood Pharmaceuticals, Inc.	7- Aug- 06	7- Aug -07	11- Nov -14
US8883790	Pharmaceutical combinations	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	11- Nov -14
US8883500	Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy	Northeastern University	5- Dec- 08	7- Dec -09	11- Nov -14
US8883481	Reverse genetics methods for virus rescue	Novartis AG	20- Oct- 09	20- Oct -10	11- Nov -14
US8883477	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23- Nov- 05	14- Jun -13	11- Nov -14

 

US8882484	Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells	Bayer Healthcare LLC	28- May- 08	27- May -09	11- Nov -14
US8881040	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	28- Aug- 08	2- Dec -09	4- Nov -14
US8877775	Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	4- Nov -14
US8877187	Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases	Avianax, LLC	25- Jul-05	23- Nov -10	4- Nov -14
US8877060	Methods for removing pathogens from a platelet preparation	Biovec Transfusion, LLC	23- Nov- 10	31- Oct -11	4- Nov -14
US8871816	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	28- Oct- 14
US8871790	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	8- Mar -12	28- Oct- 14
US8871783	Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmBh	14- Mar- 13	12- Mar -14	28- Oct- 14
US8871782	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	1- Oct -04	28- Oct- 14
US8871503	Construct	Isis Innovation Limited	28- Mar- 06	28- Mar -07	28- Oct- 14
US8871487	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5- Dec- 08	4- Dec -09	28- Oct- 14
US8871442	Enhanced deposition of chromogens	Ventana Medical Systems, Inc.	30- Dec- 10	28- Dec -11	28- Oct- 14
US8865865	N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic	Philipps-Universitat Marburg	29- Oct- 08	29- Oct -09	21- Oct- 14
US8865166	Antibodies to IL-17A and uses thereof	MedImmune Limited	23- Jun- 06	22- Jun -07	21- Oct- 14
US8859568	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	Astrazeneca AB	6- Dec- 04	3- Nov -10	14- Oct- 14
US8859251	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23- Nov- 05	1- Jul- 13	14- Oct- 14
US8858958	Adjuvant comprising aluminum, oligonucleotide and polycation	Novartis AG	27- Aug- 09	27- Aug -10	14- Oct- 14
US8858957	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12- Sep- 07	14- Mar -13	14- Oct- 14
US8854617	Compounds and markers for surface-enhanced Raman scattering	Julius-Maximilians-Universitat Wurzburg	24- Sep- 07	24- Sep -08	7- Oct- 14
US8853382	Expression of antibody or a fragment thereof in lactobacillus	Hera Pharmaceuticals, Inc.	5- Aug- 10	4- Aug -11	7- Oct- 14
US8846710	Method of preferentially inducing the biosynthesis of interferon	3M Innovative Properties Company	23- Feb- 05	22- Feb -06	30- Sep -14
US8846697	Purine analogs	The Regents of the University of California	31- May- 06	23- Apr -07	30- Sep -14
US8846643	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14- Apr- 10	11- Oct -12	30- Sep -14
US8846051	Modulation of replicative fitness by deoptimization of synonymous codons	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	8- Oct- 04	7- Oct -05	30- Sep -14
US8841100	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30- Oct- 09	16- Feb -11	23- Sep -14
US8840899	Use of mTOR inhibitors to enhance T cell immune responses	Emory University	5- Aug- 08	5- Aug -09	23- Sep -14
US8840890	Rapid expression cloning of human monoclonal antibodies from memory B cells	University of Maryland, Baltimore	12- Nov- 08	12- Nov -09	23- Sep -14
US8840873	Method of treating second and third degree burns using oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	23- Mar- 05	23- Mar -06	23- Sep -14
US8840774	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3- Jun- 05	28- Oct -13	23- Sep -14
US8835107	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18- Aug- 03	26- Jul- 10	16- Sep -14

 

US8834445	Methods of treating or preventing peritonitis with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20- Jan- 06	30- Mar -12	16- Sep -14
US8828962	SiRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11- Dec- 08	12- Dec -11	9- Sep -14
US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	4- Dec -12	9- Sep -14
US8828940	Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands	Compugen Ltd.	18- Sep- 06	14- Dec -10	9- Sep -14
US8828929	Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof	Japan as Represented by Director-General of National Institute of Infectious Diseases	28- Nov- 08	27- Nov -09	9- Sep -14
US8828673	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids Inc	24- Apr- 98	1- Mar -12	9- Sep -14
US8828659	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	11- Mar -13	9- Sep -14
US8828407	Chimaeric protein	The Pirbright Institute	7-Jul- 09	5- Jul- 10	9- Sep -14
US8828406	Influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	30- Jul-09	29- Jul- 10	9- Sep -14
US8822512	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	20- Sep -11	2- Sep -14
US8822409	Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith	Phylogica Limited	20- Jun- 07	20- Jun -08	2- Sep -14
US8821897	Viral adjuvants	The University of North Carolina at Chapel Hill	9-Jul- 04	24- Nov -10	2- Sep -14
US8816089	Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26- Dec- 03	19- Nov -12	26- Aug -14
US8816053	Methods for treating viral infection using IL-28 and IL-29 cysteine mutants	ZymoGenetics, Inc.	2- Apr- 04	7- Sep -12	26- Aug -14
US8815837	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7- Aug- 08	29- Jun -12	26- Aug -14
US8815831	Treatment of Acinetobacter with alginate oligomers and antibiotics	Algipharma AS	3- Jun- 09	3- Jun -10	26- Aug -14
US8815611	Surface for label independent detection and method thereof	Corning Incorporated	10- Apr- 08	3- Apr -09	26- Aug -14
US8815249	Ii-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	4- Sep- 99	26- Jul- 10	26- Aug -14
US8815244	Method for production of antibody using ostrich	Japan Science and Technology Agency	29- Aug- 05	16- Aug -11	26- Aug -14
US8809377	Deubiquitinase inhibitors and methods for use of the same	The Regents of the University of Michigan	24- Sep- 10	23- Sep -11	19- Aug -14
US8808703	Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc	Not Available	23- Mar- 10	23- Mar -11	19- Aug -14
US8808686	Adjuvant-sparing multi-dose influenza vaccination regimen	Novartis AG	15- Jun- 06	19- Sep -11	19- Aug -14
US8802853	Arylalkenyl and arylalkynyl substituted imidazoquinolines	3M Innovative Properties Company	29- Dec- 03	17- Dec -04	12- Aug -14
US8802647	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30- Apr- 02	17- Sep -12	12- Aug -14
US8802106	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30- Oct- 09	29- Oct -10	12- Aug -14
US8796423	Anti-TSG101 antibodies and their uses for treatment of viral infections	Eli Lilly and Company	15- Nov- 06	18- Apr -08	5- Aug -14
US8790655	Conjugates of synthetic TLR agonists and uses therefor	The Regents of The University of California	7- Feb- 07	8- Jan -13	29- Jul- 14
US8785408	Compositions and methods for reducing or protecting against delayed graft function (DGF)	Quark Pharmaceuticals, Inc.	27- Jun- 07	26- Jun -08	22- Jul- 14
US8785375	Cyclic antimicrobial peptides for treating bacterial infections	Novabiotics Ltd.	22- Dec- 05	22- Aug -12	22- Jul- 14

 

US8784900	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13- Mar- 07	13- Mar -08	22- Jul- 14
US8779132	Pharmaceutical compounds	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	15- Jul- 14
US8778963	Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	25- Nov- 03	24- Nov -04	15- Jul- 14
US8778846	Composition, device and associated method	General Electric Company	4- Dec- 06	1- Mar -07	15- Jul- 14
US8778845	Composition, device and associated method	Genral Electric Company	15- Dec- 05	1- Mar -07	15- Jul- 14
US8778358	Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae	Novartis Vaccines and Diagnostics, Inc.	29- Jul-04	18- Oct -10	15- Jul- 14
US8778275	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	15- Jul- 14
US8772471	Targeted delivery of siRNA	Immune Disease Institute	26- Jan- 07	25- Jan -08	8- Jul- 14
US8765939	Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers	AstraZeneca AB	22- Nov- 07	16- Aug -12	1- Jul- 14
US8765704	Modified small interfering RNA molecules and methods of use	Novartis AG	28- Feb- 08	14- Dec -11	1- Jul- 14
US8765643	Composition, device and associated method	General Electric Company	4- Dec- 06	1- Mar -07	1- Jul- 14
US8765146	Adenoviral vector-based malaria vaccines	GenVec, Inc.	31- Aug- 05	31- Aug -06	1- Jul- 14
US8765138	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6- Jan- 04	24- Sep -08	1- Jul- 14
US8765133	Method of producing anti-CD166 antibody in ostrich	Japan Science and Technology Agency	29- Aug- 05	16- Aug -11	1- Jul- 14
US8759307	Oligonucleotide compound and method for treating nidovirus infections	Sarepta Therapeutics, Inc.	24- Dec- 03	25- Apr -08	24- Jun- 14
US8758763	Archaeal polar lipid aggregates for administration to animals	National Research Council of Canada	15- Dec- 06	23- Jan -13	24- Jun- 14
US8758680	Method and device for cleaning air	Not Available	29- Sep- 10	27- Sep -11	24- Jun- 14
US8754071	Compounds and compositions as c-kit kinase inhibitors	Not Available	1- Sep- 11	19- Sep -13	17- Jun- 14
US8754015	Modified phage for displaying post-translationally modified proteins and uses thereof	University of Rochester	21- Nov- 06	20- Nov -07	17- Jun- 14
US8748567	Method for delivery across the blood brain barrier	Children’s Medical Center Corporation	22- May- 06	22- May -07	10- Jun- 14
US8748464	Use of SIRT1 activators or inhibitors to modulate an immune response	The J. David Gladstone Institutes	7- Feb- 08	16- Jul- 10	10- Jun- 14
US8748405	Methods and compositions for the treatment of cancer or other diseases	City of Hope	26- Jan- 07	9- Sep -11	10- Jun- 14
US8748156	Animal protein-free media for cultivation of cells	Baxter Healthcare SA	29- Oct- 04	16- Apr -13	10- Jun- 14
US8741813	Composition, device and associated method	General Electric Company	15- Dec- 05	28- Feb -07	3- Jun- 14
US8741653	Single recombination system and methods of use	Emergent Product Development GmbH	22- Dec- 08	16- Dec -09	3- Jun- 14
US8741604	Nucleic acid molecule encoding a specific IL-1R1 antibody	Medimmune Limited	7- Nov- 08	14- Sep -12	3- Jun- 14
US8741564	Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements	HTG Molecular Diagnostics, Inc.	4- May- 11	26- Apr -12	3- Jun- 14
US8741311	Methods and compositions for immunization against virus	Academia Sinica	27- Mar- 09	26- Mar -10	3- Jun- 14
US8735567	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Not Available	6- Nov- 07	6- Nov -08	27- May -14
US8735559	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11- May- 10	11- May -11	27- May -14

 

US8735421	Imidazoquinolinyl sulfonamides	3M Innovative Properties Company	30- Dec- 03	23- Dec -04	27- May -14
US8735410	Quinazoline derivatives as tyrosine kinase inhibitors	AstraZeneca AB	26- Feb- 05	24- Feb -06	27- May -14
US8735348	Casein derived peptides and uses thereof	Peptera Ltd.	1- Mar- 00	5- Sep -12	27- May -14
US8734823	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14- Dec- 05	28- May -10	27- May -14
US8728793	Amphipathic alpha-helical peptide compositions as antiviral agents	The Board of Trustees of the Leland Stanford Junior University	19- Jul-07	14- Jul- 08	20- May -14
US8722917	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	23- Jan -12	13- May -14
US8722741	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24- Aug- 04	6- Dec -11	13- May -14
US8722725	Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof	Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory	23- Mar- 07	21- Mar -08	13- May -14
US8718948	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	Gen-Probe Incorporated	24- Feb- 11	24- Feb -12	6- May -14
US8716464	Compositions and methods for silencing Ebola virus gene expression	Not Available	20- Jul-09	20- Jul- 10	6- May -14
US8716461	Human parvovirus	Blood Systems, Inc.	24- May- 04	24- May -05	6- May -14
US8710224	Heterocyclic compounds as CCR2B antagonists	AstraZeneca AB	24- Dec- 04	13- Sep -13	29- Apr- 14
US8709730	Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins	Icahn School of Medicine at Mount Sinai	5- Apr- 07	7- Apr -08	29- Apr- 14
US8709496	Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract	D2 Bioscience Group Ltd.	6- Jan- 10	23- May -12	29- Apr- 14
US8709447	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	22- Oct- 03	26- Apr -12	29- Apr- 14
US8709441	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18- May- 04	6- Jul- 10	29- Apr- 14
US8704169	Direct impact ionization (DII) mass spectrometry	The United States of America, as represented by the Secretary, Department of Health and Human Services	11- Oct- 11	11- Oct -11	22- Apr- 14
US8703748	Cleaning composition for treating tissue for transplantation derived from human/animal	CG BIO Co., Ltd.	11- Feb- 09	10- Feb -10	22- Apr- 14
US8703467	Inactivation of a pathogen in a sample by a treatment with formalin and UV light	Baxter Healthcare SA	27- May- 04	26- May -05	22- Apr- 14
US8702958	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3- Jun- 05	31- May -12	22- Apr- 14
US8697873	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines	3M Innovative Properties Company	24- Mar- 04	24- Mar -05	15- Apr- 14
US8697853	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	10- Jan -13	15- Apr- 14
US8697659	Analogues of glycolipids useful as immunoadjuvants	Luigi Panza	12- Oct- 07	10- Oct -08	15- Apr- 14
US8697140	Virucidal disinfectant	B. Braun Medical AG	28- Jan- 05	28- May -09	15- Apr- 14
US8697088	VLPs derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25- May- 07	27- May -08	15- Apr- 14
US8697087	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators	Novartis AG	4- Nov- 05	6- Nov -06	15- Apr- 14
US8691837	Substituted imidazo ring systems and methods	3M Innovative Properties Company	25- Nov- 03	24- Nov -04	8- Apr- 14
US8691826	Compounds	Chiesi Farmaceutici S.p.A.	14- Sep- 11	13- Sep -12	8- Apr- 14
US8691781	Compositions for treating respiratory viral infections and their use	Sirnaomics, Inc.	5- Nov- 04	4- Nov -05	8- Apr- 14

 

US8691777	Combination therapy	Emory University	27- Jan- 11	25- Jan -12	8- Apr- 14
US8686152	4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)	Janssen Pharmaceutica NV	10- Mar- 10	9- Mar -11	1- Apr- 14
US8682619	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14- Dec- 05	28- May -10	25- Mar -14
US8679839	Cell line from rousettus as host cell for pathogen amplification	Probiogen AG	4- Mar- 08	4- Mar -09	25- Mar -14
US8678184	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	25- Mar -14
US8678002	Devices and methods for decreasing human pathogen transmission	Filligent Limited	26- Jun- 07	25- Jun -08	25- Mar -14
US8673983	Melanins synthesized chemically or via enzyme catalysis	Loyola University Chicago	21- Dec- 07	22- Dec -08	18- Mar -14
US8673932	Oxime substituted imidazo-containing compounds	3M Innovative Properties Company	12- Aug- 03	12- Aug -04	18- Mar -14
US8673907	Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their use in therapy	AstraZeneca AB	17- Dec- 07	16- Dec -08	18- Mar -14
US8673904	Epoxide inhibitors of cysteine proteases	The Board of Trustees of the Leland Stanford Junior University	13- Jun- 06	13- Jun -07	18- Mar -14
US8673558	Luciferase biosensor	Promega Corporation	10- Oct- 03	24- Apr -12	18- Mar -14
US8673331	Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof	GP&E	18- Nov- 11	18- Nov -11	18- Mar -14
US8669263	Use of TAM receptor inhibitors as antimicrobials	Salk Institute for Biological Studies	9- Nov- 07	8- Mar -13	11- Mar -14
US8669262	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide	Parion Sciences, Inc.	27- Jun- 11	26- Jun -12	11- Mar -14
US8669240	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1- Oct- 07	19- Mar -13	11- Mar -14
US8664274	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6- Dec- 04	6- Jul- 11	4- Mar -14
US8664218	Pharmaceutical compounds	Astex Therapeutics Ltd.	11- Apr- 08	30- Jan -13	4- Mar -14
US8664188	siRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11- Dec- 08	11- Dec -09	4- Mar -14
US8663922	Systems and methods for detecting multiple optical signals	Gen-Probe Incorporated	10- Mar- 05	1- Jun -10	4- Mar -14
US8658767	Lipidated polyepitope vaccines	National Health Research Institutes	15- Nov- 10	15- Nov -11	25- Feb -14
US8658697	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies, Inc.	6- Dec- 04	26- Oct -10	25- Feb -14
US8658666	Substituted imidazoquinolines and imidazonaphthyridines	3M Innovative Properties Company	11- Feb- 05	10- Feb -06	25- Feb -14
US8658178	Carbon nanotube compositions and methods of use thereof	Yale University	19- Mar- 08	19- Mar -09	25- Feb -14
US8653252	Short interfering RNA (siRNA) analogues	Santaris Pharma A/S	21- Mar- 03	22- Mar -04	18- Feb -14
US8653084	Hydrobenzamide derivatives as inhibitors of Hsp90	Astex Therapeutics Ltd.	12- Oct- 06	12- Oct -07	18- Feb -14
US8653034	Compositions and methods comprising phosphatidylethanolamine­binding peptide derivatives	Board of Regents, The University of Texas System	15- Jul-02	8- May -08	18- Feb -14
US8652836	Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response	Providence Health System	29- Jul-05	27- Jul- 06	18- Feb -14

 

US8652782	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids	Longhorn Vaccines & Diagnostics, LLC	12- Sep- 06	26- Apr -11	18- Feb -14
US8652533	Durable biocides and disinfectants	Mitsui Norin Co., Ltd.	7-Jul- 04	5- Jul- 05	18- Feb -14
US8648076	Cysteine protease inhibitors and their therapeutic applications	Hybrigenics SA	5- Aug- 05	26- Jul- 06	11- Feb -14
US8647676	Antimicrobial composition from copepods	Nofima Ingrediens	28- Oct- 08	28- Oct -09	11- Feb -14
US8642596	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6- Dec- 04	6- Dec -05	4- Feb -14
US8642260	Single quantum-dot based aptameric nanosensors	The Research Foundation of the City University of New York	21- Oct- 08	21- Oct -09	4- Feb -14
US8633322	Alkynyl derivatives useful as DPP-1 inhibitors	Janssen Pharmaceutica NV	29- Oct- 09	28- Oct -10	21- Jan- 14
US8633308	Compounds for preventing or treating viral infections and methods of use thereof	The Governors of The University of Alberta	28- Feb- 07	27- Feb -08	21- Jan- 14
US8632764	Directed evolution and in vivo panning of virus vectors	University of North Carolina at Chapel Hill	30- Apr- 08	29- Apr -09	21- Jan- 14
US8629283	Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof	Icahn School of Medicine at Mount Sinai	6- Mar- 08	6- Mar -09	14- Jan- 14
US8629271	Compounds	AstraZeneca AB	6- Feb- 08	2- Apr -12	14- Jan- 14
US8629098	Compositions and methods for adoptive and active immunotherapy	Yale University	15- Jan- 08	14- Jan -09	14- Jan- 14
US8628786	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28- Dec- 07	2- Dec -11	14- Jan- 14
US8624011	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14- Sep- 09	14- Sep -10	7- Jan- 14
US8623419	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24- Jan- 06	4- Nov -11	7- Jan- 14
US8623382	Immunogenic compositions for inducing an immune response to HIV	Wyeth LLC	17- Jun- 04	18- Jan -11	7- Jan- 14
US8623364	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8- Feb- 06	24- Oct -12	7- Jan- 14
US8617838	Fluorescent proteins and related methods and compounds	University of Massachusetts	20- Sep- 04	20- Sep -05	31- Dec -13
US8615368	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	24- Dec -13
US8609370	Highly active glycoproteins-process conditions and an efficient method for their production	Glycotope GmbH	13- Feb- 04	14- Feb -05	17- Dec -13
US8609101	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies	Theraclone Sciences, Inc.	23- Apr- 09	23- Apr -10	17- Dec -13
US8604215	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	22- Mar -10	10- Dec -13
US8603469	Methods of treating cancer with human monoclonal antibodies against interleukin 8	Genmab A/S	16- Dec- 02	27- Dec -11	10- Dec -13
US8599383	Optical cytometry	The Regents of the University of California	6- May- 09	6- May -09	3- Dec -13
US8598192	Hydroxylamine substituted imidazoquinolines	3M Innovative Properties Company	14- Nov- 03	12- Nov -04	3- Dec -13
US8598134	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	South Alabama Medical Science Foundation	22- Oct- 04	23- Jul- 10	3- Dec -13
US8598116	Treatment of influenza virus infection	Educational Fund and Autoimmune Technologies, LLC	4- Nov- 03	29- May -12	3- Dec -13
US8598106	Anti-microbial composition exhibiting residual anti-microbial properties on a surface	Byotrol PLC	17- Sep- 07	5- Jul- 11	3- Dec -13
US8597650	Methods for treating rheumatoid arthritis with anti-bile salt- stimulated lipase (BSSL) antibodies	HERNELL OLLE	8- Apr- 09	6- Apr -10	3- Dec -13

 

US8592567	Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same	The Trustees of the University of Pennsylvania	13- Jan- 06	3- May -12	26- Nov -13
US8592391	Method for therapeutic, clinical and veterinary use poly-ICLC	SALAZAR ANDRES	1-Jul- 03	17- Oct -08	26- Nov -13
US8586770	Unsaturated steroid compounds	Harbor Therapeutics, Inc.	29- Sep- 04	18- Feb -11	19- Nov -13
US8586364	Cells and methodology to generate non-segmented negative-strand RNA viruses	Institut Pasteur	22- Dec- 06	21- Dec -07	19- Nov -13
US8586363	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	10- Dec -10	19- Nov -13
US8581584	Membrane proteins, mechanisms of action and uses thereof	Florida State University Research Foundation	26- May- 10	26- May -11	12- Nov -13
US8580927	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31- Jan- 08	30- Jan -09	12- Nov -13
US8580268	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	Coley Pharmaceutical GmbH	27- Sep- 06	27- Sep -07	12- Nov -13
US8569283	Compounds and compositions as c-Kit kinase inhibitors	LIU XIAODONG	1- Sep- 11	29- Aug -12	29- Oct- 13
US8562996	RSV-specific binding molecules and means for producing them	MedImmune Limited	1- Jun- 07	30- May -08	22- Oct- 13
US8562943	Quality control methods for oil-in-water emulsions containing squalene	Novartis AG	8- Nov- 06	6- Nov -07	22- Oct- 13
US8560339	System and method to predict the global spread of infectious agents via commercial air travel	Kamran Khan	2- Apr- 07	2- Apr -08	15- Oct- 13
US8557767	Synthetic apolipoprotein E mimicking polypeptides and methods of use	UAB Research Foundation	28- Aug- 07	27- Aug -08	15- Oct- 13
US8557248	Methods and compositions for treating malaria	Cyvax, Inc.	9- Aug- 10	9- Aug -11	15- Oct- 13
US8552051	Use of pharmaceutical compositions containing mesembrenone	H. L. Hall & Sons Limited	20- Mar- 09	16- Mar -10	8- Oct- 13
US8552032	Bicyclic derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18- Dec- 09	16- Dec -10	8- Oct- 13
US8551968	Methods for generation of antibodies	National Jewish Health	13- Mar- 07	13- Mar -08	8- Oct- 13
US8551756	Avian influenza chimeric VLPS	Novavax, Inc.	11- Jul-03	19- Jan -10	8- Oct- 13
US8551750	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23- Apr- 09	28- Jul- 09	8- Oct- 13
US8551749	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23- Apr- 09	23- Apr -09	8- Oct- 13
US8551738	Systems and methods for rapid identification of nucleic acid variants	Ibis Biosciences, Inc.	21- Jul-05	11- Nov -09	8- Oct- 13
US8551469	Treatment of tumors and viral diseases with recombinant interferon alpha	Superlab Far East Limited	28- Feb- 01	6- Oct -08	8- Oct- 13
US8546432	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	5- May -11	1- Oct- 13
US8546383	Chiral fused [1,2]imidazo[4,5-c] ring compounds	3M Innovative Properties Company	30- Dec- 04	25- May -12	1- Oct- 13
US8546082	Methods for identification of sepsis-causing bacteria	Ibis Biosciences, Inc.	11- Sep- 03	25- May -07	1- Oct- 13
US8541568	Compositions and methods using siRNA molecules for treatment of gliomas	BIGNER DARELL D	24- May- 08	26- May -09	24- Sep -13
US8541457	Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	3- Jun- 05	5- Jun -06	24- Sep -13
US8541438	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	21- Dec -10	24- Sep -13
US8541221	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	1- Jul- 10	24- Sep -13
US8541003	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	Protein Sciences Corporation	20- Jun- 03	21- Jun -04	24- Sep -13

 

US8529968	Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition	Hightech Bio-Activities Holding GmbH	29- Mar- 04	29- Mar -05	10- Sep -13
US8524715	Phenoxyacetic acid derivatives useful for treating respiratory diseases	Astrazeneca AB	23- Nov- 04	22- Nov -05	3- Sep -13
US8524488	Methods and devices for determining a cell characteristic, and applications employing the same	The Regents of the University of California	10- Sep- 02	9- Mar -05	3- Sep -13
US8524241	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20- Jul-07	18- Jul- 08	3- Sep -13
US8519106	Monoclonal human tumor-specific antibody	University of Zurich	13- Mar- 07	13- Mar -08	27- Aug -13
US8507545	Cytotoxic T cell activator comprising EP4 agonist	National University Corporation, Hamamatsu University School of Medicine	8- May- 07	7- May -08	13- Aug -13
US8507544	Bi-aryl amide compounds as CRTh2 receptor modulators	Astrazeneca AB	5-Jul- 07	3- Jul- 08	13- Aug -13
US8507455	Folate conjugates	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	4- Dec -08	13- Aug -13
US8506968	SARS vaccine compositions and methods of making and using them	Eli Lilly and Company	29- Jun- 00	28- Dec -09	13- Aug -13
US8506966	Adjuvanted influenza vaccines for pediatric use	Novartis AG	22- Feb- 08	20- Feb -09	13- Aug -13
US8501746	Organic compounds	Novartis AG	5- Jun- 06	4- Jun -07	6- Aug -13
US8501699	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Management Pty Ltd	3-Jul- 08	7- Sep -12	6- Aug -13
US8501461	System for performing multi-formatted assays	Gen-Probe Incorporated	10- Mar- 05	3- Dec -09	6- Aug -13
US8497405	Process for dispersing vaporous hydrogen peroxide	STERIS Inc.	6- Mar- 07	28- Feb -13	30- Jul- 13
US8497112	Method for producing viral vaccines	Baxter Healthcare SA	28- Aug- 07	28- Aug -08	30- Jul- 13
US8494781	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	BOGOCH ELENORE S	6- Jun- 03	10- Dec -10	23- Jul- 13
US8492329	Bioactive peptides and methods of using same	Compugen Ltd.	12- Jul-07	11- Jul- 08	23- Jul- 13
US8486959	Dibenzo[f,h]isoquinoline derivatives	National Health Research Institutes	14- Jan- 10	14- Jan -11	16- Jul- 13
US8486678	Pharmaceutical compositions for the treatment of virus infection	Kineta Two, LLC	23- Nov- 05	1- Feb -12	16- Jul- 13
US8486619	Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses	University of Rochester	2- May- 08	1- May -09	16- Jul- 13
US8486420	Live virus vaccines	Children’s Hospital, Inc.	15- Feb- 05	15- Feb -06	16- Jul- 13
US8481547	Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18- Dec- 09	16- Dec -10	9- Jul- 13
US8481270	Method for chromogenic detection of two or more target molecules in a single sample	Ventana Medical Systems, Inc.	22- Aug- 08	21- Aug -09	9- Jul- 13
US8481255	Scytovirin domain 1 related polypeptides	The United States of America, as represented by the Secretary, Department of Health and Human Services	25- May- 05	30- Sep -11	9- Jul- 13
US8476292	Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- dimethylethyl}methanesulfonamide and methods	3M Innovative Properties Company	9- Sep- 05	8- Sep -06	2- Jul- 13
US8476288	Salts 756	AstraZeneca AB	21- May- 09	20- May -10	2- Jul- 13
US8476265	Compounds-801	AstraZeneca AB	30- Jul-10	14- Sep -12	2- Jul- 13
US8470771	Method and medicament for inhibiting the infection of influenza virus	Institute of Microbiology, Chinese Academy of Sciences	14- Nov- 07	18- Dec -07	25- Jun- 13
US8470769	Method of treatment of bacterial infection by administration of poly­lysine	Novabiotics, Ltd.	18- Aug- 04	30- Nov -11	25- Jun- 13

 

US8470346	Anti-viral pharmaceutical compositions	Mast Therapeutics, Inc.	10- Dec- 03	19- May -11	25- Jun- 13
US8470335	Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it	Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation	13- Jun- 08	13- Jun -08	25- Jun- 13
US8466284	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase	Astra Zeneca AB	6- Nov- 07	5- Nov -08	18- Jun- 13
US8466167	Compounds and compositions as TLR activity modulators	IRM LLC	3- Mar- 08	27- Feb -09	18- Jun- 13
US8466124	RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles	Coley Pharmaceutical GmbH	13- Aug- 07	12- Jun -12	18- Jun- 13
US8465751	Cna—B domain antigens in vaccines against gram positive bacteria	Novartis AG	12- Jan- 09	12- Jan -10	18- Jun- 13
US8461125	Compositions and methods to treat asthma	The Children’s Hospital of Philadelphia	14- Feb- 08	13- Aug -10	11- Jun- 13
US8460914	Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens	Novartis AG	9- Sep- 04	10- Jan -13	11- Jun- 13
US8460605	Decontaminant dispenser suitable for use as a projectile	STERIS Inc.	6- Mar- 07	20- Feb -08	11- Jun- 13
US8455483	Compounds—801	AstraZeneca AB	31- Jul-09	30- Jul- 10	4- Jun- 13
US8450471	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	28- May -13
US8450467	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	14- Dec -11	28- May -13
US8450350	Triazoles as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	5- May -11	28- May -13
US8450284	Coiled-coil lipopeptide helical bundles and synthetic virus-like particles	Universitaet Zuerich	9- Dec- 06	6- Dec -07	28- May -13
US8450055	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31- Aug- 05	25- Aug -06	28- May -13
US8445650	Mutant botulinum neurotoxin serotype A polypeptide and uses thereof	Thomas Jefferson University	25- Sep- 07	25- Sep -08	21- May -13
US8445447	B7-DC variants immunogenic compositions and methods of use thereof	The Johns Hopkins University	13- Jul-07	7- Mar -12	21- May -13
US8444961	RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor	Sekisui Chemical Co., Ltd.	16- Jun- 09	16- Jun -10	21- May -13
US8440704	Quercetin-containing compositions	Quercegen Pharmaceuticals LLC	17- Jul-06	16- Dec -09	14- May -13
US8440649	Phenanthroindolizidine analogues	National Health Research Institutes	24- Feb- 09	11- Feb -10	14- May -13
US8440642	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	1- Sep -11	14- May -13
US8440432	Tal effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	14- May -13
US8440431	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	14- May -13
US8440408	Animal protein-free media for cultivation of cells	Baxter Healthcare S.A.	29- Oct- 04	10- Dec -10	14- May -13
US8436178	Imidazoquinolines with immuno-modulating properties	AstraZeneca AB	8- May- 07	6- May -08	7- May -13
US8436024	2-pyridone compounds	Astrazeneca AB	2- Oct- 09	1- Oct -10	7- May -13
US8431160	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions	Novartis AG	24- Feb- 06	24- Feb -07	30- Apr- 13
US8431134	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31- Jul-08	31- Jul- 09	30- Apr- 13
US8426565	Dendritic cell marker and uses thereof	Walter and Eliza Hall Institute of Medical Research	30- Aug- 07	29- Aug -08	23- Apr- 13
US8420798	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	31- Aug -07	16- Apr- 13

 

US8420784	Interleukin 10 receptor, (IL-10R) antibodies	Kyowa Hakko Kirin Co., Ltd.	27- May- 08	27- May -09	16- Apr- 13
US8420096	Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling	Vanderbilt University	4- Mar- 04	4- Mar -05	16- Apr- 13
US8420094	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20- Jul-07	18- Jul- 08	16- Apr- 13
US8415394	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	Astrazeneca AB	6- Oct- 05	21- Dec -11	9- Apr- 13
US8415361	Use of TAM receptor inhibitors as antimicrobials	The Salk Institute for Biological Studies	9- Nov- 07	7- Nov -08	9- Apr- 13
US8415330	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1- Oct- 07	1- Oct -12	9- Apr- 13
US8415309	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Managment Pty Ltd	1-Jul- 09	11- Jan -12	9- Apr- 13
US8415118	Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof	Virginia Tech Intellectual Properties, Inc.	29- Oct- 07	29- Oct -08	9- Apr- 13
US8415102	Methods and computer systems for identifying target-specific sequences for use in nanoreporters	NanoString Technologies, Inc.	10- Apr- 07	10- Apr -08	9- Apr- 13
US8410149	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies Inc.	6- Dec- 04	28- Oct -10	2- Apr- 13
US8410114	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial	AstraZeneca AB	8- May- 06	6- Jan -12	2- Apr- 13
US8409589	Mutant forms of streptolysin O	Novartis AG	21- Dec- 07	14- Sep -11	2- Apr- 13
US8399651	Nucleic acids encoding GAS57 mutant antigens	Novartis AG	12- Sep- 07	10- Sep -12	19- Mar -13
US8398992	Methods and compositions for polytopic vaccination	Polytopos LLC	29- Apr- 05	22- Dec -11	19- Mar -13
US8394986	Phenoxiacetic acid derivatives	AstraZeneca AB	21- Aug- 03	26- Jul- 11	12- Mar -13
US8394945	Compositions for use in identification of bacteria	Ibis Biosciences, Inc.	11- Sep- 03	7- Mar -07	12- Mar -13
US8394386	Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations	The Trustees of the University of Pennsylvania	28- Apr- 04	27- Apr -05	12- Mar -13
US7829712	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	9- Nov -10
US7829707	Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6- Dec- 04	5- Dec -05	9- Nov -10
US7829302	Method for detecting the specificity of activated lymphocyte	HU JUN	8- Dec- 03	7- Dec -04	9- Nov -10
US7820210	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3- Apr- 00	18- Mar -08	26- Oct- 10
US7812135	GITR-binding antibodies	TOLERRX, Inc.	25- Mar- 05	27- Mar -06	12- Oct- 10
US7803918	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18- Aug- 03	18- Aug -04	28- Sep -10
US7803796	Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus	Sungkyunkwan University Foundation For Corporate Collaboration	22- Dec- 06	20- Dec -07	28- Sep -10
US7803765	Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom	Phylogica Limited	20- Feb- 04	20- Feb -04	28- Sep -10
US7799800	Lipid-modified immune response modifiers	3M Innovative Properties Company	30- Oct- 03	12- Aug -04	21- Sep -10
US7794998	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	24- Feb -07	14- Sep -10
US7794659	Signal measuring system having a movable signal measuring device	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	14- Sep -10
US7790878	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22- Oct- 04	25- Jun -09	7- Sep -10

 

US7790449	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	6- Sep -07	7- Sep -10
US7790159	Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	7- Sep -10
US7786290	Double-stranded ribonucleic acid with increased effectiveness in an organism	Alnylam Pharmaceuticals, Inc.	13- Jun- 03	14- Jun -04	31- Aug -10
US7785775	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	Versitech Limited	24- Mar- 03	8- Jun -07	31- Aug -10
US7785612	Polyamino acid for use as adjuvant	Masanori Baba	20- Apr- 05	19- Apr -06	31- Aug -10
US7781226	Particle on membrane assay system	The Board of Regents of the University of Texas System	27- Feb- 04	22- Dec -04	24- Aug -10
US7781203	Supports for assaying analytes and methods of making and using thereof	Corning Incorporated	29- Dec- 05	7- Jun -06	24- Aug -10
US7777036	Heterocyclic derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	17- Aug -10
US7777022	Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof	Rosetta Genomics, Ltd.	26- Nov- 02	26- May -04	17- Aug -10
US7776521	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25- Apr- 03	14- May -07	17- Aug -10
US7767817	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof	FANG HAO	5- Sep- 03	7- Sep -04	3- Aug -10
US7767677	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	3- Aug -10
US7767658	Vaccine composition	Aventis Pasteur SA	17- Nov- 03	9- Jan -08	3- Aug -10
US7767657	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	16- Aug -06	3- Aug -10
US7767210	RNA virus vaccines and methods	The Board of Regents of the University of Oklahoma	14- Dec- 05	14- Dec -06	3- Aug -10
US7763618	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29- Jul-03	29- Jul- 04	27- Jul- 10
US7758868	Modified polymerases and attenuated viruses and methods of use thereof	The Penn State Research Foundation	22- Dec- 06	24- Dec -07	20- Jul- 10
US7754711	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	9- Feb -05	13- Jul- 10
US7750123	Antibodies against SARS-CoV and methods of use thereof	Dana Farber Cancer Institute, Inc.	25- Nov- 03	24- Nov -04	6- Jul- 10
US7749445	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2- May- 05	19- Dec -06	6- Jul- 10
US7745486	Quercetin-containing compositions	Quercegen Pharma LLC	17- Jul-06	16- Jul- 07	29- Jun- 10
US7745442	Methods of reducing risk of infection from pathogens	Parion Sciences, Inc.	20- Aug- 03	18- Aug -04	29- Jun- 10
US7745147	Methods and uses of antibodies in the purification of interferon	ViraNative AB	12- Feb- 05	13- Feb -06	29- Jun- 10
US7745119	System for detecting polynucleotides	Investigen, Inc.	20- May- 03	21- Nov -05	29- Jun- 10
US7745118	Comparative genomic resequencing	Roche Nimblegen, Inc.	8- Apr- 04	8- Apr -05	29- Jun- 10
US7741450	Antibodies to GM-CSF	Morphotek Inc.	8- Feb- 06	8- Feb -07	22- Jun- 10
US7741360	Bi-aryl or aryl-heteroaryl substituted indoles	AstraZeneca AB	26- May- 06	25- May -07	22- Jun- 10
US7740858	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21- Sep- 04	21- Sep -04	22- Jun- 10
US7737135	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24- Aug- 04	22- Aug -05	15- Jun- 10
US7736850	Strain of SARS-associated coronavirus and applications thereof	Centre National de la Recherche Scientifique	2- Dec- 03	2- Dec -04	15- Jun- 10

 

US7732177	Oligoadenylate Synthetase (OAS)	Illumigen Biosciences, Inc.	23- Nov- 05	17- Nov -06	8- Jun- 10
US7731978	Mutant forms of streptolysin O	Novartis AG	21- Dec- 07	19- Dec -08	8- Jun- 10
US7728110	Antibodies to SARS coronavirus	Amgen, Inc.	19- May- 06	21- May -07	1- Jun- 10
US7725565	System and method for detecting, collecting, analyzing, and communicating event related information	Georgetown University	25- Feb- 08	19- Nov -08	25- May -10
US7723570	Edible vaccines expressed in soybeans	SoyMeds, Inc.	12- Oct- 04	12- Oct -05	25- May -10
US7723041	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12- Sep- 03	3- Feb -09	25- May -10
US7722886	Compositions and methods for treatment of severe acute respiratory syndrome (SARS)	Wyeth	20- May- 04	20- May -04	25- May -10
US7714109	Combinations and kits for cancer treatment using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	11- May -10
US7713515	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis	R.E.D. Laboratories N.V.	27- May- 03	26- May -04	11- May -10
US7709521	Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases	AstraZeneca AB	18- Aug- 03	16- Aug -04	4- May -10
US7709511	Benzothiazolone derivatives	AstraZeneca AB	9- Aug- 05	3- Aug -06	4- May -10
US7709188	Multi-allelic detection of SARS-associated coronavirus	Birch Biomedical Research LLC	22- Aug- 03	13- Aug -04	4- May -10
US7700782	Compounds 569	AstraZeneca AB	19- Dec- 07	19- Dec -07	20- Apr- 10
US7700728	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors	Schering Corporation	24- Mar- 05	24- Mar -06	20- Apr- 10
US7700727	Compositions and kits for detecting pathogen infection	Biokit, S.A.	23- Dec- 03	27- Apr -05	20- Apr- 10
US7700273	Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor	The United States of America as represented by the Department of Health and Human Services	9- Apr- 04	11- Apr -05	20- Apr- 10
US7700120	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center	15- Jun- 04	15- Jun -05	20- Apr- 10
US7696406	Expression of a recombinant transgene	Board of Trustees Operating Michigan State University	3-Jul- 03	2- Jul- 04	13- Apr- 10
US7696330	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22- Jul-03	20- Jan -06	13- Apr- 10
US7691877	Pharmaceuticals	Pfizer Inc.	17- Feb- 06	16- Feb -07	6- Apr- 10
US7691646	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28- Mar- 03	21- Nov -08	6- Apr- 10
US7691599	Mammalian genes involved in viral infection and tumor suppression	Zirus, Inc.	2- May- 02	2- May -03	6- Apr- 10
US7691390	Viral protein	CHANG MING-FU	2- Mar- 04	19- Sep -07	6- Apr- 10
US7687535	Substituted 3-sulfur indoles	AstraZeneca AB	27- May- 03	25- May -04	30- Mar -10
US7687475	RNA interference in respiratory epithelial cells	University of Iowa Research Foundation	9-Jul- 04	16- Oct -07	30- Mar -10
US7682688	Microporous materials, methods, and articles for localizing and quantifying analytes	University of Utah Research Foundation	26- Nov- 02	20- Nov -03	23- Mar -10
US7678774	Treating severe acute respiratory syndrome	Hemispherx Biopharma	16- May- 03	26- Jan -07	16- Mar -10
US7678386	Liposomes coated with selected antibodies that bind to aminophospholipids	Board of Regents the University of Texas	15- Jul-02	15- Aug -03	16- Mar -10
US7674795	Fluorene derivatives, composition containing said derivatives and the use thereof	Aventis Pharma SA	19- May- 05	14- Nov -07	9- Mar -10

 

US7670807	RNA-dependent DNA polymerase from Geobacillus stea rothermophilus	East Tennessee State Univ. Research Foundation	10- Mar- 04	10- Mar -04	2- Mar -10
US7670565	Building decontamination with vaporous hydrogen peroxide	Steris Inc	31- Jan- 03	3- Mar -08	2- Mar -10
US7666996	Casein derived peptides and uses thereof	Peptera Pharmaceuticals Ltd	1- Mar- 00	1- Mar -04	23- Feb -10
US7666592	Methods for concurrent identification and quantification of an unknown bioagent	Ibis Biosciences, Inc.	18- Feb- 04	17- Feb -05	23- Feb -10
US7662860	3D-structure model of SARS coronavirus 3CL protease and anti- SARS drugs	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	4- Jun- 03	2- Dec -05	16- Feb -10
US7648997	Hydroxylamine substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	12- Aug- 03	12- Aug -04	19- Jan- 10
US7648844	Method and apparatus for detection of analyte using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	19- Jan- 10
US7645881	Methods for treating hepatitis C	PTC Therapeutics, Inc.	22- Jul-04	14- Jul- 05	12- Jan- 10
US7642350	Purine derivatives	Pfizer Limited	4- May- 05	3- May -06	5- Jan- 10
US7636637	Variable length probe selection	Roche NimbleGen, Inc.	18- Jun- 04	20- Jun -05	22- Dec -09
US7635557	Enzymatic diagnostic test for SARS and other viral diseases	MND Diagnostic Ltd.	23- Jun- 03	23- Jun -04	22- Dec -09
US7635485	Method of accelerated vaccination against Ebola viruses	The United States of America as represented by the Department of Health and Human Services	1- Aug- 03	17- Jan -06	22- Dec -09
US7632638	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	15- Dec -09
US7629443	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	New York Blood Center, Inc.	2- Jun- 04	8- Feb -06	8- Dec -09
US7629385	Sphingolipid-derived pharmaceutical compositions	Jado Technologies GmbH	29- Jun- 04	29- Jun -05	8- Dec -09
US7629137	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	8- Dec -09
US7629114	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer	World Sense Technology Limited	26- Aug- 03	20- Aug -04	8- Dec -09
US7625563	Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	1- Dec -09
US7625492	Charge-based water filtration systems	The University of Wyoming Research Corporation	28- Jan- 03	28- Jan -04	1- Dec -09
US7625428	Bioagent air filtration systems	The University of Wyoming Research Corporation	28- Jan- 03	28- Jan -04	1- Dec -09
US7623997	Computer-implemented biological sequence identifier system and method	The United States of America as represented by the Secretary of the Navy	2-Jul- 04	6- Jun -06	24- Nov -09
US7622559	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16- Dec- 02	27- Jun -07	24- Nov -09
US7622125	Polycistronic HIV vector constructs	Novartis Vaccines and Diagnostics, Inc.	5- May- 04	5- May -05	24- Nov -09
US7622118	Cancer treatment methods using selected antibodies to a minophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	24- Nov -09
US7622112	Anti-SARS monoclonal antibodies	Not Available	5- Dec- 03	6- Dec -04	24- Nov -09
US7619067	Evolved interferon-alpha polypeptides	Maxygen, Inc.	18- May- 05	17- May -06	17- Nov -09
US7618802	Compositions of coronaviruses with a recombination-resistant genome	The University of North Carolina at Chapel Hill	21- Jul-03	19- Jan -06	17- Nov -09
US7618788	Proteome epitope tags and methods of use thereof in protein modification analysis	Millipore Corporation	10- May- 02	5- Feb -04	17- Nov -09
US7618635	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21- Jul-04	19- Jul- 05	17- Nov -09
US7615381	Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	10- Nov -09

 

US7615223	Selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	10- Nov -09
US7611908	Method and apparatus for therapeutic drug monitoring using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	3- Nov -09
US7611704	Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	3- Nov -09
US7605161	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	20- Oct- 09
US7605135	Baicalin as a treatment for SARS infection	The University of Hong Kong	10- Nov- 03	8- Nov -04	20- Oct- 09
US7604960	Transient protein expression methods	Crucell Holland B.V.	15- Apr- 99	1- Jun -07	20- Oct- 09
US7604801	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5- May- 03	16- Oct -08	20- Oct- 09
US7598382	Aryl substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	20- Dec- 02	13- Jan -06	6- Oct- 09
US7598094	Methods and apparatus for detecting cardiac injury markers using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	6- Oct- 09
US7598072	Assay to detect viral uncoating	Wisconsin Alumni Research Foundation	9- Dec- 03	8- Dec -04	6- Oct- 09
US7597936	Method of producing a pigmented composite microporous material	University of Utah Research Foundation	26- Nov- 02	26- May -04	6- Oct- 09
US7595381	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	10- Jun -08	29- Sep -09
US7595163	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	10- Jun -08	29- Sep -09
US7592343	Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	22- Sep -09
US7592322	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22- Oct- 04	14- Jun -05	22- Sep -09
US7592008	Membrane scaffold proteins	The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois	20- Nov- 00	11- Jan -05	22- Sep -09
US7589092	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20- Jun- 03	27- Dec -06	15- Sep -09
US7585647	Nucleic acid encoding recombinant interferon	WEI GUANGWEN	28- Aug- 03	26- Aug -04	8- Sep -09
US7582740	Methods and kits for detecting SARS-associated coronavirus	The Trustees of Columbia University In the City of New York	17- Apr- 03	23- Jan -04	1- Sep -09
US7582621	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	16- Feb -06	1- Sep -09
US7579396	Polymer composite	Eastman Kodak Company	31- Jan- 07	31- Jan -07	25- Aug -09
US7579359	1-alkoxy lH-imidazo ring systems and methods	3M Innovative Properties Company	2- Sep- 04	1- Sep -05	25- Aug -09
US7572621	Detection, characterization and treatment of viral infection and methods thereof	Canadian Blood Services	9- Apr- 03	11- Oct -05	11- Aug -09
US7572448	Combined cancer treatment methods using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	11- Aug -09
US7572442	Selected antibody compositions for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Jul- 03	11- Aug -09
US7569536	Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26- Dec- 03	24- Dec -04	4- Aug -09
US7569384	Albumin fusion proteins	Human Genome Sciences, Inc.	9- Feb- 04	8- Aug -06	4- Aug -09
US7550140	Antibody to the human OX40 receptor	Crucell Holland B.V.	13- Jun- 02	13- Jun -03	23- Jun- 09
US7547698	Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	16- Jun- 09
US7547516	Method for reducing the presence of amplification inhibitors in a reaction receptacle	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	16- Jun- 09

 

US7547512	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24- Mar- 03	24- Mar -04	16- Jun- 09
US7544697	Pyrazolopyridines and analogs thereof	Coley Pharmaceutical Group, Inc.	3- Oct- 03	1- Apr -05	9- Jun- 09
US7541436	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	4- May -07	2- Jun- 09
US7541163	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	14- Aug -07	2- Jun- 09
US7531630	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	13- Sep -06	12- May -09
US7531324	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	13- Sep -06	12- May -09
US7521424	Albumin fusion proteins	Human Genome Sciences, Inc.	22- Jan- 03	7- Jul- 05	21- Apr- 09
US7521185	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12- Sep- 03	13- Sep -04	21- Apr- 09
US7514436	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	7- Apr- 09
US7511124	Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	31- Mar -09
US7504384	Use of lipid conjugates in the treatment of infection	Yissum Research Development Company of the Hebrew University of Jerusalem	10- Jan- 00	8- Sep -05	17- Mar -09
US7504382	Protease inhibitors for coronaviruses and SARS-CoV and the use thereof	Cytovia, Inc.	6- May- 03	6- May -04	17- Mar -09
US7504205	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for SARS therapy	The Burnham Institute	17- May- 04	17- May -05	17- Mar -09
US7504097	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	17- Mar -09
US7498409	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	Schering Corporation	24- Mar- 05	23- Mar -06	3- Mar -09
US7498152	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	3- Mar -09
US7495011	Anti-coronavirus drug	aRigen Pharmaceuticals, Inc.	15- Jul-03	14- Jul- 04	24- Feb -09
US7491793	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4- Nov- 03	3- Nov -04	17- Feb -09
US7491706	Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof	Changchun Huapu Biotechnology Co., Ltd.	25- Jul-03	26- Jul- 04	17- Feb -09
US7491508	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20- Jun- 03	15- Jun -04	17- Feb -09
US7491489	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	The University of Hong Knog	22- Nov- 04	28- Oct -05	17- Feb -09
US7491397	Receptor binding polypeptides	National Health Research Institutes	9- Jan- 04	10- Jan -05	17- Feb -09
US7488801	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7488589	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7488473	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7485432	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27- Feb- 03	27- Feb -04	3- Feb -09
US7482334	Therapeutic treatment methods	Hollis-Eden Pharmaceuticals, Inc.	28- Aug- 02	12- Feb -07	27- Jan- 09
US7482149	Inhibition of SARS coronavirus infection with clinically approved antiviral drugs	Genome Institute of Singapore	9- Jun- 03	9- Jun -04	27- Jan- 09
US7479484	Peptides and peptidomimetics having immune-modulating, anti­inflammatory, and anti-viral activity	Takeda Pharmaceutical Company Limited	25- Jun- 03	25- Jun -04	20- Jan- 09
US7470666	Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome	Guangdong Techpool Biochem. Pharma. Co., Ltd.	26- May- 03	25- May -04	30- Dec -08

 

US7470548	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28- Mar- 03	26- Mar -04	30- Dec -08
US7468418	Compositions for enhancing transport of molecules into cells	AVI BioPharma., Inc.	29- Apr- 03	29- Apr -04	23- Dec -08
US7465836	Hydrolytically-resistant boron-containing therapeutics and methods of use	Anacor Pharmaceuticals, Inc.	16- Jun- 03	15- Jun -04	16- Dec -08
US7462615	Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications	Hybrigenics SA	8- Dec- 05	8- Dec -05	9- Dec -08
US7460960	Proteome epitope tags and methods of use thereof in protein modification analysis	Epitome Biosystems, Inc.	10- May- 02	13- Nov -03	2- Dec -08
US7456180	Piperazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	25- Nov -08
US7455833	Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	25- Nov -08
US7452542	Live attenuated coronavirus vaccines	Vanderbilt University	21- May- 04	23- May -05	18- Nov -08
US7445889	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5- May- 03	5- May -04	4- Nov -08
US7442761	Replikin peptides and uses thereof	BOGOCH ELENORE S	6- Jun- 03	4- Jun -04	28- Oct- 08
US7442508	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24- Apr- 98	28- Apr -06	28- Oct- 08
US7439349	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof	Not Available	3-Jul- 02	1- Jul- 03	21- Oct- 08
US7439052	Method of making modified immunodeficiency virus particles	Lipid Sciences	29- Jun- 00	10- Apr -06	21- Oct- 08
US7435588	Systems for detection and production of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	20- Sep- 05	28- Apr -06	14- Oct- 08
US7435538	High throughput screening method of drug for physiologically active protein	CellFree Sciences Co., Ltd.	8- Sep- 03	8- Sep -04	14- Oct- 08
US7432045	Method of inhibiting influenza infection with antiviral peptides	Wisconsin Alumni Research Foundation	1- Dec- 03	1- Dec -04	7- Oct- 08
US7429656	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of Hong Kong	19- May- 03	14- Jun -06	30- Sep -08
US7427479	Methods and kits for identifying target nucleotides in mixed populations	Applera Corporation	30- Apr- 04	29- Apr -05	23- Sep -08
US7424370	Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential	Council of Scientific and Industrial Research	20- Jul-04	7- Feb -05	9- Sep -08
US7407663	Modified immunodeficiency virus particles	Lipid Sciences, Inc.	29- Jun- 00	20- Jun -03	5- Aug -08
US7407662	Modified viral particles with immunogenic properties and reduced lipid content	Lipid Sciences, Inc.	29- Jun- 00	21- Jun -04	5- Aug -08
US7405207	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof	Epigenesis Pharmaceuticals, Inc.	17- Jun- 02	17- Jun -03	29- Jul- 08
US7405046	Compositions and methods for treatment of rhinovirus	The Quigley Corporation	6- Aug- 01	27- Oct -06	29- Jul- 08
US7399588	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	15- Jun -04	15- Jul- 08
US7396914	SARS nucleic acids, proteins, antibodies, and uses thereof	University of Massachusetts	4- Aug- 03	4- Aug -04	8- Jul- 08
US7393856	Anti-viral uses of borinic acid complexes	Anacor Pharmaceuticals, Inc.	14- Jun- 04	14- Jun -05	1- Jul- 08
US7393638	Assay system and methods for detecting SARS-CV	AsiaGEN Corporation	1-Jul- 03	1- Jul- 03	1- Jul- 08
US7387271	Immunostimulatory combinations	3M Innovative Properties Company	30- Dec- 02	30- Dec -03	17- Jun- 08

 

US7384909	Anti-viral treatment methods using phosphatidylethanolamine­binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	10- Jun- 08
US7378386	Anti-viral treatment methods using phosphatidylethanolamine­binding peptide derivatives	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	27- May -08
US7375210	PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the same	Samsung Electronics Co., Ltd.	12- Dec- 03	24- Nov -04	20- May -08
US7375202	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	The University of Hong Kong	24- Mar- 03	24- Mar -04	20- May -08
US7375180	Methods and compositions related to IRM compounds and Toll-like receptor 8	3M Innovative Properties Company	13- Feb- 03	12- Feb -04	20- May -08
US7374883	Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)	QIAGEN Diagnostics GmbH	30- Apr- 03	30- Apr -04	20- May -08
US7371850	Method and composition for reducing expression of ROCK-II	Myriad Genetics, Inc.	20- Aug- 03	20- Aug -04	13- May -08
US7371837	Human virus causing respiratory tract infection and uses thereof	The University of Hong Kong	21- Jul-04	16- May -05	13- May -08
US7371525	Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)	The Chinese University of Hong Kong	29- Jul-03	28- Jul- 04	13- May -08
US7361747	Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus	The University of Hong Kong	22- May- 03	24- May -04	22- Apr- 08
US7361304	Building decontamination with vaporous hydrogen peroxide	Steris Inc.	31- Jan- 03	29- Jan -04	22- Apr- 08
US7358068	Antiviral oligonucleotides	Replicor, Inc.	13- Sep- 02	12- Sep -03	15- Apr- 08
US7354908	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30- Apr- 02	30- Apr -03	8- Apr- 08
US7354551	Room decontamination with hydrogen peroxide vapor	Steris Inc	8-Jul- 04	8- Jul- 04	8- Apr- 08
US7344740	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3- Apr- 00	27- Nov -04	18- Mar -08
US7344720	Vaccine composition	Sanofi Pasteur SA	17- Nov- 03	15- Nov -04	18- Mar -08
US7339051	Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)	Isis Pharmaceuticals, Inc.	28- Apr- 03	26- Apr -04	4- Mar -08
US7335658	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	26- Feb -08
US7332475	Preventive or therapeutic composition for viral infectious disease	Kyowa Hakko Kogyo Co., Ltd.	22- Jul-03	22- Jul- 04	19- Feb -08
US7332294	CXCL10-based diagnosis and treatment of respiratory illnesses	University Health Network	17- Aug- 04	17- Aug -04	19- Feb -08
US7320857	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	Chinese National Human Genome Center at Shanghai	9-Jul- 04	9- Jul- 04	22- Jan- 08
US7318918	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	18- May -05	15- Jan- 08
US7314613	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	19- May -04	1- Jan- 08
US7312036	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22- Mar- 04	21- Mar -05	25- Dec -07
US7297786	RNA interference in respiratory epitheial cells	University of Iowa Research Foundation	9-Jul- 04	11- Jul- 05	20- Nov -07
US7291498	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20- Jun- 03	20- Jun -03	6- Nov -07
US7282568	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16- Dec- 02	16- Dec -03	16- Oct- 07
US7282199	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	25- Apr -03	16- Oct- 07
US7267942	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24- Mar- 03	24- Mar -04	11- Sep -07

 

US7261867	Production of silver sulfate grains using organo-sulfate or organo- sulfonate additives	Eastman Kodak Company	7- Apr- 06	7- Apr -06	28- Aug -07
US7247303	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	24- Jul- 07
US7244732	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20- Jun- 03	31- Mar -04	17- Jul- 07
US7223787	Prenylation inhibitors reduce host cell permissiveness to viral replication	Board of Regents, The University of Texas System	21- Oct- 03	21- Oct -03	29- May -07
US7220852	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25- Apr- 03	12- Apr -04	22- May -07
US7183300	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof	AGARWAL ATUL	11- Nov- 04	10- Nov -05	27- Feb -07
US7166435	Compositions and methods for reducing the transmissivity of illnesses	The Quigley Corporation	6- Aug- 01	14- Dec -04	23- Jan- 07
US7163947	1-Amino lH-imidazoquinolines	3M Innovative Properties Company	7- Mar- 03	3- Sep -04	16- Jan- 07
US7151163	Antiviral agents for the treatment, control and prevention of infections by coronaviruses	Sequoia Pharmaceuticals, Inc.	28- Apr- 03	28- Apr -04	19- Dec -06
US7151091	Compositions and methods for preventing infection	La Jolla Biosciences LLC	20- Sep- 02	22- Sep -03	19- Dec -06
US7148248	Method of treating or inhibiting the development of brain inflammation and sepsis	NOZAKI MASAKO	29- Nov- 02	26- Nov -03	12- Dec -06
US7129223	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of HongKong	19- May- 03	19- May -04	31- Oct- 06
US7129042	Compositions and methods for detecting severe acute respiratory syndrome coronavirus	Diagnostic Hybrids, Inc.	3- Nov- 03	3- Nov -03	31- Oct- 06
US7115563	Composition and its therapeutic use	Insignion Holding Limited	29- May- 02	29- May -03	3- Oct- 06
US7091214	Aryl substituted Imidazoquinolines	3M Innovative Properties Co.	20- Dec- 02	18- Dec -03	15- Aug -06
US7048953	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)	Inhalation, Inc.	3- Apr- 00	2- May -03	23- May -06
US7023593	Apparatus for forming nano-grating device	Industrial Technology Research Institute	28- Nov- 03	17- Mar -04	4- Apr- 06
US6946291	Mixed cell diagnostic systems	Diagnostic Hybrids, Inc.	24- Apr- 98	30- Mar -04	20- Sep -05
US20200176 079	METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES	Not Available	19- Jul-17	18- Jul- 18	4- Jun- 20
US20200173 925	MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICE	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29- Mar- 17	28- Mar -18	4- Jun- 20
US20200172 883	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19- Nov- 09	13- Sep -19	4- Jun- 20
US20200172 879	DHFR TUNABLE PROTEIN REGULATION	Not Available	3- Mar- 17	2- Sep -19	4- Jun- 20
US20200172 600	RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME	GLAXOSMITHKLINE BIOLOGICALS, SA	15- Jul-09	16- Aug -17	4- Jun- 20
US20200172 513	DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	12- Jun- 16	5- Feb -20	4- Jun- 20
US20200172 480	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12- Jul-12	5- Feb -20	4- Jun- 20
US20200171 085	Method of Treating Respiratory Tract Infection	Not Available	19- May- 17	18- May -18	4- Jun- 20
US20200171 060	FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES	Not Available	31- Jul-17	26- Jan -18	4- Jun- 20
US20200166 505	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human Services	1- Sep- 15	30- Jan -20	28- May -20
US20200165 632	ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION	Spark Therapeutics, Inc.	7- Jun- 17	6- Jun -18	28- May -20

 

US20200165 630	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29- Apr- 16	28- Apr -17	28- May -20
US20200165 613	VIRUS LIKE PARTICLE	The University of Leeds	1- Jun- 17	31- May -18	28- May -20
US20200165 594	CRISPR SYSTEM BASED ANTIVIRAL THERAPY	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7-Jul- 17	6- Jul- 18	28- May -20
US20200165 585	NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS	Not Available	27- Jul-17	27- Jul- 18	28- May -20
US20200165 357	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2- Dec- 05	21- Oct -19	28- May -20
US20200164 334	MICROSPOTTING DEVICE	Not Available	18- Apr- 12	11- Oct -19	28- May -20
US20200164 067	Methods and Compositions for Inhibiting Akt3	Not Available	15- Jan- 16	5- Feb -20	28- May -20
US20200164 058	TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS	King Abdulaziz University	27- Nov- 18	27- Nov -18	28- May -20
US20200164 020	PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION	Not Available	12- Apr- 17	12- Apr -17	28- May -20
US20200163 878	LIPID NANOPARTICLE MRNA VACCINES	Not Available	26- Oct- 16	26- Oct -17	28- May -20
US20200157 600	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	19- Nov- 18	19- Nov -18	21- May -20
US20200157 222	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	29- Mar- 18	29- Mar -19	21- May -20
US20200157 221	ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30- Jun- 16	28- Jan -20	21- May -20
US20200155 704	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	30- Jan -20	21- May -20
US20200155 699	MODIFIED VIRUS-LIKE PARTICLES OF CMV	Not Available	22- Oct- 14	26- Nov -19	21- May -20
US20200155 667	VACCINE COMPOSITIONS	Not Available	27- Jul-17	24- Jan -20	21- May -20
US20200155 664	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Not Available	10- Feb- 09	26- Jun -19	21- May -20
US20200155 662	COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS	Not Available	26- May- 17	25- May -18	21- May -20
US20200155 660	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY	Not Available	23- Sep- 15	22- Nov -19	21- May -20
US20200155 646	EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract	Volution Immuno Pharmaceuticals SA	8- Jan- 10	7- Jun -19	21- May -20
US20200149 062	ENGINEERED TSC2	Not Available	14- Jul-17	13- Jul- 18	14- May -20
US20200149 048	Transbiotic Regulation of Bacterial Gene Expression	Not Available	22- May- 17	22- May -18	14- May -20
US20200148 749	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16- May- 08	10- Oct -19	14- May -20
US20200147 203	VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26- Sep- 14	10- Jan -20	14- May -20
US20200147 193	COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS	Not Available	2- Jun- 17	2- Jun -18	14- May -20
US20200147 171	COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS	Not Available	18- Sep- 18	18- Sep -19	14- May -20
US20200140 547	MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE	Not Available	26- May- 17	25- May -18	7- May -20
US20200140 493	Engineering Virus-like Nanocarriers for Biomolecule Delivery	Not Available	26- Oct- 18	25- Oct -19	7- May -20
US20200140 398	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	AZIENDA OSPEDALIERA UNIVERSITARIA SENESE	13- Feb- 15	6- Jan -20	7- May -20

 

US20200138 937	Genetically Attenuated Nucleic Acid Vaccine	Not Available	2- Jun- 17	1- Jun -18	7- May -20
US20200138 936	Phenotypically Wild-Type and Genetically Attenuated Viruses	Not Available	2- Jun- 17	1- Jun -18	7- May -20
US20200138 818	METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB	Not Available	7- Nov- 18	6- Nov -19	7- May -20
US20200138 780	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14- Mar- 13	19- Dec -19	7- May -20
US20200131 518	CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE	Not Available	14- Mar- 17	14- Mar -18	30- Apr- 20
US20200129 487	CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND	TAIHO PHARMACEUTICAL CO., LTD.	30- Jun- 17	29- Jun -18	30- Apr- 20
US20200127 954	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22- Aug- 17	31- Dec -18	23- Apr- 20
US20200124 599	ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL	CELLEMEDY CO., LTD	13- Apr- 17	13- Apr -18	23- Apr- 20
US20200123 233	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5- Jun- 08	1- Aug -19	23- Apr- 20
US20200123 205	Inhibition Of TCR Signaling With Peptide Variants	Not Available	22- Oct- 18	18- Dec -19	23- Apr- 20
US20200123 203	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	FLAGSHIP PIONEERING INNOVATIONS V, INC.	13- Jun- 17	13- Jun -18	23- Apr- 20
US20200115 448	CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF	Not Available	26- Apr- 17	22- Oct -19	16- Apr- 20
US20200115 434	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23- Oct- 15	29- Oct -19	16- Apr- 20
US20200113 996	CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES	Not Available	23- Jun- 17	21- Jun -18	16- Apr- 20
US20200113 967	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	26- May- 17	26- May -17	16- Apr- 20
US20200113 831	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 11	16- Dec -19	16- Apr- 20
US20200113 830	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA	GLAXOSMITHKLINE BIOLOGICALS S.A.	31- Aug- 11	16- Dec -19	16- Apr- 20
US20200109 403	IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12- Dec- 11	18- Dec -19	9- Apr- 20
US20200108 136	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6- Apr- 07	22- Nov -19	9- Apr- 20
US20200102 558	TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY	Not Available	3- Apr- 17	3- Oct -19	2- Apr- 20
US20200102 550	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10- Dec- 09	28- Aug -19	2- Apr- 20
US20200102 544	POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAME	Not Available	30- Dec- 13	11- Sep -19	2- Apr- 20
US20200102 362	TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY	Not Available	6- Apr- 17	5- Apr -18	2- Apr- 20
US20200102 292	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul- 13	10- Jul- 19	2- Apr- 20
US20200101 158	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	1- Oct- 15	22- Oct -19	2- Apr- 20
US20200101 153	MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN	Not Available	6- Apr- 17	6- Apr -18	2- Apr- 20
US20200101 142	PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY	Not Available	12- Jun- 17	12- Jun -18	2- Apr- 20

 

US20200101 119	METHODS OF TREATMENT OF INFECTIONS USING BACTERIA	Not Available	27- Sep- 18	26- Sep -19	2- Apr- 20
US20200101 087	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3- Aug- 15	21- Nov -19	2- Apr- 20
US20200100 480	TRAIT SELECTION IN AVIANS	Not Available	31- May- 17	31- May -18	2- Apr- 20
US20200095 324	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	30- Mar- 17	30- Mar -18	26- Mar -20
US20200093 919	MODIFIED PEDV SPIKE PROTEIN	Not Available	20- Sep- 18	18- Sep -19	26- Mar -20
US20200093 909	PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO	Not Available	19- Apr- 17	19- Apr -18	26- Mar -20
US20200093 855	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE	Not Available	11- Sep- 17	3- Jun -19	26- Mar -20
US20200093 841	Broad Spectrum Antiviral and Methods of Use	Not Available	17- Apr- 06	30- Apr -19	26- Mar -20
US20200087 655	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14- Jul-15	22- Nov -19	19- Mar -20
US20200087 646	OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE	Not Available	31- May- 17	31- May -18	19- Mar -20
US20200087 630	INFLUENZA VIRUS AND TYPE 1 DIABETES	Istituto Zooprofilattico Sperimentale delle Venezie	10- Oct- 12	25- Jul- 19	19- Mar -20
US20200087 359	GRIFFITHSIN MUTANTS	The United States of America,as represented by the Secretary,Department of Health and Human Services	10- Feb- 15	27- Nov -19	19- Mar -20
US20200087 313	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29- Jul-11	25- Apr -19	19- Mar -20
US20200087 298	Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups	Not Available	1- Mar- 17	27- Feb -18	19- Mar -20
US20200087 280	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	25- Nov -19	19- Mar -20
US20200086 324	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	30- Jun- 16	27- Dec -18	19- Mar -20
US20200085 984	APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7- Mar- 11	25- Nov -19	19- Mar -20
US20200085 947	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7- Sep- 12	14- May -19	19- Mar -20
US20200085 943	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN	CureVac AG	31- Jan- 12	29- Aug -19	19- Mar -20
US20200085 872	IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS	Not Available	19- Apr- 17	19- Apr -18	19- Mar -20
US20200085 852	EPIDERMAL MRNA VACCINE	Not Available	5- Aug- 15	5- Aug -16	19- Mar -20
US20200085 756	NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF	Not Available	14- Sep- 18	12- Jul- 19	19- Mar -20
US20200080 141	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	11- Dec- 13	19- Nov -19	12- Mar -20
US20200080 111	Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof	Not Available	18- Sep- 15	19- Sep -16	12- Mar -20
US20200079 820	DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd.	20- Apr- 16	20- Apr -16	12- Mar -20
US20200079 781	Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases	Not Available	5- Sep- 18	1- Aug -19	12- Mar -20
US20200078 335	COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS	Not Available	1- May- 17	1- May -18	12- Mar -20
US20200072 836	MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF	Not Available	5- May- 14	2- Apr -19	5- Mar -20
US20200071 723	RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL	Not Available	30- Aug- 18	29- Aug -19	5- Mar -20

 

US20200071 421	BISPECIFIC ANTIBODY	Not Available	20- Nov- 13	8- Apr -19	5- Mar -20
US20200069 814	CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE	Hangzhou DAC Biotech Co., Ltd.	6- Apr- 17	6- Apr -17	5- Mar -20
US20200062 764	ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME	Not Available	17- Nov- 16	17- Nov -17	27- Feb -20
US20200061 187	METHODS FOR PREPARING SQUALENE	Not Available	12- May- 10	4- Nov -19	27- Feb -20
US20200061 185	PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE	The Scripps Research Institute	25- Oct- 16	25- Oct -17	27- Feb -20
US20200060 981	CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES	Not Available	9- Dec- 16	11- Dec -17	27- Feb -20
US20200056 221	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	Not Available	8- Nov- 13	25- Oct -19	20- Feb -20
US20200056 159	NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR	Not Available	28- Feb- 17	27- Feb -18	20- Feb -20
US20200055 927	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	25- Oct -19	20- Feb -20
US20200055 926	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	25- Oct -19	20- Feb -20
US20200054 731	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7- Jan- 14	15- Jul- 19	20- Feb -20
US20200054 660	DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY	St. Jude Children’s Research Hospital	9- Dec- 16	7- Dec -17	20- Feb -20
US20200054 259	HIGH DENSITY ANALOG MULTIPEXING	EnLiSense, LLC	17- Aug- 18	16- Aug -19	20- Feb -20
US20200048 722	METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS	Not Available	8- May- 15	24- Aug -19	13- Feb -20
US20200048 649	VIRUS-LIKE PARTICLES AND USES THEREOF	Not Available	13- Mar- 17	13- Mar -18	13- Feb -20
US20200048 636	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	18- Oct -19	13- Feb -20
US20200046 865	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29- Dec- 17	22- Aug -19	13- Feb -20
US20200046 826	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27- Mar- 09	4- Jun -19	13- Feb -20
US20200046 692	SPECIFIC AKT3 INHIBITOR AND USES THEREOF	Not Available	15- Jan- 16	2- Oct -19	13- Feb -20
US20200040 408	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8- Feb- 16	6- May -19	6- Feb -20
US20200040 042	CHIMERIC MOLECULES AND USES THEREOF	Not Available	30- Mar- 17	29- Mar -18	6- Feb -20
US20200038 871	DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS	Not Available	29- Mar- 17	29- Mar -18	6- Feb -20
US20200038 373	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9- May- 12	16- May -19	6- Feb -20
US20200033 343	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	14- Oct -19	30- Jan- 20
US20200032 255	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	Not Available	26- Jan- 07	6- Mar -19	30- Jan- 20
US20200031 871	NOVEL DEPSIPEPTIDES AND USES THEREOF	Not Available	4- Apr- 17	30- Mar -18	30- Jan- 20
US20200031 819	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	26- Jun -19	30- Jan- 20
US20200030 441	Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods	Not Available	17- Aug- 10	8- Jul- 19	30- Jan- 20

 

US20200030 432	ZOONOTIC DISEASE RNA VACCINES	ModernaTX, Inc.	17- Mar- 17	16- Mar -18	30- Jan- 20
US20200030 422	COMBINATION OF VACCINATION AND OX40 AGONISTS	CureVac AG	9- Sep- 16	15- Apr -19	30- Jan- 20
US20200024 616	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM	Not Available	30- Mar- 18	29- Mar -19	23- Jan- 20
US20200024 310	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3- Dec- 12	1- Aug -19	23- Jan- 20
US20200020 420	Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof	Not Available	8- Dec- 16	7- Dec -17	16- Jan- 20
US20200017 926	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF	Not Available	7- Nov- 13	28- Aug -19	16- Jan- 20
US20200017 832	COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOF	Not Available	5- Apr- 17	5- Apr -18	16- Jan- 20
US20200017 588	MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM	Not Available	14- Oct- 16	16- Oct -17	16- Jan- 20
US20200017 554	SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS	Not Available	23- Mar- 17	22- Mar -18	16- Jan- 20
US20200017 514	ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION	Not Available	12- Jul-18	12- Jul- 18	16- Jan- 20
US20200017 455	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24- Jan- 14	19- Mar -19	16- Jan- 20
US20200016 589	LOADING VIALS	Not Available	10- Nov- 11	24- Sep -19	16- Jan- 20
US20200016 286	Production of Immune-Response-Stimulating Aerosols By Non­Thermal Plasma Treatment Of Airborne Pathogens	Not Available	13- Jul-18	12- Jul- 19	16- Jan- 20
US20200016 280	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29- Apr- 03	9- Apr -19	16- Jan- 20
US20200016 161	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24- Sep- 09	22- Jul- 19	16- Jan- 20
US20200010 883	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	9- Oct- 15	7- Jun -19	9- Jan- 20
US20200010 519	NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION	Not Available	10- Mar- 17	9- Mar -18	9- Jan- 20
US20200009 244	NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS	Not Available	13- Jun- 18	13- Jun -19	9- Jan- 20
US20200002 674	ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE	Not Available	18- Nov- 13	16- Sep -19	2- Jan- 20
US20200000 931	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15- Jul-16	10- Apr -19	2- Jan- 20
US20190391 150	COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES	Not Available	1- May- 15	10- Sep -19	26- Dec -19
US20190390 249	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	19- Jun -17	26- Dec -19
US20190390 229	GENE EDITING REAGENTS WITH REDUCED TOXICITY	Not Available	21- Apr- 16	20- Apr -17	26- Dec -19
US20190390 179	SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF	Not Available	12- Apr- 16	12- Apr -17	26- Dec -19
US20190390 176	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM	Not Available	2- Dec- 15	3- Jul- 19	26- Dec -19
US20190389 816	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26- Jun- 03	29- Aug -19	26- Dec -19
US20190388 473	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1- Apr- 14	30- Aug -19	26- Dec -19
US20190382 799	VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS	Not Available	27- Oct- 16	19- Apr -19	19- Dec -19

 

US20190382 433	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4- Apr- 14	25- Jul- 19	19- Dec -19
US20190381 180	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	Not Available	9- Jun- 16	9- Jun -17	19- Dec -19
US20190381 162	PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING	Not Available	28- Mar- 16	27- Mar -17	19- Dec -19
US20190381 155	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22- Feb- 13	29- Aug -19	19- Dec -19
US20190380 995	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2- Jun- 16	3- Jul- 19	19- Dec -19
US20190380 891	MOBILE CLINICS	Baylor College of Medicine	12- Nov- 14	28- Aug -19	19- Dec -19
US20190376 151	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS	Not Available	4- Apr- 12	8- Feb -19	12- Dec -19
US20190376 034	PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF	Not Available	18- Nov- 13	23- Aug -19	12- Dec -19
US20190375 801	HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS DISEASE	Not Available	9- Sep- 16	8- Sep -17	12- Dec -19
US20190374 650	COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE CONJUGATES	Not Available	22- Feb- 17	21- Feb -18	12- Dec -19
US20190374 610	MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS	Not Available	20- Dec- 16	20- Dec -17	12- Dec -19
US20190374 576	VIRAL METHODS OF T CELL THERAPY	Not Available	27- Oct- 16	19- Apr -19	12- Dec -19
US20190370 834	SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENS	Not Available	1- Jun- 18	1- Jun -18	5- Dec -19
US20190367 553	COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1	Not Available	27- Oct- 17	26- Apr -19	5- Dec -19
US20190367 525	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	19- Jul- 19	5- Dec -19
US20190367 453	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12- Jul-12	13- Aug -19	5- Dec -19
US20190365 925	AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM	Not Available	21- Nov- 14	13- Jun -19	5- Dec -19
US20190365 756	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	4- Jun- 18	3- Jun -19	5- Dec -19
US20190359 990	VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF	Not Available	25- Jan- 17	25- Jan -18	28- Nov -19
US20190359 635	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	18- Jul- 19	28- Nov -19
US20190359 629	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	18- Jul- 19	28- Nov -19
US20190358 335	STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER CONJUGATES	Not Available	12- Jan- 17	12- Jan -18	28- Nov -19
US20190358 312	ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE	Not Available	19- Dec- 17	19- Dec -18	28- Nov -19
US20190358 304	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPOERIMENTALLY INDUCED OCULAR DISORDERS	Not Available	18- Oct- 13	29- May -19	28- Nov -19
US20190358 170	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19- Dec- 13	12- Aug -19	28- Nov -19
US20190352 639	GENOME EDITING REAGENTS AND THEIR USE	Not Available	10- Feb- 17	12- Feb -18	21- Nov -19
US20190352 615	METHOD FOR PURIFYING VIRUS	Not Available	22- Dec- 16	21- Dec -17	21- Nov -19

 

US20190352 608	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16- Sep- 13	30- Jan -19	21- Nov -19
US20190352 357	HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS	Colorado State University Research Foundation	7- Nov- 14	7- Aug -19	21- Nov -19
US20190346 443	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	28- Jun -19	14- Nov -19
US20190345 504	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30- Dec- 14	26- Jul- 19	14- Nov -19
US20190345 503	CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION	Not Available	20- Jun- 16	15- Jun -17	14- Nov -19
US20190345 481	PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDES	Not Available	14- Jul-15	5- Jul- 19	14- Nov -19
US20190345 221	BROAD SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOF	Tianjin Dongya Biological Technology Co., Ltd.	9- May- 18	9- May -18	14- Nov -19
US20190345 166	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	Not Available	1- May- 14	24- Jul- 19	14- Nov -19
US20190343 862	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul- 10	16- Jul- 19	14- Nov -19
US20190337 990	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	Not Available	13- Feb- 15	5- Jun -19	7- Nov -19
US20190336 969	PARALLELIZED SAMPLE HANDLING	Not Available	19- Apr- 13	27- Mar -19	7- Nov -19
US20190336 611	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	CureVac AG	9- Jun- 16	9- Jun -17	7- Nov -19
US20190336 608	CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY	CureVac AG	9- Jun- 16	9- Jun -17	7- Nov -19
US20190336 597	METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES	Not Available	8- Jan- 13	17- May -19	7- Nov -19
US20190336 456	USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS	ABIOGEN PHARMA S.P.A.	15- Jul-16	13- Jul- 17	7- Nov -19
US20190330 618	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES	Not Available	1- Dec- 05	22- Jan -19	31- Oct- 19
US20190330 572	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8- Sep- 16	21- Jun -19	31- Oct- 19
US20190330 245	Boron-Containing Small Molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	12- Jul- 19	31- Oct- 19
US20190330 187	Chemical Compounds	Not Available	18- Mar- 14	10- May -19	31- Oct- 19
US20190330 164	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29- Jul-11	28- Nov -18	31- Oct- 19
US20190330 149	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12- Jul-12	9- May -19	31- Oct- 19
US20190328 869	IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY	Transgene SA	10- Oct- 16	10- Oct -17	31- Oct- 19
US20190328 865	IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION	Not Available	28- Jul-14	17- Nov -17	31- Oct- 19
US20190328 804	AAV Vectors Targeted to Oligodendrocytes	Not Available	28- Sep- 12	15- Jul- 19	31- Oct- 19
US20190323 068	PCR Ready Compositions and Methods for Screening Biological Samples	Longhorn Vaccines and Diagnostics, LLC	12- Sep- 06	28- Jun -19	24- Oct- 19
US20190322 989	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24- Nov- 15	25- Jan -19	24- Oct- 19
US20190322 725	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13- May- 14	2- Jul- 19	24- Oct- 19
US20190321 481	IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS	NantBio, Inc.	11- Nov- 16	9- Nov -17	24- Oct- 19
US20190321 403	ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS	Juno Therapeutics, Inc.	2- Dec- 16	30- Nov -17	24- Oct- 19

 

US20190316 109	COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE SENESCENT CELLS	Not Available	17- Apr- 12	10- Jun -19	17- Oct- 19
US20190316 091	ERYTHROID CELLS COMPRISING ARGINASE	Not Available	18- Nov- 13	30- May -19	17- Oct- 19
US20190316 090	ERYTHROID CELLS COMPRISING ARGININE DEIMINASE	RUBIUS THERAPEUTICS, INC.	18- Nov- 13	30- May -19	17- Oct- 19
US20190316 089	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	10- May -19	17- Oct- 19
US20190315 840	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE	Not Available	16- Sep- 16	10- Jun -19	17- Oct- 19
US20190315 807	VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIES	Not Available	27- Jul-16	26- Jul- 17	17- Oct- 19
US20190314 496	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT	CureVac AG	1- Apr- 14	18- Jun -19	17- Oct- 19
US20190314 483	Vaccines Including Antigen From Four Strains of Influenza Virus	Not Available	6- Dec- 06	30- Nov -18	17- Oct- 19
US20190314 482	VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES	Medigen, Inc.	28- Nov- 16	21- Nov -17	17- Oct- 19
US20190314 480	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25- Mar- 15	23- Apr -19	17- Oct- 19
US20190314 471	MOLECULAR VACCINES FOR INFECTIOUS DISEASE	Not Available	2- Oct- 08	27- Jun -19	17- Oct- 19
US20190314 455	CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES	Not Available	3- Aug- 17	7- Jun -19	17- Oct- 19
US20190314 372	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	5- Dec- 16	25- Mar -19	17- Oct- 19
US20190310 168	AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS	Not Available	22- Jul-14	4- Mar -19	10- Oct- 19
US20190309 357	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9- Dec- 16	25- Feb -19	10- Oct- 19
US20190309 262	ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE	Not Available	18- Nov- 13	4- Jun -19	10- Oct- 19
US20190309 261	ERYTHROID CELLS COMPRISING LYSINE OXIDASE	Not Available	18- Nov- 13	4- Jun -19	10- Oct- 19
US20190309 048	Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use	Not Available	6- Feb- 15	20- May -19	10- Oct- 19
US20190309 039	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29- Jan- 15	22- Apr -19	10- Oct- 19
US20190308 980	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	24- Jun -19	10- Oct- 19
US20190308 969	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	11- Nov- 16	13- Nov -17	10- Oct- 19
US20190308 943	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS	Parion Sciences, Inc.	17- Dec- 12	13- Mar -19	10- Oct- 19
US20190307 878	IMMUNE COMPLEX	The Rockefeller University	20- Mar- 15	10- May -19	10- Oct- 19
US20190307 722	ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES	Not Available	21- Oct- 16	20- Oct -17	10- Oct- 19
US20190298 824	ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv	4- May- 16	4- May -17	3- Oct- 19
US20190298 752	METHODS FOR THE USE OF 5′-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)	Invirsa, Inc.	27- Mar- 18	26- Mar -19	3- Oct- 19
US20190298 750	Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto	Not Available	11- Sep- 13	21- Nov -18	3- Oct- 19
US20190293 656	NON-RADIOACTIVE CYTOTOXICITY ASSAYS	Not Available	19- Sep- 16	19- Sep -17	26- Sep -19
US20190292 580	DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR BIOCHEMICAL SENSING	Rutgers, The State University of New Jersey	23- Mar- 18	22- Mar -19	26- Sep -19

 

US20190292 563	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	The Trustees of the University of Pennsylvania	17- Dec- 01	8- Apr -19	26- Sep -19
US20190292 561	SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO- ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE	SPARK THERAPEUTICS, INC.	1- Dec- 15	1- Dec -16	26- Sep -19
US20190292 236	MODULATION OF IFI16 AND STING ACTIVITY	Not Available	9- Aug- 16	9- Aug -17	26- Sep -19
US20190292 216	Cyclic Di-Nucleotide Induction of Type I Interferon	Not Available	3- May- 13	19- Feb -19	26- Sep -19
US20190292 178	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES	Dana-Farber Cancer Institute, Inc.	11- Apr- 12	26- Jan -18	26- Sep -19
US20190290 674	Composition for Promoting Production of Immunostimulatory Factor	Kyoto University	2- Aug- 16	31- Jul- 17	26- Sep -19
US20190285 632	METABALOMICS AND VIRAL DIAGNOSTICS SUITE	Excision Biotherapeutics, Inc.	24- May- 16	24- May -17	19- Sep -19
US20190284 575	REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS	Not Available	21- May- 09	30- Jan -19	19- Sep -19
US20190284 531	DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOF	Not Available	15- May- 15	24- May -19	19- Sep -19
US20190284 230	ASSEMBLED GLYCOPROTEINS	Not Available	29- Sep- 16	22- Sep -17	19- Sep -19
US20190282 694	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	AUTOIMMUNE TECHNOLOGIES, LLC	14- Mar- 13	30- May -19	19- Sep -19
US20190282 608	Method Of Treating Inflammation	Not Available	1- Apr- 10	29- May -19	19- Sep -19
US20190276 523	COMPOSITION AND METHODS OF TREATING B CELL DISORDERS	Not Available	2- Sep- 16	5- Sep -17	12- Sep -19
US20190275 519	SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS	Not Available	8- Nov- 16	8- Nov -17	12- Sep -19
US20190275 101	STRUCTURE OF GII.4 NOROVIRUS PROTEASE – DESIGN OF BROAD- SPECTRUM PROTEASE INHIBITORS	Not Available	5- Oct- 16	5- Oct -17	12- Sep -19
US20190269 694	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8- Mar- 11	11- Oct -18	5- Sep -19
US20190269 672	Specific Akt3 Inhibitor and Uses Thereof	Not Available	15- Jan- 16	20- May -19	5- Sep -19
US20190264 267	PHASING	Wave Life Sciences Ltd.	25- Jul-16	24- Jul- 17	29- Aug -19
US20190264 177	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	10- May -19	29- Aug -19
US20190263 934	FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFE	Not Available	26- Jan- 18	25- Jan -19	29- Aug -19
US20190262 448	Cationic Oil-In-Water Emulsions	GLAXOSMITHKLINE BIOLOGICALS, SA	18- Sep- 11	7- Mar -19	29- Aug -19
US20190262 371	METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS	Not Available	20- Oct- 16	20- Oct -17	29- Aug -19
US20190256 585	ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE PEPTIDE	Not Available	10- Jun- 15	10- Jun -16	22- Aug -19
US20190256 579	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The U.S.A., as represented by the Secretary, Department of Health and Human Services	24- Feb- 15	3- May -19	22- Aug -19
US20190255 085	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS	Not Available	16- Sep- 15	1- Feb -19	22- Aug -19
US20190254 968	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul- 11	2- May -19	22- Aug -19
US20190250 153	MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING SAME	Board of Regents, The University of Texas System	20- Oct- 16	19- Oct -17	15- Aug -19
US20190248 883	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16- Dec- 02	20- Feb -19	15- Aug -19
US20190248 866	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION	Not Available	30- Jun- 11	30- Apr -18	15- Aug -19

 

US20190248 865	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23- Oct- 15	21- Oct -16	15- Aug -19
US20190247 529	METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES	Not Available	29- Dec- 17	23- Apr -19	15- Aug -19
US20190247 489	ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING	Not Available	20- Oct- 11	16- Nov -18	15- Aug -19
US20190247 485	Dimethyl Fumarate and Vaccination Regimens	Biogen MA Inc.	14- Mar- 14	23- Apr -19	15- Aug -19
US20190247 440	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1- Apr- 14	12- Apr -19	15- Aug -19
US20190247 367	TREATMENT OF INFECTIOUS DISEASES	CHILDREN’S MEDICAL CENTER CORPORATION	26- Jan- 15	23- Apr -19	15- Aug -19
US20190241 646	ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION	Not Available	15- Mar- 17	15- Apr -19	8- Aug -19
US20190241 618	INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS	Not Available	30- Sep- 09	22- Oct -18	8- Aug -19
US20190240 317	HPIV3 RNA VACCINES	ModernaTX, Inc.	22- Oct- 15	28- Mar -19	8- Aug -19
US20190233 447	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS	Not Available	28- Aug- 15	25- Feb -19	1- Aug -19
US20190232 282	METHODS AND COMPOSITIONS FOR DETECTING ANALYTES	Not Available	23- Sep- 16	20- Sep -17	1- Aug -19
US20190231 004	MASK	NBC MESHTEC INC.	17- Oct- 16	13- Oct -17	1- Aug -19
US20190225 986	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	Not Available	28- Oct- 05	30- Nov -18	25- Jul- 19
US20190225 971	METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE	Not Available	10- Aug- 15	4- Aug -16	25- Jul- 19
US20190224 339	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29- Apr- 16	28- Apr -17	25- Jul- 19
US20190223 445	ANTIMICROBIAL GEOPOLYMER COMPOSITIONS	Not Available	14- Jul-16	13- Jul- 17	25- Jul- 19
US20190220 524	DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHS	Not Available	16- Jan- 18	29- Mar -18	18- Jul- 19
US20190219 563	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16- May- 14	17- Dec -18	18- Jul- 19
US20190218 574	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	The Trustees of the University of Pennsylvania	2- Oct- 07	28- Mar -19	18- Jul- 19
US20190218 277	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE	Not Available	16- Sep- 16	15- Sep -17	18- Jul- 19
US20190218 207	3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NaMPT Modulators	Not Available	17- Aug- 15	17- Aug -16	18- Jul- 19
US20190216 951	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21- Aug- 13	1- Apr -19	18- Jul- 19
US20190216 917	HMPV RNA VACCINES	ModernaTX, Inc.	22- Oct- 15	28- Mar -19	18- Jul- 19
US20190216 915	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2- Oct- 15	15- Feb -19	18- Jul- 19
US20190216 841	Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens	Not Available	20- Apr- 11	20- Mar -19	18- Jul- 19
US20190211 361	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	Not Available	13- Jun- 17	27- Mar -19	11- Jul- 19
US20190211 355	DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF	Not Available	5- Jan- 15	4- Jan -16	11- Jul- 19
US20190211 024	SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES	General Research Laboratory	19- Aug- 16	19- Aug -17	11- Jul- 19

 

US20190209 678	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY	Not Available	2- Dec- 14	12- Mar -19	11- Jul- 19
US20190209 604	OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF	WAVE LIFE SCIENCES LTD.	3- Jun- 16	2- Jun -17	11- Jul- 19
US20190207 890	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22- Aug- 17	31- Dec -18	4- Jul- 19
US20190204 330	APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS	Not Available	28- Jun- 16	19- Dec -18	4- Jul- 19
US20190203 268	LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROBES	Not Available	2- Jan- 18	31- Dec -18	4- Jul- 19
US20190203 186	PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24- Nov- 15	25- Jan -19	4- Jul- 19
US20190203 170	Avian Cells for Improved Virus Production	Not Available	5- Jun- 13	21- Dec -18	4- Jul- 19
US20190202 929	COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS	Not Available	20- Sep- 16	20- Sep -17	4- Jul- 19
US20190202 868	CORONAVIRUS PROTEINS AND ANTIGENS	Phibro Animal Health Corporation	7- Feb- 14	15- Mar -19	4- Jul- 19
US20190202 854	ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN A	Not Available	4- Aug- 14	8- Mar -19	4- Jul- 19
US20190201 565	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29- Dec- 17	11- Sep -18	4- Jul- 19
US20190201 564	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29- Dec- 17	29- Dec -17	4- Jul- 19
US20190201 552	Aptamer Compositions and Methods of Use Thereof	Not Available	28- Dec- 17	28- Dec -18	4- Jul- 19
US20190201 433	2′-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT	Atea Pharmaceuticals, Inc.	7- Sep- 16	5- Mar -19	4- Jul- 19
US20190201 352	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30- Jan- 15	12- Mar -19	4- Jul- 19
US20190201 337	HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS	Not Available	3- Dec- 09	3- Jan -19	4- Jul- 19
US20190194 728	Systemic inflammatory and pathogen biomarkers and uses therefor	Not Available	24- Aug- 16	24- Aug -17	27- Jun- 19
US20190194 717	METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM	JAPAN SCIENCE AND TECHNOLOGY AGENCY	5- Sep- 16	4- Sep -17	27- Jun- 19
US20190194 628	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Pharmaceutical Company Limited	1- Sep- 16	1- Sep -17	27- Jun- 19
US20190194 322	IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY	BIO-TECHNE CORPORATION	3- Aug- 16	3- Aug -17	27- Jun- 19
US20190194 299	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25- Apr- 14	19- Nov -18	27- Jun- 19
US20190194 226	FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS	Not Available	26- Aug- 16	1- Aug -17	27- Jun- 19
US20190194 150	COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION	Arrakis Therapeutics, Inc.	1-Jul- 16	30- Jun -17	27- Jun- 19
US20190192 691	REGULATED BIOCIRCUIT SYSTEMS	Not Available	11- Apr- 16	11- Apr -17	27- Jun- 19
US20190192 581	Methods of Populating a Gastrointestinal Tract	Not Available	4- Feb- 13	1- Aug -18	27- Jun- 19
US20190187 151	ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPE STANDARDS	UVic Industry Partnerships Inc.	6- Jun- 16	7- Apr -17	20- Jun- 19
US20190187 130	COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI­DYE QUINONE METHIDE AND TYRAMIDE CONJUGATES	Not Available	28- Jun- 16	19- Dec -18	20- Jun- 19
US20190185 922	LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS	CapitalBio Corporation	5- Dec- 13	20- Nov -18	20- Jun- 19

 

US20190185 832	DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOF	Not Available	3- Jun- 16	2- Jun -17	20- Jun- 19
US20190184 067	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1- Nov- 15	28- Feb -19	20- Jun- 19
US20190184 018	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4- Dec- 07	20- Nov -18	20- Jun- 19
US20190183 968	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS	Not Available	13- Jan- 11	27- Feb -19	20- Jun- 19
US20190183 918	SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12- Jun- 13	29- Oct -18	20- Jun- 19
US20190177 739	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS	Not Available	21- Jan- 08	13- Dec -18	13- Jun- 19
US20190175 716	Adenoviral Vector	Not Available	23- Jun- 16	23- Jun -17	13- Jun- 19
US20190175 528	INHIBITION OF BIOFILM ORGANISMS	Not Available	31- Mar- 09	13- Feb -19	13- Jun- 19
US20190169 677	PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSES	Click Diagnostics, Inc.	9- Nov- 17	9- Nov -18	6- Jun- 19
US20190169 639	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS	EDITAS MEDICINE, INC.	7- Nov- 13	24- Jan -19	6- Jun- 19
US20190169 595	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22- Aug- 17	25- Jan -19	6- Jun- 19
US20190167 787	Methods and Compositions for Inhibiting Akt3	Not Available	15- Jan- 16	6- Feb -19	6- Jun- 19
US20190167 786	EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES	Not Available	4- Nov- 05	9- Jul- 18	6- Jun- 19
US20190167 636	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14- Mar- 13	8- Feb -19	6- Jun- 19
US20190166 866	METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCH	Not Available	4- Dec- 17	30- Nov -18	6- Jun- 19
US20190160 129	Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents	Not Available	1- Oct- 15	1- Feb -19	30- May -19
US20190160 063	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31- Dec- 15	30- Dec -16	30- May -19
US20190154 687	DETECTION DEVICE AND DETECTION METHOD	Kabushiki Kaisha Toshiba	17- Nov- 17	7- Mar -18	23- May -19
US20190154 550	BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE	Not Available	6- Apr- 16	6- Apr -17	23- May -19
US20190153 471	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29- Apr- 16	28- Apr -17	23- May -19
US20190153 086	Heterodimeric Immunoglobulins	Not Available	21- Nov- 12	5- Feb -19	23- May -19
US20190151 844	DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL	Click Diagnostics, Inc.	29- Jun- 16	21- Dec -18	23- May -19
US20190151 474	RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES	Kyoto University	8- Sep- 14	8- Sep -15	23- May -19
US20190144 930	ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION	Not Available	6- Dec- 13	9- Jan -19	16- May -19
US20190144 929	DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	Not Available	15- Mar- 17	15- Mar -18	16- May -19
US20190144 827	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	RUBIUS THERAPEUTICS, INC.	18- Nov- 13	19- Nov -18	16- May -19
US20190144 556	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES	Not Available	13- May- 16	12- May -17	16- May -19
US20190144 484	ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	28- Apr- 16	28- Apr -17	16- May -19

 

US20190142 929	INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINS	Not Available	10- Feb- 09	15- Oct -18	16- May -19
US20190142 927	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27- Jun- 07	26- Jun -18	16- May -19
US20190136 226	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	11- May- 16	9- Nov -18	9- May -19
US20190136 215	Replication Conditional Virus that Specifically Kills Senescent Cells	Not Available	17- Apr- 12	6- Jul- 18	9- May -19
US20190135 875	TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS	Not Available	18- May- 16	17- May -17	9- May -19
US20190135 873	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE	Not Available	19- Dec- 16	19- Dec -18	9- May -19
US20190135 788	DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	12- Jun- 16	7- Dec -18	9- May -19
US20190134 214	GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof	Not Available	6- May- 16	4- May -17	9- May -19
US20190134 193	USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS	SALK INSTITUTE FOR BIOLOGICAL STUDIES	9- Nov- 07	9- Aug -18	9- May -19
US20190134 186	INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT	Not Available	4- Nov- 05	10- Jul- 18	9- May -19
US20190134 062	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3- Aug- 15	8- Jan -19	9- May -19
US20190128 893	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24- Feb- 14	7- Nov -18	2- May -19
US20190128 810	SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCE	Not Available	31- Dec- 15	13- Dec -18	2- May -19
US20190127 441	METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY	University of Vermont and State Agricultural College	13- Apr- 16	13- Apr -17	2- May -19
US20190127 405	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	(Ml) LL	7- Nov -18	2- May -19
US20190127 401	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12- Aug- 16	20- Dec -18	2- May -19
US20190127 400	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12- Aug- 16	20- Dec -18	2- May -19
US20190127 399	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12- Aug- 16	20- Dec -18	2- May -19
US20190125 858	COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY	Not Available	18- Apr- 16	18- Apr -17	2- May -19
US20190125 806	Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral Agent	Murata Manufacturing Co., Ltd.	13- Jun- 16	13- Dec -18	2- May -19
US20190125 724	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2- Jun- 16	27- Nov -18	2- May -19
US20190119 744	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS	Not Available	31- Jul-09	5- Nov -18	25- Apr- 19
US20190119 743	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15- Aug- 16	26- Oct -18	25- Apr- 19
US20190119 701	METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF	Not Available	8- Sep- 17	7- Sep -18	25- Apr- 19
US20190119 266	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	24- Oct -18	25- Apr- 19
US20190119 220	CARBOXYLIC ACID COMPOUNDS	Sumitomo Dainippon Pharma Co., Ltd.	18- May- 12	23- Oct -18	25- Apr- 19
US20190117 793	MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES	Not Available	15- Feb- 07	1- Oct -18	25- Apr- 19
US20190117 702	USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS	Indiana University Research and Technology Corporation	6- May- 14	31- Oct -18	25- Apr- 19
US20190112 596	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS	Not Available	4- Apr- 12	12- Apr -18	18- Apr- 19
US20190112 394	USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION	Whitehead Institute for Biomedical Research	28- Jun- 11	24- Sep -18	18- Apr- 19

 

US20190111 141	A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE	Ewha University – Industry Collaboration Foundation	6- Apr- 16	6- Apr -17	18- Apr- 19
US20190105 653	PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENS	Not Available	5- Oct- 17	5- Oct -18	11- Apr- 19
US20190105 381	METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING CANCER	Not Available	16- Mar- 16	16- Mar -16	11- Apr- 19
US20190105 334	Anti-Viral Azide Containing Compounds	Not Available	28- Jul-10	3- Dec -18	11- Apr- 19
US20190100 586	Humanized Anti-Claudin-1 Antibodies and Uses Thereof	Chu Strasbourg, Les HA’pitaux Universitaires de Strasbourg	22- Mar- 16	21- Mar -17	4- Apr- 19
US20190099 493	Targeting Lipids	Arbutus Biopharma Corporation	4- Dec- 07	10- Oct -17	4- Apr- 19
US20190099 479	RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF	Not Available	14- May- 10	27- Apr -18	4- Apr- 19
US20190094 224	METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL RECEPTOR AFFINITY AND SEQUENCE	Not Available	11- Apr- 16	6- Apr -17	28- Mar -19
US20190091 329	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul- 11	6- Dec -18	28- Mar -19
US20190091 221	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS	TRUSTEES OF BOSTON UNIVERSITY	11- Mar- 10	23- Apr -18	28- Mar -19
US20190085 057	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	15- Nov -18	21- Mar -19
US20190085 024	Alpha-Ketoamide Inhibitors Of Cysteine Proteases	Not Available	15- Sep- 17	17- Sep -18	21- Mar -19
US20190085 013	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	7- Mar- 16	7- Mar -17	21- Mar -19
US20190084 943	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY	Parion Sciences, Inc.	17- Dec- 12	23- Aug -18	21- Mar -19
US20190083 602	METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS	Not Available	22- Dec- 15	22- Dec -16	21- Mar -19
US20190083 592	IMMUNOSTIMULATORY COMBINATIONS	Not Available	30- Dec- 02	22- Oct -18	21- Mar -19
US20190083 569	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS	Not Available	11- Jun- 15	24- Jul- 18	21- Mar -19
US20190083 525	COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS	Not Available	11- Jul-17	10- Jul- 18	21- Mar -19
US20190083 520	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto	Not Available	10- Mar- 16	10- Mar -17	21- Mar -19
US20190083 408	CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF	Not Available	2- Dec- 11	4- Dec -18	21- Mar -19
US20190083 397	OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID	NOVARTIS AG	23- Dec- 15	21- Dec -16	21- Mar -19
US20190078 060	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9- Sep- 04	8- Nov -18	14- Mar -19
US20190078 051	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29- Oct- 04	29- Oct -18	14- Mar -19
US20190077 847	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5- Jun- 08	17- Oct -17	14- Mar -19
US20190077 764	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION	Hoffmann-La Roche Inc.	23- May- 16	13- Nov -18	14- Mar -19
US20190077 763	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION	Hoffmann-La Roche Inc.	23- May- 16	13- Nov -18	14- Mar -19
US20190076 520	VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING	Not Available	4- Apr- 08	11- Sep -18	14- Mar -19
US20190076 468	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE	Not Available	11- Sep- 17	11- Sep -17	14- Mar -19

 

US20190071 423	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190071 422	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190071 421	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190071 420	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190071 419	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190071 418	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	2- Nov -18	7- Mar -19
US20190062 785	MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES	Not Available	4- Apr- 16	31- Mar -17	28- Feb -19
US20190062 724	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22- Aug- 17	27- Mar -18	28- Feb -19
US20190062 713	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11- Jul-03	22- Mar -18	28- Feb -19
US20190062 408	CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE	Not Available	25- Aug- 08	20- Jun -18	28- Feb -19
US20190062 380	FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE THEREOF	Not Available	7- Sep- 12	28- Aug -18	28- Feb -19
US20190062 326	2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A] PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS	BAYER PHARMA AKTIENGESELLSCHAFT	10- Dec- 15	7- Dec -16	28- Feb -19
US20190062 323	PI-Kinase Inhibitors with Anti-Infective Activity	Not Available	26- Feb- 16	24- Feb -17	28- Feb -19
US20190060 435	PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE	The United States of America, as represented by the Secretary, Dept of Health and Human Service	27- Feb- 16	27- Feb -17	28- Feb -19
US20190060 364	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31- Jul-15	6- Nov -18	28- Feb -19
US20190060 363	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31- Jul-15	6- Nov -18	28- Feb -19
US20190060 262	ENHANCED EXPRESSION OF RNA VECTORS	UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH	25- Mar- 13	5- Sep -18	28- Feb -19
US20190060 239	Technology for the Preparation of Microparticles	Not Available	24- Jul-07	17- Oct -18	28- Feb -19
US20190056 122	Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use Thereof	Synexis LLC	20- Apr- 15	20- Apr -16	21- Feb -19
US20190055 256	ANTI-VIRAL DRUG	DORING INTERNATIONAL GMBH	24- Feb- 16	24- Feb -17	21- Feb -19
US20190055 241	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31- Aug- 15	22- Oct -18	21- Feb -19
US20190055 234	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	24- Oct -18	21- Feb -19
US20190054 188	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	2- Oct -18	21- Feb -19
US20190054 127	ANTIVIRAL AGENT AND ANTIVIRAL FOOD	EDUCATIONAL CORPORATION MUKOGAWA GAKUIN	4- Mar- 16	22- Nov -16	21- Feb -19
US20190054 122	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31- Jul-15	5- Nov -18	21- Feb -19
US20190049 378	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10- Mar- 05	21- Jun -18	14- Feb -19
US20190048 344	CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION	Not Available	23- Sep- 08	16- Aug -18	14- Feb -19
US20190048 082	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30- Jun- 16	25- Oct -18	14- Feb -19

 

US20190048 049	CARGOMERS	CERENIS THERAPEUTICS HOLDING SA	10- Aug- 17	10- Aug -18	14- Feb -19
US20190048 026	Boron-Containing Small Molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	18- Oct -18	14- Feb -19
US20190046 690	MATERIALS WITH IMPROVED PROPERTIES	Not Available	1- Nov- 15	2- Nov -16	14- Feb -19
US20190046 654	ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF	Not Available	9- Aug- 17	9- Aug -18	14- Feb -19
US20190046 635	COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	2- Feb- 16	1- Feb -17	14- Feb -19
US20190040 451	FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCES	Not Available	8- Jan- 16	9- Jan -17	7- Feb -19
US20190040 378	NOVEL NUCLEIC ACID MOLECULES	Not Available	4-Jul- 17	3- Jul- 18	7- Feb -19
US20190040 370	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9	Not Available	23- Nov- 15	3- Aug -18	7- Feb -19
US20190040 105	Method for Preventing and Treating Hyperpermeability	Not Available	5- Mar- 09	19- Oct -18	7- Feb -19
US20190038 742	MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME	Longeveron LLC	4- Feb- 16	2- Feb -17	7- Feb -19
US20190032 077	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30- Dec- 13	9- Jul- 18	31- Jan- 19
US20190032 041	COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS	Not Available	21- Feb- 06	12- Feb -18	31- Jan- 19
US20190031 740	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13- May- 14	15- Oct -18	31- Jan- 19
US20190031 679	NOVEL MONOTHIOL MUCOLYTIC AGENTS	Not Available	30- Jan- 15	5- Sep -18	31- Jan- 19
US20190031 605	TETRAHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL CO., LTD.	29- Jan- 16	27- Jan -17	31- Jan- 19
US20190030 187	sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection	Sirnaomics, Inc.	8- Sep- 15	7- Sep -16	31- Jan- 19
US20190030 094	BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY DISORDERS	Not Available	27- Jan- 16	27- Jan -17	31- Jan- 19
US20190025 292	ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh – Of the Com monwealth System of Higher Education	8- Apr- 10	25- Sep -18	24- Jan- 19
US20190024 096	PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL	Not Available	7- Aug- 15	7- Aug -15	24- Jan- 19
US20190023 799	GITR Antibodies And Methods Of Inducing Or Enhancing An Immune Response	Not Available	25- Mar- 05	28- Jun -18	24- Jan- 19
US20190023 779	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY	Not Available	28- Dec- 11	5- Oct -18	24- Jan- 19
US20190023 769	COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION	Not Available	29- Oct- 12	21- Sep -18	24- Jan- 19
US20190022 249	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	2- Oct -18	24- Jan- 19
US20190022 216	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23- Oct- 15	4- Sep -18	24- Jan- 19
US20190022 214	Attenuated Infectious Bronchitis Virus	Not Available	27- Jan- 16	26- Jan -17	24- Jan- 19
US20190022 213	MERS-CoV Vaccine	Not Available	29- Nov- 13	29- Jun -18	24- Jan- 19
US20190022 116	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto	Not Available	26- Dec- 14	16- Dec -15	24- Jan- 19
US20190017 112	METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTION	HTG Molecular Diagnostics, Inc.	11- Feb- 16	10- Feb -17	17- Jan- 19
US20190017 068	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17- Dec- 01	26- Sep -18	17- Jan- 19

 

US20190017 000	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8- Sep- 16	19- Sep -18	17- Jan- 19
US20190016 785	ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF	Not Available	7- Oct- 15	7- Oct -16	17- Jan- 19
US20190016 772	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto	Not Available	23- Oct- 12	2- Oct -18	17- Jan- 19
US20190016 710	MULTICYCLIC COMPOUNDS AND USES THEREOF	Not Available	31- Dec- 15	29- Dec -16	17- Jan- 19
US20190016 690	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31- Dec- 15	30- Dec -16	17- Jan- 19
US20190015 527	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	25- Jul- 18	17- Jan- 19
US20190015 522	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	5- Apr- 12	19- Jul- 18	17- Jan- 19
US20190015 501	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23- Apr- 14	27- Sep -18	17- Jan- 19
US20190015 432	Lipid Disulfide Prodrugs and Uses Related Thereto	Not Available	13- Jul-17	13- Jul- 18	17- Jan- 19
US20190010 469	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30- Mar- 07	16- Jul- 18	10- Jan- 19
US20190010 240	COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND	Not Available	15- Mar- 13	2- Aug -18	10- Jan- 19
US20190010 132	ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	Parion Sciences, Inc.	13- Dec- 13	4- Apr -18	10- Jan- 19
US20190008 954	NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION	CureVac AG	31- Jan- 12	11- Jun -18	10- Jan- 19
US20190008 948	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23- Apr- 14	16- Jul- 18	10- Jan- 19
US20190008 833	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9- May- 12	17- Jul- 18	10- Jan- 19
US20190004 061	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	Not Available	2-Jul- 10	4- Aug -18	3- Jan- 19
US20190002 477	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9- May- 14	31- Jan -18	3- Jan- 19
US20190002 448	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	31- Dec- 15	29- Dec -16	3- Jan- 19
US20190002 393	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	5- Sep- 14	19- Sep -18	3- Jan- 19
US20190001 010	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8- Dec- 14	13- Jul- 18	3- Jan- 19
US20190000 959	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23- Apr- 14	27- Jul- 18	3- Jan- 19
US20190000 745	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28- Jul-16	4- Sep -18	3- Jan- 19
US20180372 747	METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUE	Not Available	22- Nov- 15	21- May -18	27- Dec -18
US20180372 733	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES	Not Available	27- Apr- 10	21- Jun -18	27- Dec -18
US20180371 536	METHODS FOR RNA QUANTIFICATION	Not Available	1- Jun- 15	26- May -16	27- Dec -18
US20180371 461	APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTION	Not Available	10- Dec- 15	1- Dec -16	27- Dec -18
US20180371 410	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS	Not Available	4- Dec- 09	28- Aug -18	27- Dec -18
US20180369 386	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Not Available	8- Mar- 13	29- Aug -18	27- Dec -18
US20180369 364	RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEIN	Not Available	2-Jul- 15	1- Jul- 16	27- Dec -18

 

US20180368 417	ANTIMICROBIAL COMPOSITIONS AND METHODS	Not Available	23- Sep- 14	19- Jun -18	27- Dec -18
US20180365 375	METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC CLASSIFICATION	Not Available	24- Apr- 15	4- Oct -17	20- Dec -18
US20180363 027	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID	Not Available	6- Oct- 06	15- May -18	20- Dec -18
US20180362 625	REGULATION OF CYTOKINE PRODUCTION	Not Available	4- Dec- 15	2- Dec -16	20- Dec -18
US20180360 877	METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURE	Not Available	8- Dec- 15	8- Dec -16	20- Dec -18
US20180360 736	FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES	Intelgenx Corp.	2- Dec- 13	23- Aug -18	20- Dec -18
US20180355 017	COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES	Not Available	7- Jun- 17	6- Jun -18	13- Dec -18
US20180353 594	METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS	Not Available	26- Jul-13	21- Aug -18	13- Dec -18
US20180346 574	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13- Jun- 16	9- Aug -18	6- Dec -18
US20180346 573	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13- Jun- 16	9- Aug -18	6- Dec -18
US20180346 522	HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME	Not Available	10- Apr- 12	6- Aug -18	6- Dec -18
US20180346 516	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	27- Nov- 15	28- Nov -16	6- Dec -18
US20180346 485	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	27- Feb -18	6- Dec -18
US20180346 480	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	1- Mar -18	6- Dec -18
US20180344 877	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF	Children’s Healthcare of Atlanta, Inc.	16- Apr- 15	8- Aug -18	6- Dec -18
US20180344 832	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	20- Apr- 15	20- Apr -16	6- Dec -18
US20180344 751	Broad Spectrum Antiviral and Methods of Use	Not Available	17- Apr- 06	26- Dec -17	6- Dec -18
US20180340 219	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9- Dec- 16	9- Mar -18	29- Nov -18
US20180340 218	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9- Dec- 16	9- Mar -18	29- Nov -18
US20180340 215	SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCE	Not Available	28- Aug- 15	26- Aug -16	29- Nov -18
US20180340 154	PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24- Nov- 15	23- Nov -16	29- Nov -18
US20180340 153	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24- Nov- 15	23- Nov -16	29- Nov -18
US20180339 991	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	24- May -18	29- Nov -18
US20180339 988	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	18- Jan -18	29- Nov -18
US20180339 014	PEPTIDOMIMETIC MACROCYCLES	Not Available	14- Jan- 09	7- Jun -18	29- Nov -18
US20180334 480	CORONAVIRUSES EPITOPE-BASED VACCINES	RAMOT AT TEL-AVIV UNIVERSITY LTD.	17- Sep- 15	15- Sep -16	22- Nov -18
US20180333 485	Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same	Not Available	12- Dec- 11	9- May -18	22- Nov -18
US20180327 800	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26- Feb- 03	21- May -18	15- Nov -18

 

US20180327 738	STABILIZED REAGENTS FOR GENOME MODIFICATION	Not Available	20- Nov- 15	18- Nov -16	15- Nov -18
US20180327 697	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8- Sep- 16	12- Jun -18	15- Nov -18
US20180327 484	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	Not Available	1- Jun- 07	23- Jul- 18	15- Nov -18
US20180326 070	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4- Dec- 07	20- Nov -17	15- Nov -18
US20180326 051	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	17- Aug- 10	24- Jul- 18	15- Nov -18
US20180326 045	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22- Oct- 15	20- Jul- 18	15- Nov -18
US20180326 044	NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONS	Not Available	13- Oct- 15	13- Oct -16	15- Nov -18
US20180326 039	VACCINE COMPOSITIONS	Not Available	16- Sep- 15	16- Sep -16	15- Nov -18
US20180325 076	ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM	OXISCIENCE, LLC	28- Aug- 14	24- Jul- 18	15- Nov -18
US20180321 242	VIRAL BIOMARKERS AND USES THEREFOR	Not Available	6- Nov- 15	4- Nov -16	8- Nov -18
US20180319 811	DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS	Not Available	30- Oct- 15	28- Oct -16	8- Nov -18
US20180319 779	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul- 13	4- Dec -17	8- Nov -18
US20180318 447	COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY	Not Available	3- Dec- 15	30- Nov -16	8- Nov -18
US20180318 366	METHOD OF TREATMENT USING ONCOLYTIC VIRUSES	Not Available	15- Jun- 15	15- Jun -16	8- Nov -18
US20180318 350	Immune Cells with DNMT3A Gene Modifications and Methods Related Thereto	Not Available	4- Nov- 15	4- Nov -16	8- Nov -18
US20180312 575	ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF	Not Available	6- Dec- 07	20- Mar -18	1- Nov -18
US20180312 545	OPTIMIZED NUCLEIC ACID MOLECULES	Not Available	9- Nov- 15	9- Nov -16	1- Nov -18
US20180312 544	RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND USES THEREOF	The United States of America, as represented by the Secretary, Dept. of Health and Human Services	20- Jan- 15	20- Jan -16	1- Nov -18
US20180311 338	MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME	Not Available	11- Jan- 16	11- Jul- 18	1- Nov -18
US20180311 273	Method of Treating Inflammation	Not Available	1- Apr- 10	26- Jun -18	1- Nov -18
US20180305 773	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTION	Not Available	12- Apr- 17	12- Apr -18	25- Oct- 18
US20180305 760	Pathogen biomarkers and uses therefor	Not Available	30- Sep- 15	30- Sep -16	25- Oct- 18
US20180305 451	HIDE1 COMPOSITIONS AND METHODS	Not Available	13- Jul-15	13- Jul- 16	25- Oct- 18
US20180305 412	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE	Not Available	19- Dec- 16	9- Jul- 18	25- Oct- 18
US20180305 357	IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS	Not Available	22- Dec- 06	25- Jun -18	25- Oct- 18
US20180305 356	NOVEL KINASE INHIBITORS	Not Available	19- Oct- 12	18- May -18	25- Oct- 18
US20180303 874	Compositions and Methods for the Prevention of Microbial Infections	Not Available	10- Nov- 11	30- Nov -17	25- Oct- 18
US20180303 768	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30- Jan- 15	2- Jul- 18	25- Oct- 18
US20180303 090	TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT	Not Available	30- Oct- 15	17- Oct -16	25- Oct- 18

 

US20180267 031	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human Services	1- Sep- 15	8- Aug -16	20- Sep -18
US20180265 847	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	29- Mar -18	20- Sep -18
US20180265 822	LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8- Sep- 16	21- May -18	20- Sep -18
US20180265 574	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection	Not Available	15- Mar- 17	15- Mar -17	20- Sep -18
US20180265 507	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES	Dana-Farber Cancer Institute, Inc.	11- Apr- 12	26- Jan -18	20- Sep -18
US20180264 098	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	The Government of the USA as represented by the Secretary of the Dept. of Health and Human Service	8- Oct- 04	31- May -18	20- Sep -18
US20180258 162	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2- Jan- 15	22- May -18	13- Sep -18
US20180258 160	Optimized Crosslinkers for Trapping a Target on a Substrate	Not Available	13- Nov- 15	11- May -18	13- Sep -18
US20180258 159	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28- Oct- 14	14- May -18	13- Sep -18
US20180258 151	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	Not Available	28- Feb- 01	2- Mar -18	13- Sep -18
US20180251 737	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	Not Available	5- Dec- 08	28- Dec -17	6- Sep -18
US20180251 540	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16- Dec- 02	30- Apr -18	6- Sep -18
US20180251 436	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24- Jan- 14	19- Sep -17	6- Sep -18
US20180250 602	PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSE	Not Available	11- Feb- 14	1- May -18	6- Sep -18
US20180250 381	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20- Aug- 10	12- Oct -17	6- Sep -18
US20180245 056	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19- Nov- 09	9- Oct -17	30- Aug -18
US20180245 053	VIRAL VACCINES AND METHODS OF FORMING THE SAME	Not Available	27- Feb- 17	27- Feb -18	30- Aug -18
US20180244 759	NOVEL METHODS OF GENERATING ANTIBODIES	Rutgers, The State University of New Jersey	19- Aug- 15	18- Aug -16	30- Aug -18
US20180244 756	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The United States of America, as Represented by the Secretary, Dept. of Health and Human Services	24- Feb- 15	24- Feb -16	30- Aug -18
US20180244 669	IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS	Not Available	31- Aug- 15	26- Aug -16	30- Aug -18
US20180244 660	CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS	Not Available	17- Aug- 15	17- Aug -16	30- Aug -18
US20180243 347	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	25- Aug- 15	22- Aug -16	30- Aug -18
US20180237 835	METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS	American International Biotechnology, LLC	31- Jul-15	29- Jul- 16	23- Aug -18
US20180237 788	IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION	The Regents of the University of California	8- Aug- 15	5- Aug -16	23- Aug -18
US20180237 786	ARTIFICIAL NUCLEIC ACID MOLECULES	CUREVAC AG	28- Aug- 15	22- Aug -16	23- Aug -18
US20180237 502	PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILS	Integrated BioTherapeutics, Inc.	11- Mar- 15	11- Mar -16	23- Aug -18
US20180237 435	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31- Aug- 15	26- Aug -16	23- Aug -18
US20180236 058	REVERSE GENETICS SYSTEMS	Not Available	31- Jul-09	16- Oct -17	23- Aug -18
US20180236 054	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14- Nov- 13	19- Apr -18	23- Aug -18

 

US20180235 948	(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3- METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4- FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCER	Not Available	18- Aug- 15	18- Aug -16	23- Aug -18
US20180230 521	BIOAGENT DETECTION OLIGONUCLEOTIDES	Not Available	27- Dec- 11	13- Apr -18	16- Aug -18
US20180230 447	ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)	Northwestern University	24- Jan- 17	24- Jan -18	16- Aug -18
US20180228 695	DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS	Not Available	11- Aug- 15	11- Aug -16	16- Aug -18
US20180223 290	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS	GenVec, Inc.	10- Nov- 05	7- Sep -17	9- Aug -18
US20180222 906	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	3M Innovative Properties Company	18- Jun- 04	9- Apr -18	9- Aug -18
US20180221 464	IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSES	Not Available	3- Aug- 15	3- Aug -16	9- Aug -18
US20180216 164	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	Not Available	15- Nov- 06	19- Mar -18	2- Aug -18
US20180216 067	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	29- Mar -18	2- Aug -18
US20180215 831	Antibody Derivatives with Conditionally Enabled Effector Function	Not Available	27- Jul-15	27- Jul- 16	2- Aug -18
US20180215 801	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29- Jan- 15	29- Jan -16	2- Aug -18
US20180215 794	TREATING CANCER WITH VIRAL NUCLEIC ACID	Mayo Foundation for Medical Education and Research	20- Feb- 07	27- Mar -18	2- Aug -18
US20180214 430	Selective Inhibitors Of i-NOS For Use Against Viral Infection	UCL Business PLC	17- Jul-15	15- Jul- 16	2- Aug -18
US20180209 960	Method of Determining, Identifying or Isolating Cell-Penetrating Peptides	Not Available	23- May- 11	11- Dec -17	26- Jul- 18
US20180208 897	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	19- Mar -18	26- Jul- 18
US20180208 659	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13- Jun- 16	13- Jun -17	26- Jul- 18
US20180208 653	METHODS FOR ENHANCING AN IMMUNE RESPONSE	Not Available	20- Jan- 17	19- Jan -18	26- Jul- 18
US20180207 258	ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE	Not Available	22- Feb- 08	5- Mar -18	26- Jul- 18
US20180207 145	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GlaxoSmithKline Intellectual Property (No. 2) Limited	12- May- 14	19- Mar -18	26- Jul- 18
US20180201 998	COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC DEAFNESS GENE MUTATION	CapitalBio Corporation	14- Jul-15	14- Jul- 15	19- Jul- 18
US20180201 907	METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES	Not Available	26- Jan- 12	13- Mar -18	19- Jul- 18
US20180201 687	ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES THEREOF	Not Available	7-Jul- 15	7- Jul- 16	19- Jul- 18
US20180200 365	Methods and Compositions for Inhibiting Akt3	Not Available	17- Jan- 17	20- Feb -18	19- Jul- 18
US20180200 364	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	3M Innovative Properties Company	17- Aug- 10	27- Nov -17	19- Jul- 18
US20180200 224	Antiviral Activity from Medicinal Mushrooms and Their Active Constituents	Not Available	31- Mar- 15	12- Mar -18	19- Jul- 18
US20180200 196	Modular Particulars for Immunotherapy	Not Available	1- Nov- 13	3- Jan -18	19- Jul- 18
US20180196 061	INFLUENZA POTENCY ASSAYS	Not Available	7-Jul- 15	7- Jul- 16	12- Jul- 18
US20180195 048	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Vaccines, Inc.	13- Feb- 15	12- Feb -16	12- Jul- 18

 

US20180194 850	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES	Not Available	15- May- 15	13- May -16	12- Jul- 18
US20180194 829	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER	Not Available	15- Apr- 11	13- Nov -17	12- Jul- 18
US20180194 735	Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines	Hoffmann La-Roche Inc.	17- Sep- 15	8- Mar -18	12- Jul- 18
US20180193 477	DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS	Not Available	15- Jul-15	15- Jul- 16	12- Jul- 18
US20180187 213	Variant AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues	The Children’s Hospital of Philadelphia	22- Jul-13	6- Dec -17	5- Jul- 18
US20180187 211	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	9- Jan- 15	7- Jan -16	5- Jul- 18
US20180187 165	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7- Nov- 14	27- Oct -17	5- Jul- 18
US20180187 154	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	20- Feb -18	5- Jul- 18
US20180187 153	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	20- Feb -18	5- Jul- 18
US20180187 131	DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOF	COMMISSARIAT A L’ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES	16- Jun- 15	15- Jun -16	5- Jul- 18
US20180186 897	NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA	Not Available	26- Jun- 15	24- Jun -16	5- Jul- 18
US20180186 821	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED HAPTENS	Not Available	28- Aug- 15	28- Feb -18	5- Jul- 18
US20180186 802	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	Not Available	1- May- 14	27- Feb -18	5- Jul- 18
US20180186 792	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM	3M Innovative Properties Company	3- Jun- 11	26- Feb -18	5- Jul- 18
US20180186 534	Powdered Pouch And Method Of Making Same	MONOSOL, LLC	16- Apr- 12	29- Dec -17	5- Jul- 18
US20180185 469	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME	Not Available	24- Apr- 12	14- Dec -17	5- Jul- 18
US20180185 392	Pharmaceutical Compositions and Methods	Not Available	3- Aug- 15	29- Nov -17	5- Jul- 18
US20180185 345	METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS	Not Available	19- Jun- 15	17- Jun -16	5- Jul- 18
US20180180 544	USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A FLUOROMETER	Not Available	14- Jun- 12	22- Feb -18	28- Jun- 18
US20180179 300	GENERATION OF BINDING MOLECULES	Merus N.V.	26- Sep- 11	22- Nov -17	28- Jun- 18
US20180179 274	PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES THEREOF	Not Available	26- Jun- 15	24- Jun -16	28- Jun- 18
US20180177 863	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23- Sep- 15	31- Oct -17	28- Jun- 18
US20180177 862	ANTIGENICALLY MATCHED INFLUENZA VACCINES	Not Available	26- Jun- 15	24- Jun -16	28- Jun- 18
US20180177 860	VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD THEREFOR	Not Available	11- Jun- 15	7- Jun -16	28- Jun- 18
US20180163 182	PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS	Human Services	10- Jun- 15	10- Jun -16	14- Jun- 18
US20180162 838	Chemical Compounds	Not Available	18- Mar- 14	13- Dec -17	14- Jun- 18
US20180162 835	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	11- Dec -17	14- Jun- 18
US20180161 425	NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATION	Not Available	10- Dec- 14	10- Dec -15	14- Jun- 18

 

US20180161 422	NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM- LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN	CureVac AG	15- Feb- 12	8- Feb -18	14- Jun- 18
US20180161 279	GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF	Not Available	14- Dec- 16	13- Dec -17	14- Jun- 18
US20180160 662	Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha	Institut Pasteur	26- Mar- 12	25- Jan -18	14- Jun- 18
US20180149 659	DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE	Not Available	4- Jun- 15	3- Jun -16	31- May -18
US20180148 727	ARTIFICIAL NUCLEIC ACID MOLECULES	Not Available	30- Dec- 14	29- Dec -15	31- May -18
US20180142 239	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	Not Available	26- Jan- 07	14- Jun -17	24- May -18
US20180142 198	DELIVERY OF BIOMOLECULES TO IMMUNE CELLS	Not Available	31- Oct- 14	30- Oct -15	24- May -18
US20180142 006	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	12- Jan -18	24- May -18
US20180142 005	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	12- Jan -18	24- May -18
US20180142 004	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	11- Jan -18	24- May -18
US20180142 003	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	9- Jan -18	24- May -18
US20180142 002	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	5- Jan -18	24- May -18
US20180140 659	ANALOGS OF C5a AND METHODS OF USING SAME	Not Available	29- Jun- 10	12- Jan -18	24- May -18
US20180140 625	PRODUCTION OF STABLE NON-POLYADENYLATED RNAS	Massachusetts Institute of Technology	16- Oct- 12	31- Jul- 17	24- May -18
US20180140 580	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29- Nov- 02	23- Oct -17	24- May -18
US20180135 099	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF	Not Available	23- Dec- 05	2- Jan -18	17- May -18
US20180135 012	MEMBRANE-RECEIVER COMPLEX THERAPEUTICS	Not Available	13- May- 15	13- May -16	17- May -18
US20180134 783	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16- Dec- 02	26- Apr -16	17- May -18
US20180134 770	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27- Jun- 08	12- Jan -18	17- May -18
US20180133 246	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7- Mar- 12	1- Nov -17	17- May -18
US20180127 836	IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF VIRUSES	Not Available	7- May- 15	6- May -16	10- May -18
US20180127 783	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS	EDITAS MEDICINE, INC.	7- Nov- 13	29- Nov -17	10- May -18
US20180127 384	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29- Jul-11	21- Jun -17	10- May -18
US20180125 965	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7- Nov- 14	6- Nov -15	10- May -18
US20180125 952	PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT	Not Available	15- May- 15	13- May -16	10- May -18
US20180125 883	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7- Mar- 12	20- Sep -17	10- May -18
US20180112 270	C-CBL MUTATIONS AND USES THEREOF	Not Available	4- Jun- 10	22- Mar -16	26- Apr- 18
US20180111 991	MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS	Not Available	2- Dec- 14	2- Jun -17	26- Apr- 18

 

US20180U1 907	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES	Not Available	29- May- 12	20- Dec -17	26- Apr- 18
US20180110 845	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS	Not Available	31- Aug- 07	18- Dec -17	26- Apr- 18
US20180105 815	Bivalent siRNA Chimeras and Methods of Use Thereof	Not Available	18- Oct- 16	6- Oct -17	19- Apr- 18
US20180105 596	ANTI-TYRO3 ANTIBODIES AND USES THEREOF	Not Available	17- Apr- 15	15- Apr -16	19- Apr- 18
US20180105 514	HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS	Not Available	7- Apr- 16	3- Jan -18	19- Apr- 18
US20180104 241	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY	PARION SCIENCES, INC.	27- Jun- 11	15- Dec -17	19- Apr- 18
US20180100 181	METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME	Not Available	17- Apr- 15	15- Apr -16	12- Apr- 18
US20180099 999	FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA	Not Available	17- Sep- 14	14- Dec -17	12- Apr- 18
US20180098 972	TREATMENT OF INFECTIOUS DISEASES	CHILDREN’S MEDICAL CENTER CORPORATION	26- Jan- 15	26- Jan -16	12- Apr- 18
US20180092 932	Anti-Viral Azide Containing Compounds	Not Available	28- Jul-10	7- Dec -17	5- Apr- 18
US20180087 049	MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBES	Not Available	27- Sep- 16	7- Sep -17	29- Mar -18
US20180086 818	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28- Oct- 14	13- Nov -17	29- Mar -18
US20180085 457	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23- Oct- 15	1- Dec -17	29- Mar -18
US20180085 432	STING (Stimulator of Interferon Genes), A Regulator of Innate Immune Responses	Not Available	4- Aug- 08	15- Sep -17	29- Mar -18
US20180085 388	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul- 10	5- Oct -17	29- Mar -18
US20180079 746	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	19- Mar- 15	15- Mar -16	22- Mar -18
US20180078 625	COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS	Not Available	25- Mar- 15	25- Mar -16	22- Mar -18
US20180078 532	IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB	AMGEN INC.	21- Sep- 16	18- Sep -17	22- Mar -18
US20180078 507	BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF	Not Available	16- Sep- 16	15- Sep -17	22- Mar -18
US20180073 073	METHODS AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASING	Not Available	18- Mar- 15	16- Mar -16	15- Mar -18
US20180072 813	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2- Dec- 05	9- May -17	15- Mar -18
US20180072 796	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	17- Nov -17	15- Mar -18
US20180072 752	COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE	Not Available	30- Mar- 15	2- Feb -16	15- Mar -18
US20180071 219	Technology for Preparation of Macromolecular Microspheres	Not Available	24- Jan- 06	25- Sep -17	15- Mar -18
US20180067 299	ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION MONITORING	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE	7- Sep- 16	31- May -17	8- Mar -18
US20180066 228	Detection of T Cell Exhaustion or Lack of T Cell Costimulation and Uses Thereof	Not Available	15- May- 15	15- Nov -17	8- Mar -18
US20180066 216	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8- Sep- 16	6- Sep -17	8- Mar -18
US20180065 981	HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR	Not Available	26- Mar- 15	21- Mar -16	8- Mar -18

 

US20180064 790	Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Active Ingredient	Not Available	26- Feb- 15	25- Aug -17	8- Mar -18
US20180064 752	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE	Not Available	29- Jul-14	25- Oct -17	8- Mar -18
US20180058 988	SAMPLE FIXATION AND STABILISATION	Not Available	1- Mar- 13	14- Aug -17	1- Mar -18
US20180057 871	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15- Aug- 16	1- Nov -17	1- Mar -18
US20180057 841	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7- Apr- 05	27- Oct -17	1- Mar -18
US20180057 817	Particle-Nucleic Acid Conjugates and Therapeutic Uses Related Thereto	Not Available	25- Jun- 12	9- Oct -17	1- Mar -18
US20180057 594	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30- Jun- 16	29- Sep -17	1- Mar -18
US20180057 509	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	Not Available	9- Feb- 05	2- Nov -17	1- Mar -18
US20180057 488	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	7- Nov -17	1- Mar -18
US20180055 925	DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS	The United States of America, as represented by the Secretary, Department of Health and Human Serv	3- Mar- 15	7- Aug -15	1- Mar -18
US20180055 769	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS	Not Available	3- Dec- 09	26- Jun -17	1- Mar -18
US20180051 267	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10- Dec- 09	5- Oct -17	22- Feb -18
US20180051 266	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10- Dec- 09	21- Aug -17	22- Feb -18
US20180050 059	DELIVERY OF RNA TO DIFFERENT CELL TYPES	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul- 10	30- Aug -17	22- Feb -18
US20180044 687	ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION	Not Available	12- Dec- 14	11- Dec -15	15- Feb -18
US20180044 328	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Prozymex A/S	5- Mar- 15	4- Mar -16	15- Feb -18
US20180043 007	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17- Mar- 14	21- Aug -17	15- Feb -18
US20180037 952	SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS	Nanomedical Diagnostics, Inc.	28- Apr- 14	21- Aug -17	8- Feb -18
US20180037 942	ENZYME-INDEPENDENT MOLECULAR INDEXING	Not Available	3- Aug- 16	1- Aug -17	8- Feb -18
US20180037 871	CANCER INITIATING CELL AND USE THEREOF	Not Available	8- Aug- 16	8- Aug -16	8- Feb -18
US20180037 636	STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE	DANA-FARBER CANCER INSTITUTE, INC.	18- Jun- 09	21- Sep -17	8- Feb -18
US20180037 634	ENGINEERED POLYPEPTIDES AND USES THEREOF	Not Available	2- Aug- 16	2- Aug -17	8- Feb -18
US20180037 617	METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS	Institute of Biophysics, Chinese Academy of Sciences	22- Aug- 14	21- Aug -15	8- Feb -18
US20180036 398	FLAVIVIRUS REPLICONS	Not Available	27- Feb- 15	25- Feb -16	8- Feb -18

 

US20180036 237	OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION	GLAXOSMITHKLINE BIOLOGICALS, SA	23- Feb- 15	23- Feb -16	8- Feb -18
US20180031 555	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES	Menus N.V.	27- Jun- 08	18- Jul- 17	1- Feb -18
US20180030 429	Polypeptide Assemblies and Methods for the Production Thereof	Not Available	27- Feb- 15	29- Feb -16	1- Feb -18
US20180030 411	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	13- Oct -17	1- Feb -18
US20180028 677	Peptides for Assisting Delivery Across the Blood Brain Barrier	Children’s Medical Center Corporation	22- May- 06	30- Jun -17	1- Feb -18
US20180028 626	IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY	Tnansgene SA	13- Feb- 15	12- Feb -16	1- Feb -18
US20180028 562	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	SONOMA PHARMACEUTICALS, INC.	20- Jan- 06	10- Oct -17	1- Feb -18
US20180028 449	Technology for the Preparation of Microparticles	Not Available	24- Jul-07	27- Jun -17	1- Feb -18
US20180028 431	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28- Jul-16	27- Jul- 17	1- Feb -18
US20180023 048	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Not Available	29- Oct- 04	22- Sep -17	25- Jan- 18
US20180022 781	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)	13- Feb- 15	12- Feb -16	25- Jan- 18
US20180021 448	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	12- Jul-12	16- Apr -14	25- Jan- 18
US20180016 307	GRIFFITHSIN MUTANTS	The United States of America, as represented by the Secretary, Department of Health and Human Serv	10- Feb- 15	10- Feb -16	18- Jan- 18
US20180016 285	Boron-Containing Small Molecules	Not Available	20- Jun- 07	28- Sep -17	18- Jan- 18
US20180016 243	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	Not Available	13- Feb- 15	12- Feb -16	18- Jan- 18
US20180015 174	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15- Jul-16	14- Jul- 17	18- Jan- 18
US20180015 052	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30- Jan- 15	28- Jan -16	18- Jan- 18
US20180010 167	ORGANISM IDENTIFICATION PANEL	Not Available	2- Apr- 07	26- Jul- 17	11- Jan- 18
US20180010 125	DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF	Quark Pharmaceuticals Inc.	12- Sep- 12	15- Feb -17	11- Jan- 18
US20180009 787	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31- May- 16	22- Sep -17	11- Jan- 18
US20180008 689	RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE SPACE	Not Available	28- Jan- 15	28- Jan -16	11- Jan- 18
US20180002 743	FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF TARGET RNA SEQUENCES	Not Available	18- Jun- 16	16- Jun -17	4- Jan- 18
US20180002 406	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human	7- Nov- 11	8- Sep -17	4- Jan- 18
US20180000 929	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30- Nov- 12	14- Sep -17	4- Jan- 18
US20180000 926	METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS	Not Available	15- Jan- 15	15- Jan -16	4- Jan- 18
US20180000 868	Induced Hepatocytes and Uses Thereof	Not Available	26- Nov- 14	15- Sep -17	4- Jan- 18
US20180000 724	METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE	Not Available	26- Jul-10	10- May -17	4- Jan- 18
US20170369 843	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18- Nov- 13	29- Mar -17	28- Dec -17
US20170369 470	Cyclic Compounds and Uses Thereof	Not Available	16- Dec- 14	16- Dec -15	28- Dec -17

 

US20170368 203	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29- Apr- 03	10- Jan -17	28- Dec -17
US20170368 201	SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM	The Children’s Hospital of Philadelphia	15- Mar- 13	8- Sep -17	28- Dec -17
US20170368 167	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS	Not Available	21- Aug- 12	6- Jun -16	28- Dec -17
US20170362 300	OLIGOPEPTIDE-FREE CELL CULTURE MEDIA	Not Available	4- Jan- 06	7- Aug -17	21- Dec -17
US20170362 297	CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF	Not Available	19- Dec- 14	21- Dec -15	21- Dec -17
US20170362 187	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS	Parion Sciences, Inc.	17- Dec- 12	29- Jun -17	21- Dec -17
US20170362 170	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	Not Available	3- Aug- 07	29- Jun -17	21- Dec -17
US20170360 962	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES	Not Available	16- Feb- 16	18- Aug -17	21- Dec -17
US20170360 960	AAV Vectors Targeted to the Central Nervous System	Not Available	21- Nov- 14	20- Nov -15	21- Dec -17
US20170360 908	VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING BISPHOSPHONATES	NITTO DENKO CORPORATION	3- Sep- 14	2- Sep -15	21- Dec -17
US20170360 881	PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF	Not Available	17- Jun- 16	16- Jun -17	21- Dec -17
US20170360 875	METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS	MIDDLE TENNESSEE STATE UNIVERSITY	22- Dec- 14	22- Dec -15	21- Dec -17
US20170358 082	STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING	Not Available	15- Mar- 13	2- Aug -17	14- Dec -17
US20170354 727	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	Not Available	8- Oct- 04	23- Aug -17	14- Dec -17
US20170348 433	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES	The Board of Trustees of the Leland Stanford Junior University	16- Feb- 16	16- Feb -17	7- Dec -17
US20170348 402	SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR PROTEIN TO CELLS	Not Available	30- Jul-14	30- Jul- 15	7- Dec -17
US20170348 369	Plant Extract and Its Therapeutic Use	Not Available	16- May- 08	18- Jul- 17	7- Dec -17
US20170342 442	RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS, SA	11- Oct- 11	15- Aug -17	30- Nov -17
US20170342 405	MOLECULAR INDEXING OF INTERNAL SEQUENCES	Not Available	31- May- 16	16- May -17	30- Nov -17
US20170342 056	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31- May- 16	26- May -17	30- Nov -17
US20170340 735	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1- Oct- 15	19- Jun -17	30- Nov -17
US20170340 725	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22- Oct- 15	11- Aug -17	30- Nov -17
US20170340 721	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES	Not Available	3- Sep- 14	3- Sep -15	30- Nov -17
US20170340 611	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31- May- 16	26- May -17	30- Nov -17
US20170337 459	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27- Feb- 15	2- Aug -17	23- Nov -17
US20170336 412	Multiplex Immuno Screening Assay	Institut Pasteur	4- May- 12	19- Jul- 17	23- Nov -17
US20170336 411	B-CELL ANTIGEN PRESENTING CELL ASSAY	The University of Pittsburgh – Of the Commonwealth System of Higher Education	8- Apr- 10	9- Aug -17	23- Nov -17
US20170335 408	Methods and Systems of Multi-Assay Processing and Analysis	Not Available	15- Mar- 16	15- Mar -17	23- Nov -17

 

US20170335 374	METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A SAMPLE	Not Available	6- Mar- 12	6- Jul- 17	23- Nov -17
US20170334 984	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16- Dec- 02	26- Apr -16	23- Nov -17
US20170334 973	NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS	Not Available	28- Oct- 14	27- Oct -15	23- Nov -17
US20170334 941	2′,2′-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER	Not Available	31- Oct- 14	30- Oct -15	23- Nov -17
US20170334 919	2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H- PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS	RESPIVERT LTD.	15- Mar- 13	27- Jul- 17	23- Nov -17
US20170334 864	3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6- PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE	Parion Sciences, Inc.	27- Jun- 11	1- Mar -17	23- Nov -17
US20170333 586	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8- Dec- 14	23- May -15	23- Nov -17
US20170333 553	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	21- May- 13	1- Aug -17	23- Nov -17
US20170333 494	PROBIOTIC THERAPEUTIC APPLICATIONS	Not Available	10- Nov- 14	9- Nov -15	23- Nov -17
US20170333 457	Anti-Viral Azide Containing Compounds	Not Available	28- Jul-10	8- Aug -17	23- Nov -17
US20170333 267	MOBILE CLINICS	Baylor College of Medicine	12- Nov- 14	11- Nov -15	23- Nov -17
US20170328 819	SAMPLE FIXATION AND STABILISATION	Not Available	1- Mar- 13	30- May -17	16- Nov -17
US20170327 543	POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES	Not Available	8- Sep- 10	31- Jan -17	16- Nov -17
US20170327 472	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY	Parion Sciences, Inc.	17- Dec- 12	7- Mar -17	16- Nov -17
US20170327 439	DIHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL CO., LTD.	3- Dec- 14	3- Dec -14	16- Nov -17
US20170326 256	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF	Children’s Healthcare of Atlanta, Inc.	16- Apr- 15	15- Apr -16	16- Nov -17
US20170326 123	Throat solution for treatment of cold, flu and sore throat	Not Available	12- May- 16	12- May -16	16- Nov -17
US20170322 682	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATION	Georgetown University	25- Feb- 08	27- Jul- 17	9- Nov -17
US20170322 201	ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh – Of the Com monwealth System of Higher Education	8- Apr- 10	20- Jul- 17	9- Nov -17
US20170321 192	Recombinant RNA Viruses and Uses Thereof	Icahn School of Medicine at Mount Sinai	6- Jun- 10	6- Apr -17	9- Nov -17
US20170319 712	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE	3M INNOVATIVE PROPERTIES COMPANY	10- Apr- 03	27- Jul- 17	9- Nov -17
US20170319 673	TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS	Not Available	13- Nov- 14	12- Nov -15	9- Nov -17
US20170319 551	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9- May- 12	24- Jan -17	9- Nov -17
US20170313 765	DIRECT EXPRESSION OF ANTIBODIES	Not Available	29- Oct- 14	28- Oct -15	2- Nov -17
US20170313 685	BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS	Purdue Research Foundation	28- Apr- 16	28- Apr -17	2- Nov -17
US20170312 371	MODIFIED VIRUS-LIKE PARTICLES OF CMV	SAIBA GMBH	22- Oct- 14	20- Oct -15	2- Nov -17

 

US20170312 357	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS	Not Available	2- Dec- 14	2- Dec -15	2- Nov -17
US20170308 679	BIOSECURITY SCREENING SYSTEM AND METHOD	Not Available	16- Oct- 14	12- Oct -15	26- Oct- 17
US20170307 562	CHEMICALLY DIFFERENTIATED SENSOR ARRAY	Nanomedical Diagnostics, Inc.	28- Apr- 14	8- May -17	26- Oct- 17
US20170306 354	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17- Dec- 01	1- May -17	26- Oct- 17
US20170306 293	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS	Not Available	9- Dec- 05	2- Jun -17	26- Oct- 17
US20170306 001	CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADES	NATIONAL UNIVERSITY OF SINGAPORE	27- Mar- 14	27- Mar -15	26- Oct- 17
US20170305 868	ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	Parion Sciences, Inc.	13- Dec- 13	1- Mar -17	26- Oct- 17
US20170304 829	PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULE	Click Diagnostics, Inc.	22- Apr- 16	21- Apr -17	26- Oct- 17
US20170304 466	AAV-Based Gene Therapy	Not Available	6- Oct- 14	6- Oct -15	26- Oct- 17
US20170304 459	METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE	Not Available	10- Oct- 14	7- Oct -15	26- Oct- 17
US20170304 429	VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26- Sep- 14	25- Sep -15	26- Oct- 17
US20170304 420	POLYMER ADJUVANT	Oxford University Innovation Limited	10- Oct- 14	9- Oct -15	26- Oct- 17
US20170304 354	TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS	Marine Polymer Technologies, Inc.	15- Apr- 11	13- Mar -17	26- Oct- 17
US20170299 591	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	13- Dec -16	19- Oct- 17
US20170298 100	ANTI-VIRAL PEPTIDES	Not Available	1- Oct- 14	30- Sep -15	19- Oct- 17
US20170296 663	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	16- Apr- 14	16- Apr -14	19- Oct- 17
US20170296 574	Method of Treating Inflammation	Not Available	1- Apr- 10	28- Jun -17	19- Oct- 17
US20170292 132	TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF	Not Available	29- Apr- 13	20- Jun -17	12- Oct- 17
US20170290 909	METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLIN	Bavarian Nordic A/S	26- Sep- 14	25- Sep -15	12- Oct- 17
US20170281 966	Device to Kill Micro-Organisms Inside the Respiratory Tract	Not Available	1- Apr- 16	28- Mar -17	5- Oct- 17
US20170281 759	BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITY	NITTO DENKO CORPORATION	3- Sep- 14	2- Sep -15	5- Oct- 17
US20170275 621	CHIRAL CONTROL	Not Available	13- Jul-12	17- Mar -17	28- Sep -17
US20170275 592	CULTURE MEDIUM	Koninklijke Nederlandse Akademie Van Wetenschappen	27- Nov- 14	27- Nov -15	28- Sep -17
US20170275 323	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4- Apr- 14	7- Apr -15	28- Sep -17
US20170275 253	BENZAZEPINE SULFONAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	18- Dec- 14	14- Jun -17	28- Sep -17
US20170275 243	Lipids and Lipid Compositions for the Delivery of Active Agents	Novartis AG	5- Sep- 14	4- Sep -15	28- Sep -17
US20170274 064	MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES	Not Available	5- Sep- 14	4- Sep -15	28- Sep -17
US20170274 024	AAV Vectors Targeted to Oligodendrocytes	Not Available	28- Sep- 12	17- Apr -17	28- Sep -17

 

US20170267 969	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29- Oct- 04	18- May -17	21- Sep -17
US20170267 722	INHIBITORY PEPTIDES OF VIRAL INFECTION	Not Available	17- Jul-14	25- May -17	21- Sep -17
US20170267 649	STABLE SODIUM CHANNEL BLOCKERS	PARION SCIENCES, INC.	30- Jun- 14	30- Jan -17	21- Sep -17
US20170266 272	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2- Oct- 15	6- Apr -17	21- Sep -17
US20170266 190	DRUG COMBINATION	Not Available	15- Mar- 13	5- Jun -17	21- Sep -17
US20170266 160	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14- Mar- 13	6- Jun -17	21- Sep -17
US20170261 431	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10- Mar- 05	19- May -17	14- Sep -17
US20170260 223	ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN A	Not Available	4- Aug- 14	17- May -17	14- Sep -17
US20170260 147	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26- Jun- 03	23- May -17	14- Sep -17
US20170259 976	DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME	MONOSOL, LLC	3- Oct- 14	2- Oct -15	14- Sep -17
US20170258 904	Antagonism of the VIP Signaling Pathway	Not Available	2- Feb- 11	22- May -17	14- Sep -17
US20170258 893	MERS-CoV Vaccine	Not Available	29- Nov- 13	26- Nov -14	14- Sep -17
US20170253 861	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11- Jul-03	6- Oct -16	7- Sep -17
US20170252 430	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT	Not Available	1- Apr- 14	1- Apr -15	7- Sep -17
US20170252 417	PROTEIN-CHAPERONED T-CELL VACCINES	Not Available	7- Mar- 16	7- Mar -17	7- Sep -17
US20170247 688	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES	NUEVOLUTION A/S	1- Dec- 05	12- Dec -16	31- Aug -17
US20170247 453	SOLUBLE ENGINEERED MONOMERIC FC	The United States of America, as represented by the Secretary, Department of Health and Human Serv	16- Mar- 12	9- May -17	31- Aug -17
US20170247 423	STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION	Not Available	29- Feb- 16	28- Feb -17	31- Aug -17
US20170246 347	MATERIALS WITH IMPROVED PROPERTIES	Not Available	1- Nov- 15	5- May -17	31- Aug -17
US20170241 998	METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES	Not Available	22- Feb- 16	17- Feb -17	24- Aug -17
US20170240 639	ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY	Not Available	22- Feb- 16	22- Feb -17	24- Aug -17
US20170239 397	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1- Nov- 15	5- May -17	24- Aug -17
US20170239 364	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	28- Mar- 11	2- Mar -17	24- Aug -17
US20170239 349	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS	Not Available	20- Feb- 15	6- Jun -16	24- Aug -17
US20170239 291	METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	SONOMA PHARMACEUTICALS, INC.	30- Dec- 03	9- May -17	24- Aug -17
US20170234 781	MEMBRANE-ASSISTED PURIFICATION	Accelerate Diagnostics, Inc.	7- Mar- 11	3- May -17	17- Aug -17
US20170226 593	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8- Feb- 16	8- Feb -16	10- Aug -17
US20170226 511	APTAMERS FOR BINDING FLAVIVIRUS PROTEINS	National University of Singapore	13- Nov- 13	13- Nov -14	10- Aug -17
US20170226 232	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1- Nov- 15	2- Nov -16	10- Aug -17

 

US20170226 222	BISPECIFIC ANTIBODY	Not Available	20- Nov- 13	18- Jan -17	10- Aug -17
US20170226 173	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto	Not Available	23- Oct- 12	19- Apr -17	10- Aug -17
US20170224 813	VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL	NITTO DENKO CORPORATION	4- Aug- 14	4- Aug -15	10- Aug -17
US20170224 812	LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG	NITTO DENKO CORPORATION	4- Aug- 14	4- Aug -15	10- Aug -17
US20170224 616	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 11	24- Apr -17	10- Aug -17
US20170219 560	MALARIA ANTIGEN SCREENING METHOD	United States of America as Represented by the Secretary of the Navy	31- Aug- 05	10- Apr -17	3- Aug -17
US20170216 431	VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION	NITTO DENKO CORPORATION	2- Oct- 14	1- Oct -15	3- Aug -17
US20170216 430	IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	4- Aug- 14	4- Aug -15	3- Aug -17
US20170216 429	COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	4- Aug- 14	4- Aug -15	3- Aug -17
US20170216 427	Coronavirus	Not Available	23- Jul-14	23- Jul- 15	3- Aug -17
US20170216 348	METAL NANOCLUSTERS AND USES THEREOF	Not Available	7- Aug- 14	7- Aug -15	3- Aug -17
US20170216 347	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE	UNIWERSYTET JAGIELLONSKI	29- Jul-14	29- Jul- 15	3- Aug -17
US20170212 116	BIOSENSORS FOR THE DETECTION OF INFECTION AND ASSOCIATED MALADIES	ULISSE BIOMED SRL	31- Jan- 14	26- Jan -15	27- Jul- 17
US20170212 019	POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS	Not Available	23- Jan- 12	10- Apr -17	27- Jul- 17
US20170211 096	LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus- Producing Cells for the Therapy of Tumors	Not Available	29- Jun- 11	7- Apr -17	27- Jul- 17
US20170211 069	USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY	University of Pittsburgh – Of the Com monwealth System of Higher Education	7- Mar- 12	27- Jan -17	27- Jul- 17
US20170211 058	METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLES	Not Available	6- Aug- 14	5- Aug -15	27- Jul- 17
US20170209 844	MICROSPOTTING DEVICE	Not Available	18- Apr- 12	5- Jan -17	27- Jul- 17
US20170209 595	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15- Jul-15	5- Apr -17	27- Jul- 17
US20170209 590	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS	Not Available	13- Jan- 11	10- Jan -17	27- Jul- 17
US20170209 570	Carbon Nanotube Compositions and Methods of Use Thereof	Not Available	19- Mar- 08	17- Mar -17	27- Jul- 17
US20170209 376	COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES	Not Available	14- Apr- 04	10- Mar -17	27- Jul- 17
US20170205 399	POLYMERS AND CONJUGATES COMPRISING THE SAME	Not Available	2- Oct- 14	31- Mar -17	20- Jul- 17

 

US20170204 143	Constrained proteins and uses therefor	Not Available	21- Jul-14	21- Jul- 15	20- Jul- 17
US20170204 083	THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	11- Sep- 12	13- Jan -17	20- Jul- 17
US20170202 975	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15- Jul-15	5- Apr -17	20- Jul- 17
US20170202 960	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul- 11	23- Mar -17	20- Jul- 17
US20170202 959	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24- Mar- 15	23- Mar -17	20- Jul- 17
US20170202 956	Methods and Compositions for Inhibiting Akt3	Not Available	15- Jan- 16	17- Jan -17	20- Jul- 17
US20170202 955	Adjuvanted Influenza Vaccines for Pediatric Use	Not Available	22- Feb- 08	30- Dec -16	20- Jul- 17
US20170202 949	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE	Providence Health & Services – Oregon	29- Jul-05	29- Dec -16	20- Jul- 17
US20170202 829	Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications	Not Available	15- Jan- 16	17- Jan -17	20- Jul- 17
US20170196 979	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Novartis AG	8- Mar- 13	27- Sep -16	13- Jul- 17
US20170196 954	PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR	Not Available	15- Jul-14	14- Jul- 15	13- Jul- 17
US20170191 933	Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal Detector	Not Available	31- Dec- 15	23- Dec -16	6- Jul- 17
US20170191 079	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7- Apr- 05	18- Jan -17	6- Jul- 17
US20170190 770	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	CORMORANT PHARMACEUTICALS AB	16- Dec- 02	26- Apr -16	6- Jul- 17
US20170189 521	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	3M Innovative Properties Company	17- Aug- 10	19- Aug -16	6- Jul- 17
US20170175 140	METHODS FOR USING A 5′-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS	Not Available	16- Dec- 15	14- Dec -16	22- Jun- 17
US20170173 585	POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION	Not Available	11- Jul-14	10- Jul- 15	22- Jun- 17
US20170173 176	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	3- Mar -17	22- Jun- 17
US20170173 168	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	3- Mar -17	22- Jun- 17
US20170173 164	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM	Not Available	3- Jun- 11	6- Mar -17	22- Jun- 17
US20170168 052	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	13- Dec -16	15- Jun- 17
US20170168 044	QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING	XIAMEN UNIVERSITY	9- Jun- 14	24- Sep -14	15- Jun- 17
US20170166 574	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	14- Dec- 15	12- Dec -16	15- Jun- 17
US20170165 366	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1- Oct- 15	13- Feb -17	15- Jun- 17
US20170165 359	IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE	Not Available	11- Aug- 10	23- Aug -16	15- Jun- 17
US20170165 341	REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION	Not Available	24- Aug- 12	15- Feb -17	15- Jun- 17
US20170165 230	USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY	Not Available	9- Apr- 14	9- Apr -15	15- Jun- 17
US20170160 218	APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONS	Not Available	31- Jul-12	23- Feb -17	8- Jun- 17

 

US20170159 027	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	15- Feb -17	8- Jun- 17
US20170159 026	Novel Recombinant Adeno-Associated Virus Capsids with Enhanced Human Skeletal Muscle Tropism	Not Available	2- Dec- 15	2- Dec -16	8- Jun- 17
US20170158 752	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25- Apr- 14	27- Apr -15	8- Jun- 17
US20170157 262	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	Not Available	12- Jul-12	12- Jul- 12	8- Jun- 17
US20170157 151	Broad Spectrum Antiviral and Methods of Use	Not Available	17- Apr- 06	16- Feb -17	8- Jun- 17
US20170152 274	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	Hangzhou DAC Biotech Co., Ltd.	28- Feb- 14	28- Feb -14	1- Jun- 17
US20170152 271	GAK MODULATORS AS ANTIVIRALS	Katholieke Universiteit Leuven	23- Jul-14	23- Jul- 15	1- Jun- 17
US20170151 346	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	13- Feb -17	1- Jun- 17
US20170151 291	SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF	Not Available	25- Nov- 13	25- Nov -14	1- Jun- 17
US20170145 394	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9	Not Available	23- Nov- 15	22- Nov -16	25- May -17
US20170144 984	MODULATORS OF THE RELAXIN RECEPTOR 1	Not Available	4- May- 12	25- Aug -16	25- May -17
US20170143 845	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD	15- Jul-15	3- Feb -17	25- May -17
US20170143 820	IMMUNOGENIC COMBINATIONS	GLAXOSMITHKLINE SA	13- Jun- 14	12- Jun -15	25- May -17
US20170143 758	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd.	11- Sep- 13	4- Jan -17	25- May -17
US20170143 749	SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF	Not Available	24- Jun- 14	2- Feb -17	25- May -17
US20170137 527	GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSE	Not Available	25- Mar- 05	7- Nov -16	18- May -17
US20170137 430	Nuclear Transport Modulators And Uses Thereof	Not Available	29- Jul-11	22- Jul- 16	18- May -17
US20170136 118	NEUTRALIZING MOLECULES TO VIRAL ANTIGENS	Not Available	28- Mar- 08	8- Jun -16	18- May -17
US20170136 043	THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY	The University of North Carolina at Chapel Hill	11- Apr- 14	30- Jan -17	18- May -17
US20170131 271	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES	Not Available	27- Apr- 10	12- Sep -16	11- May -17
US20170130 200	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31- Jul-15	29- Jul- 16	11- May -17
US20170129 947	REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE	Kolltan Pharmaceuticals, Inc.	25- Jul-12	20- Sep -16	11- May -17
US20170129 891	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	Not Available	18- Jun- 04	23- Jan -17	11- May -17
US20170128 465	Pharmaceutical Compositions and Methods	Not Available	3- Aug- 15	6- Dec -16	11- May -17
US20170122 853	PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV	8- Aug- 14	7- Aug -15	4- May -17
US20170121 372	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3- Dec- 12	15- Jun -16	4- May -17
US20170119 872	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20- Aug- 10	11- Oct -16	4- May -17
US20170119 871	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27- Jun- 07	24- Jun -16	4- May -17
US20170119 820	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31- Jul-15	29- Jul- 16	4- May -17

 

US20170119 786	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8- Mar- 11	11- Nov -16	4- May -17
US20170119 734	TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE	Not Available	5- May- 10	22- Apr -16	4- May -17
US20170118 995	MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING UNICELLULAR ORGANISMS AND/OR VIRUSES	Riken Techno System Co., Ltd.	17- Sep- 14	6- Dec -16	4- May -17
US20170114 053	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF	The United States of America, as represented by the Secretary, Department of Health and Human Serv	12- Jun- 14	12- Jun -15	27- Apr- 17
US20170112 929	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7- Sep- 12	6- Jun -16	27- Apr- 17
US20170107 254	Modified Antimicrobial Peptides	Not Available	2- Apr- 14	2- Apr -15	20- Apr- 17
US20170107 195	Chemical Compounds	AstraZeneca AB	18- Mar- 14	17- Mar -15	20- Apr- 17
US20170106 077	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17- Mar- 14	13- Mar -15	20- Apr- 17
US20170101 459	CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES	Not Available	6- Jun- 14	5- Jun -15	13- Apr- 17
US20170101 413	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	12- Jun- 14	12- Jun -14	13- Apr- 17
US20170100 474	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6- Apr- 07	22- Jul- 16	13- Apr- 17
US20170100 385	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED	12- May- 14	8- May -15	13- Apr- 17
US20170096 646	Modified Adenovirus Hexon Protein and Uses Thereof	Not Available	28- Apr- 06	20- Dec -16	6- Apr- 17
US20170096 455	METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS	The University of North Carolina at Chapel Hill	20- Mar- 14	20- Mar -15	6- Apr- 17
US20170096 441	PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS	Not Available	14- Apr- 10	9- Sep -16	6- Apr- 17
US20170096 417	Multicyclic Compounds And Methods Of Using Same	Karyopharm Therapeutics Inc.	20- Sep- 13	19- Sep -14	6- Apr- 17
US20170095 818	INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION AND MICROARRAY DETECTION	CapitalBio Corporation	31- Mar- 14	31- Mar -15	6- Apr- 17
US20170095 521	Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents	Not Available	1- Oct- 15	30- Sep -16	6- Apr- 17
US20170089 911	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24- Feb- 14	24- Aug -16	30- Mar -17
US20170088 858	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17- Dec- 01	20- Oct -16	30- Mar -17
US20170088 848	Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing Hemagglutinin	Medicago Inc.	21- Jan- 08	2- Sep -16	30- Mar -17
US20170088 559	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	Not Available	9- Feb- 05	12- Dec -16	30- Mar -17
US20170086 463	ANTIVIRAL AGENT	Not Available	3- Sep- 08	12- Dec -16	30- Mar -17
US20170082 608	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16- May- 14	15- May -15	23- Mar -17
US20170082 607	MALARIA ANTIGEN SCREENING METHOD	Not Available	31- Aug- 05	19- Apr -13	23- Mar -17
US20170081 655	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14- Jul-15	13- Jul- 16	23- Mar -17
US20170081 393	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	The U.S.A., as represented by the Secretary, Department of Health and Human Services	31- Jan- 08	2- Dec -16	23- Mar -17
US20170081 392	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13- May- 14	13- May -15	23- Mar -17

 

US20170080 084	OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION	Not Available	17- Mar- 14	17- Mar -15	23- Mar -17
US20170080 079	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23- Sep- 15	23- Sep -16	23- Mar -17
US20170080 078	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME	Not Available	24- Apr- 12	3- Oct -16	23- Mar -17
US20170079 920	Technology for the Preparation of Microparticles	Not Available	24- Jul-07	5- Dec -16	23- Mar -17
US20170079 916	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY	Not Available	23- Sep- 15	23- Sep -16	23- Mar -17
US20170079 253	TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS	INSTITUT PASTEUR	30- Jul-03	17- Jul- 12	23- Mar -17
US20170073 738	Compositions and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood Samples	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	25- Nov -16	16- Mar -17
US20170073 730	METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION	Not Available	11- Sep- 15	8- Sep -16	16- Mar -17
US20170073 727	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	Not Available	8- Nov- 13	2- Nov -16	16- Mar -17
US20170073 390	Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay	Not Available	6- Jan- 06	5- Dec -14	16- Mar -17
US20170073 352	NOVEL SUBSTITUTED SPIROCYCLES	Not Available	12- Sep- 14	29- Nov -16	16- Mar -17
US20170072 053	METHODS FOR PREPARING SQUALENE	Not Available	12- May- 10	22- Nov -16	16- Mar -17
US20170071 980	METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL APPLICATIONS	OCULUS INNOVATIVE SCIENCES, INC.	2- May- 05	22- Nov -16	16- Mar -17
US20170071 964	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS	Not Available	16- Sep- 15	16- Sep -16	16- Mar -17
US20170071 867	NOVEL NANOPARTICLE COMPOSITIONS	Not Available	3- Apr- 13	28- Nov -16	16- Mar -17
US20170067 030	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30- Mar- 07	7- Sep -16	9- Mar -17
US20170067 021	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31- Jul-15	2- Sep -16	9- Mar -17
US20170066 788	BORON-CONTAINING SMALL MOLECULES	Not Available	16- Feb- 05	18- Nov -16	9- Mar -17
US20170066 787	BORON-CONTAINING SMALL MOLECULES	Not Available	16- Feb- 05	18- Nov -16	9- Mar -17
US20170066 731	SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS	Not Available	7- Mar- 14	5- Mar -15	9- Mar -17
US20170065 706	METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS	Not Available	2-Jul- 07	14- Sep -16	9- Mar -17
US20170065 693	Sequential administration of a replication defective adenovirus vector in vaccination protocols	Not Available	2-Jul- 07	14- Sep -16	9- Mar -17
US20170065 677	EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT	Volution Immuno Pharmaceuticals SA	8- Jan- 10	22- Jul- 16	9- Mar -17
US20170065 636	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31- Jul-15	29- Aug -16	9- Mar -17
US20170058 430	BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS	Not Available	18- Feb- 14	18- Feb -15	2- Mar -17
US20170058 365	SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS	Not Available	1- Sep- 15	3- Feb -16	2- Mar -17
US20170057 978	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9- May- 14	8- May -15	2- Mar -17
US20170057 968	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	NOVARTIS AG	1- May- 14	29- Apr -15	2- Mar -17
US20170057 938	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24- Jan- 14	8- Nov -16	2- Mar -17

 

US20170052 190	Covalently Linked Thermostable Kinase for Decontamination Process Validation	Not Available	20- Feb- 08	8- Jul- 16	23- Feb -17
US20170051 053	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY	Not Available	28- Dec- 11	7- Sep -16	23- Feb -17
US20170051 046	H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES	MEDIGEN BIOTECHNOLOGY CORPORATION	20- Aug- 15	20- Aug -15	23- Feb -17
US20170051 022	ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY	Not Available	30- Apr- 14	30- Apr -15	23- Feb -17
US20170051 007	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3- Aug- 15	28- Jul- 16	23- Feb -17
US20170049 813	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAME	OCULUS INNOVATIVE SCIENCES, INC.	13- Mar- 07	8- Nov -16	23- Feb -17
US20170044 603	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS	Not Available	31- Jul-09	15- Aug -16	16- Feb -17
US20170044 595	PCR Ready Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences	Longhorn Vaccines and Diagnostics, LLC	24- Aug- 07	26- Oct -16	16- Feb -17
US20170044 237	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16- May- 08	23- Aug -16	16- Feb -17
US20170044 168	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	NOVARTIS AG	1- May- 14	29- Apr -15	16- Feb -17
US20170042 994	COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS	ASSISTANCE PUBLIQUE – HOPITAUX DE PARIS	22- Jul-11	29- Jul- 16	16- Feb -17
US20170042 898	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS	HEMAQUEST PHARMACEUTICALS, INC.	11- Mar- 10	27- Oct -16	16- Feb -17
US20170039 316	Compositions, processes and algorithms for microbial detection	Not Available	12- Nov- 03	25- Oct -04	9- Feb -17
US20170039 314	BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING	IOGENETICS, LLC	23- Mar- 10	13- Sep -12	9- Feb -17
US20170038 085	AIR CURTAIN DEVICE	Not Available	7- Aug- 15	19- Nov -15	9- Feb -17
US20170037 457	NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME	Not Available	5- Feb- 14	29- Jan -15	9- Feb -17
US20170037 379	CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOF	Icahn School of Medicine at Mount Sinai	2- Dec- 05	3- Mar -16	9- Feb -17
US20170037 376	METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND USES THEREOF	GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES	15- Nov- 13	12- Nov -14	9- Feb -17
US20170037 090	RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING POLYGENES	Not Available	8- Nov- 05	26- Oct -16	9- Feb -17
US20170037 045	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM	3M Innovative Properties Company	3- Jun- 11	24- Oct -16	9- Feb -17
US20170035 878	Multi-Functional Mucosal Vaccine Platform	Not Available	11- Feb- 14	11- Feb -15	9- Feb -17
US20170035 845	Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression	Not Available	7- Aug- 15	5- Aug -16	9- Feb -17
US20170029 877	POLYTAG PROBES	Not Available	26- Feb- 10	31- Mar -16	2- Feb -17
US20170029 847	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30- Dec- 13	28- Jun -16	2- Feb -17
US20170029 489	HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF	Not Available	14- Dec- 10	1- Jun -16	2- Feb -17
US20170028 082	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	3- Aug -16	2- Feb -17
US20170028 054	VACCINE COMPOSITION	NITTO DENKO CORPORATION	4- Apr- 12	11- Oct -16	2- Feb -17
US20170027 975	Methods of Treating Coronavirus Infection	United States Government as represented by the Secretary, Department of Health and Human Services	7- Apr- 14	7- Apr -15	2- Feb -17

 

US20170027 944	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24- Sep- 09	18- Feb -15	2- Feb -17
US20170022 577	METHODS OF TESTING FOR INTRACELLULAR PATHOGENS	Novartis AG	8- Mar- 10	23- Sep -16	26- Jan- 17
US20170022 242	NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS	KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D	17- Apr- 14	17- Apr -15	26- Jan- 17
US20170021 013	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30- Nov- 12	31- Mar -16	26- Jan- 17
US20170020 926	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1- Apr- 14	13- Mar -15	26- Jan- 17
US20170016 048	COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDS	Not Available	18- May- 15	17- May -16	19- Jan- 17
US20170015 716	STABILIZED ANTI-MICROBIAL PEPTIDES	Not Available	2-Jul- 15	1- Jul- 16	19- Jan- 17
US20170014 496	COMBINATION OF VACCINATION AND OX40 AGONISTS	Not Available	12- Mar- 14	12- Mar -14	19- Jan- 17
US20170014 423	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6- Mar- 15	28- Sep -16	19- Jan- 17
US20170011 131	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT RELATED INFORMATION	Georgetown University	25- Feb- 08	23- Sep -16	12- Jan- 17
US20170010 264	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	20- Sep -16	12- Jan- 17
US20170009 237	Short Interfering RNA (siRNA) Analogues	Not Available	21- Mar- 03	28- Mar -16	12- Jan- 17
US20170007 577	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29- Nov- 02	19- Sep -16	12- Jan- 17
US20170002 042	PEPTIDOMIMETIC MACROCYCLES	Not Available	1-Jul- 15	1- Jul- 16	5- Jan- 17
US20170000 878	CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR	Not Available	23- Jun- 10	9- Aug -16	5- Jan- 17
US20170000 873	Dimethyl Fumarate and Vaccination Regimens	Not Available	14- Mar- 14	13- Mar -15	5- Jan- 17
US20160376 596	COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS	Bavarian Nordic A/S	28- Nov- 13	25- Nov -14	29- Dec -16
US20160376 321	A NOVEL SARS IMMUNOGENIC COMPOSITION	BAYLOR COLLEGE OF MEDICINE	26- Nov- 13	21- Nov -14	29- Dec -16
US20160375 137	TARGETING LIPIDS	Tekmira Pharmaceuticals Corporation	4- Dec- 07	22- Oct -13	29- Dec -16
US20160375 132	HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF	Not Available	15- Dec- 09	5- Jul- 16	29- Dec -16
US20160369 268	TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USE	The Board of Regents of the University of Texas System	1-Jul- 13	25- Jun -14	22- Dec -16
US20160368 956	METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS	Not Available	9- May- 13	23- Aug -16	22- Dec -16
US20160368 904	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul- 13	3- Jul- 14	22- Dec -16
US20160367 587	Systemic In Vivo Delivery of Oligonucleotides	OncoImmunin, Inc.	12- Jun- 13	12- Jun -14	22- Dec -16
US20160367 188	ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND DEVELOPERS’ TOOL KIT	Not Available	17- Jun- 15	10- Sep -15	22- Dec -16
US20160363 557	AMPEROMETRIC GAS SENSOR	Not Available	25- Jun- 12	25- Aug -16	15- Dec -16
US20160362 730	PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS	Not Available	26- Feb- 14	26- Aug -16	15- Dec -16
US20160362 454	Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses	Not Available	7- Oct- 11	10- Jun -16	15- Dec -16
US20160361 382	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS	Not Available	11- Jun- 15	13- Jun -16	15- Dec -16

 

US20160361 259	Methods for the Preparation of Liposomes	Not Available	23- Sep- 09	2- Aug -16	15- Dec -16
US20160354 451	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS	Not Available	31- Aug- 07	9- Jun -16	8- Dec -16
US20160354 428	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	8- Feb- 07	2- Jun -16	8- Dec -16
US20160354 347	Nuclear Transport Modulators and Uses Thereof	Not Available	9- May- 12	6- Jan -16	8- Dec -16
US20160348 153	EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv	29- May- 15	31- May -16	1- Dec -16
US20160348 132	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	Not Available	18- May- 04	11- Aug -16	1- Dec -16
US20160348 115	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity	Not Available	27- Sep- 06	26- May -16	1- Dec -16
US20160348 110	NUCLEIC ACID CHEMICAL MODIFICATIONS	Not Available	2- Mar- 09	11- Aug -16	1- Dec -16
US20160347 816	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER	Not Available	15- Apr- 11	29- Feb -16	1- Dec -16
US20160347 814	VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES	Not Available	11- Sep- 13	10- Mar -16	1- Dec -16
US20160347 784	NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF	Not Available	6-Jul- 09	27- May -16	1- Dec -16
US20160346 309	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	Not Available	1- Jun- 07	21- Dec -15	1- Dec -16
US20160340 713	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID	Not Available	6- Oct- 06	20- May -16	24- Nov -16
US20160340 319	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	6- Feb- 13	5- Aug -16	24- Nov -16
US20160339 097	CORONAVIRUS PROTEINS AND ANTIGENS	MJ Biologics, Inc.	7- Feb- 14	4- Aug -16	24- Nov -16
US20160338 998	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF	3-V Biosciences, Inc.	20- Dec- 13	19- Dec -14	24- Nov -16
US20160333 356	OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY	Not Available	3- Mar- 11	28- Jul- 16	17- Nov -16
US20160333 089	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	Not Available	8- Feb- 06	18- Jul- 16	17- Nov -16
US20160333 076	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human Serv	7- Nov- 11	2- Aug -16	17- Nov -16
US20160331 828	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23- Apr- 14	5- Apr -16	17- Nov -16
US20160331 816	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS	Not Available	18- Oct- 13	18- Apr -16	17- Nov -16
US20160331 758	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	Not Available	1- Aug- 08	21- Dec -15	17- Nov -16
US20160327 506	CAPACITIVE LIQUID CRYSTAL BIOSENSORS	Not Available	6- May- 15	5- May -16	10- Nov -16
US20160327 484	A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE AND ITS USE	Not Available	30- Dec- 13	18- Dec -14	10- Nov -16
US20160326 598	METHODS AND COMPOSITIONS FOR PROSTATE CANCER METASTASIS	Not Available	25- Mar- 11	27- May -16	10- Nov -16
US20160326 325	POWDERED POUCH AND METHOD OF MAKING SAME	Not Available	16- Apr- 12	19- Jul- 16	10- Nov -16

 

US20160326 233	NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN	Not Available	16- Jan- 14	15- Jan -15	10- Nov -16
US20160326 141	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS	Not Available	7- Jan- 14	7- Jan -15	10- Nov -16
US20160325 283	BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS	Not Available	30- Mar- 09	18- Jul- 16	10- Nov -16
US20160324 834	Use of mTOR Inhibitors to Enhance T Cell Immune Responses	Not Available	5- Aug- 08	16- May -16	10- Nov -16
US20160320 390	COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES	Not Available	1- May- 15	1- May -15	3- Nov -16
US20160318 985	Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored GM-CSF and IL-4 Conjugates	Not Available	29- Apr- 15	29- Apr -16	3- Nov -16
US20160318 861	NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	30- Apr- 15	2- May -16	3- Nov -16
US20160317 647	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23- Apr- 14	1- Apr -16	3- Nov -16
US20160317 637	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7- Jan- 14	7- Jan -15	3- Nov -16
US20160317 496	METHODS OF TREATING CANCER AND OTHER DISORDERS	Not Available	12- Nov- 10	27- Jun -16	3- Nov -16
US20160317 458	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19- Dec- 13	17- Dec -14	3- Nov -16
US20160312 276	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	23- Apr- 15	21- Apr -16	27- Oct- 16
US20160311 886	Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging	Not Available	24- Jan- 05	12- Jul- 16	27- Oct- 16
US20160311 835	NOVEL ANTIBIOTICS	Not Available	26- May- 11	30- Nov -15	27- Oct- 16
US20160311 816	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	22- Apr -16	27- Oct- 16
US20160311 759	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19- Dec- 13	17- Dec -14	27- Oct- 16
US20160310 511	Myxovirus Therapeutics, Compounds, and Uses Related Thereto	Not Available	24- Oct- 11	7- Jul- 16	27- Oct- 16
US20160305 936	DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY	Not Available	13- Jul-10	18- Feb -16	20- Oct- 16
US20160304 954	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	11- Dec- 13	11- Dec -14	20- Oct- 16
US20160304 942	Enhanced Methods of Ribonucleic Acid Hybridization	Not Available	6- Dec- 13	5- Dec -14	20- Oct- 16
US20160304 904	Directed Evolution and In Vivo Panning of Virus Vectors	Not Available	CO 1 1	28- Jun -16	20- Oct- 16
US20160304 883	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30- Dec- 13	28- Jun -16	20- Oct- 16
US20160304 882	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS	GenVec, Inc.	10- Nov- 05	27- Jun -16	20- Oct- 16
US20160304 586	PROCESS FOR PREPARING INFLUENZA VACCINES	Crucell Holland B.V.	5- Dec- 13	4- Dec -14	20- Oct- 16
US20160304 579	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION	Not Available	30- Jun- 11	29- Feb -16	20- Oct- 16
US20160304 472	Hydrazide Containing Nuclear Transport Modulators and Uses Thereof	Not Available	29- Jul-11	13- Nov -15	20- Oct- 16
US20160303 194	Compositions And Method For Treatment Of Inflammatory Bowel Disease	Not Available	2- Jun- 11	21- Apr -16	20- Oct- 16
US20160303 052	MODULAR PARTICLES FOR IMMUNOTHERAPY	Not Available	1- Nov- 13	31- Oct -14	20- Oct- 16
US20160299 141	NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS	Biolog Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH	8- Apr- 15	1- Apr -16	13- Oct- 16
US20160298 179	LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS	CapitalBio Corporation	5- Dec- 13	2- Dec -14	13- Oct- 16

 

US20160296 617	Immunogenic Composition for MERS Coronavirus Infection	Not Available	1- Mar- 13	28- Feb -14	13- Oct- 16
US20160296 616	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25- Mar- 15	25- Mar -16	13- Oct- 16
US20160295 844	GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF	Not Available	13- Apr- 15	12- Apr -16	13- Oct- 16
US20160292 393	SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF	Not Available	24- Oct- 13	13- Apr -16	6- Oct- 16
US20160289 740	METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING	Not Available	30- Mar- 15	29- Mar -16	6- Oct- 16
US20160289 191	ORGANIC COMPOUNDS	NOVARTIS AG	27- Jun- 08	9- Oct -15	6- Oct- 16
US20160288 121	Slip Chip Device and Methods	Not Available	24- Mar- 09	25- May -16	6- Oct- 16
US20160287 697	INJECTABLE VACCINE COMPOSITION	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	6- Oct- 16
US20160287 622	COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTION	Massachusetts Institute of Technology	18- Nov- 13	7- Nov -14	6- Oct- 16
US20160281 109	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	Not Available	28- Oct- 05	10- Jun -16	29- Sep -16
US20160280 707	ALKOXY SUBSTITUTED IMIDAZOQUINOLINES	Not Available	3- Oct- 03	13- Jun -16	29- Sep -16
US20160279 237	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24- Mar- 15	24- Mar -16	29- Sep -16
US20160279 193	IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY	Not Available	6- Nov- 13	6- Nov -14	29- Sep -16
US20160279 165	PULSE INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	24- Mar- 15	24- Mar -16	29- Sep -16
US20160279 163	Method of Treating Inflammation	Not Available	1- Apr- 10	3- Jun -16	29- Sep -16
US20160278 349	Immunocompromised Ungulates	Not Available	27- Oct- 08	23- Mar -15	29- Sep -16
US20160272 707	VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES	Not Available	11- Sep- 13	11- Sep -14	22- Sep -16
US20160271 241	BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING THESE VIRUSES	Stichting Dienst Landbouwkundig Onderzoek	21- May- 13	21- May -14	22- Sep -16
US20160271 240	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14- Nov- 13	14- Nov -15	22- Sep -16
US20160271 137	INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS	Not Available	18- Feb- 10	27- Oct -15	22- Sep -16
US20160267 244	METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS	Not Available	8- Aug- 08	19- May -16	15- Sep -16
US20160265 025	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF	Not Available	23- Dec- 05	20- May -16	15- Sep -16
US20160264 971	COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION	Not Available	20- Jul-09	9- Oct -15	15- Sep -16
US20160264 962	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS	Not Available	4- Apr- 12	28- Jul- 15	15- Sep -16
US20160263 156	RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG DISEASE	University of Pittsburgh – Of the Com monwealth System of Higher Education	7- Nov- 13	6- Nov -14	15- Sep -16
US20160258 949	CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGY	Not Available	9- Oct- 13	9- Oct -14	8- Sep -16
US20160257 932	GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER POLYPEPTIDE	Not Available	18- Nov- 13	17- May -16	8- Sep -16
US20160257 653	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6- Mar- 15	4- Mar -16	8- Sep -16

 

US20160256 870	Slip Chip Device and Methods	Not Available	24- Mar- 09	25- May -16	8- Sep -16
US20160256 541	Cationic Oil-In-Water Emulsions	Not Available	6-Jul- 10	11- Mar -16	8- Sep -16
US20160253 584	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27- Feb- 15	26- Feb -16	1- Sep -16
US20160251 637	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19- Nov- 09	11- Mar -16	1- Sep -16
US20160251 631	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9- Sep- 04	9- May -16	1- Sep -16
US20160251 399	PEPTIDOMIMETIC MACROCYCLES	Not Available	14- Jan- 09	7- Apr -16	1- Sep -16
US20160251 362	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	18- Dec- 12	10- May -16	1- Sep -16
US20160251 319	CARBOXYLIC ACID COMPOUNDS	Astrazeneca Aktiebolag	18- May- 12	11- May -16	1- Sep -16
US20160250 326	Conjugates of GM-CSF and IL-7, and Compositions Thereof	Not Available	14- Nov- 11	18- May -16	1- Sep -16
US20160250 278	PEPTIDOMIMETIC MACROCYCLES	Not Available	14- Jan- 09	7- Apr -16	1- Sep -16
US20160250 168	ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS	Not Available	3- Oct- 12	3- Mar -16	1- Sep -16
US20160238 601	METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS	Not Available	14- Oct- 13	14- Oct -14	18- Aug -16
US20160238 600	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES	Merus B.V.	30- May- 03	27- Apr -16	18- Aug -16
US20160237 455	CRISPR-RELATED METHODS AND COMPOSITIONS	Editas Medicine, Inc.	27- Sep- 13	26- Sep -14	18- Aug -16
US20160237 123	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS	Not Available	23- Jan- 08	4- May -16	18- Aug -16
US20160237 082	DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME	Not Available	10- Oct- 13	10- Oct -14	18- Aug -16
US20160235 840	Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same	Not Available	12- Dec- 11	26- Feb -16	18- Aug -16
US20160235 837	THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)	Not Available	16- Oct- 13	16- Oct -14	18- Aug -16
US20160235 835	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Seqirus UK Limited	10- Feb- 09	27- Jan -16	18- Aug -16
US20160235 675	Technology for the Preparation of Microparticles	Not Available	24- Jul-07	24- Mar -16	18- Aug -16
US20160230 190	Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof	Not Available	17- Sep- 13	17- Sep -14	11- Aug -16
US20160229 904	Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use	Not Available	6- Feb- 15	5- Feb -16	11- Aug -16
US20160229 872	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	4- Feb -16	11- Aug -16
US20160229 864	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	4- Feb -16	11- Aug -16
US20160229 833	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	4- Feb -16	11- Aug -16
US20160228 540	NASAL MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	11- Aug -16
US20160228 533	Use of EGFR Pathway Inhibitors to Increase Immune Responses to Antigens	Emory University	23- Sep- 13	23- Sep -14	11- Aug -16
US20160228 532	METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONS	Merck Sharp & Dohme Corp.	16- Oct- 13	13- Oct -14	11- Aug -16
US20160228 463	BORON-CONTAINING SMALL MOLECULES	Not Available	16- Feb- 05	20- Apr -16	11- Aug -16

 

US20160222 414	CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES	Not Available	14- Mar- 13	15- Apr -16	4- Aug -16
US20160222 072	Universal Protein Tag for Double Stranded Nucleic Acid Delivery	Not Available	23- Oct- 13	22- Oct -14	4- Aug -16
US20160222 023	NOVEL MONOTHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	30- Jan- 15	29- Jan -16	4- Aug -16
US20160222 010	4-AMINO-IMIDAZOQUINOLINE COMPOUNDS	Hoffmann-La Roche Inc.	22- Apr- 14	7- Apr -16	4- Aug -16
US20160221 994	Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof	Not Available	29- Nov- 12	27- Nov -13	4- Aug -16
US20160220 664	ANTIGEN AND METHOD FOR PRODUCTION THEREOF	Not Available	13- Sep- 13	12- Sep -14	4- Aug -16
US20160220 595	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	11- Sep- 13	10- Sep -14	4- Aug -16
US20160220 536	USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL­LIKE RECEPTOR OVEREXPRESSION	Not Available	16- Mar- 04	19- Feb -16	4- Aug -16
US20160215 282	SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES	Not Available	28- Jan- 15	20- Jan -16	28- Jul- 16
US20160215 262	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16- Sep- 13	16- Sep -14	28- Jul- 16
US20160213 776	ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS	GlaxoSmithKline Biologicals SA	1- Sep- 10	7- Apr -16	28- Jul- 16
US20160213 773	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	28- Jul- 16
US20160213 761	CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	19- Mar- 08	5- Apr -16	28- Jul- 16
US20160213 647	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION	Not Available	28- Jan- 15	27- Jan -16	28- Jul- 16
US20160213 610	MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB	Not Available	24- Oct- 12	28- Jan -16	28- Jul- 16
US20160207 980	FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES	AMGEN INC.	5- Sep- 13	5- Sep -14	21- Jul- 16
US20160207 949	NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd	2- Sep- 13	2- Sep -13	21- Jul- 16
US20160207 900	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	PROZYMEX A/S	9- Sep- 13	8- Sep -14	21- Jul- 16
US20160206 729	IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS	Not Available	19- Sep- 13	19- Sep -14	21- Jul- 16
US20160206 719	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22- Feb- 13	5- Apr -16	21- Jul- 16
US20160206 638	BORON-CONTAINING SMALL MOLECULES	Not Available	16- Feb- 05	5- Apr -16	21- Jul- 16
US20160206 575	Inhibition of Biofilm Organisms	NOVABIOTICS LIMITED	31- Mar- 09	28- Mar -16	21- Jul- 16
US20160202 258	B-CELL ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh – Of the Com monwealth System of Higher Education	8- Apr- 10	21- Mar -16	14- Jul- 16
US20160201 110	DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES	Not Available	9- Jan- 15	17- Nov -15	14- Jul- 16
US20160201 088	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17- Dec- 01	30- Mar -16	14- Jul- 16
US20160199 486	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Not Available	3- Dec- 09	22- Mar -16	14- Jul- 16
US20160199 449	METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON	Hemispherx Biopharma, Inc.	21- Aug- 13	21- Aug -14	14- Jul- 16

 

US20160199 416	Induced Hepatocytes and Uses Thereof	Not Available	26- Nov- 14	25- Nov -15	14- Jul- 16
US20160199 407	HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION	THE UNIVERSITY OF IOWA RESEARCH FOUNDATION	25- Jan- 08	17- Dec -15	14- Jul- 16
US20160194 387	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2- Jan- 15	31- Dec -15	7- Jul- 16
US20160194 322	SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS	Not Available	25- Nov- 03	14- Mar -16	7- Jul- 16
US20160194 278	DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	23- Aug- 13	11- Mar -16	7- Jul- 16
US20160193 603	SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE	Not Available	29- Jan- 10	5- Aug -15	7- Jul- 16
US20160193 327	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	7- Jul- 16
US20160193 321	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS	Novartis AG	11- Sep- 06	5- Nov -15	7- Jul- 16
US20160193 315	PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES	Not Available	7- Aug- 09	17- Mar -16	7- Jul- 16
US20160192 658	HYDROGEN-CONTAINING ANTIMICROBIAL AGENT	Not Available	13- Aug- 13	5- Aug -14	7- Jul- 16
US20160185 786	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	29- Dec -15	30- Jun- 16
US20160185 785	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30- Dec- 14	29- Dec -15	30- Jun- 16
US20160184 424	INTRANASAL VACCINATION DOSAGE REGIMEN	Not Available	17- Dec- 12	17- Dec -13	30- Jun- 16
US20160184 334	BORON-CONTAINING SMALL MOLECULES	Not Available	16- Feb- 05	11- Mar -16	30- Jun- 16
US20160177 337	METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR	Not Available	16- Jul-08	8- Mar -16	23- Jun- 16
US20160177 336	Expression Tools for Multiprotein Applications	Not Available	9- Mar- 04	11- Dec -15	23- Jun- 16
US20160175 433	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	17- Aug- 10	15- Dec -15	23- Jun- 16
US20160175 394	Compositions and Uses of Lectins	Emory University	12- Feb- 10	11- Dec -15	23- Jun- 16
US20160175 387	Use of Immune Suppressive Domains as Medicaments	Not Available	10- Apr- 13	10- Apr -14	23- Jun- 16
US20160174 631	PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER, FORMULATIONS FORMING THE SAME, AND METHOD OF PRODUCING THEREOF	Not Available	23- Dec- 14	10- Dec -15	23- Jun- 16
US20160168 203	Cyclic Antimicrobial Peptides	NOVABIOTICS LIMITED	24- Feb- 06	9- Nov -15	16- Jun- 16
US20160168 101	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	15- Dec- 14	27- Nov -15	16- Jun- 16
US20160166 710	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21- Aug- 13	19- Feb -16	16- Jun- 16
US20160166 676	Use of Immune Suppressive Peptides as Adjuvants	Not Available	10- Apr- 13	10- Apr -14	16- Jun- 16
US20160160 258	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26- Feb- 03	8- Feb -16	9- Jun- 16
US20160160 178	IMMUNOTHERAPY USING STEM CELLS	Not Available	9- Dec- 14	2- Dec -15	9- Jun- 16
US20160159 927	IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V- R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS	Not Available	5- Dec- 14	7- Dec -15	9- Jun- 16
US20160158 341	PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS	Novartis AG	18- Mar- 08	7- Dec -15	9- Jun- 16

 

US20160158 340

INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS

Not Available

27- Jan- 06